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9ABSTRACT
In this study we investigated the neurophysiological effects, as well as the binding 
properties and complement activating ability of neuropathy-associated human anti- 
ganglioside antisera and monoclonal antibodies on isolated nerves and nerve-muscle 
preparations. Two categories of antibodies were studied: anti-GMl antisera and 
monoclonal antibodies from patients with chronic motor neuropathies and Guillain- 
Barre syndrome, and anti-GQlb and related anti-disialosyl antisera and monoclonal 
antibodies from patients with chronic ataxic neuropathies and Miller Fisher syndrome. 
In vitro recordings for up to 4 hours of compound nerve action potentials, latencies, rise 
times and stimulus thresholds from isolated ensheathed and desheathed sciatic nerve and 
rabbit desheathed sural nerve as well as twitch tension from mouse phrenic nerve- 
hemidiaphragm preparation were performed, in the presence of anti-ganglioside 
antibodies and fresh human serum as an additional source of complement. No changes 
were observed over this time course, with all electrophysiological parameters being 
within 15% of the starting values for both normal and antibody containing sera. 
Immunohistological evaluation of desheathed nerves exposed to anti-ganglioside 
antibodies demonstrated antibody deposition with complement activation at up to 90% 
of nodes of Ranvier in some preparations. These data indicate that anti-ganglioside 
antibodies can diffuse into nerve, bind to nodes of Ranvier and fix complement in vitro 
without resulting in any acute physiological deterioration, suggesting that the node of 
Ranvier is relatively resistant to acute anti-ganglioside antibody mediated injury. The 
data also suggest that anti-ganglioside antibodies are unlikely to exert major direct 
pharmacological effects on nodal function and neuromuscular transmission. The models 
used in this study failed to give an in vitro approval of the suggested pathophysiological 
effects of anti-ganglioside antibodies on nerve and nerve-muscle function, possibly
because their limited viability does not allow time for the evolution of a full 
inflammatory lesion, and in vivo models may be more suitable for identifying the effects 
of these antibodies on nerve conduction.
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PART ONE -  GENERAL INTRODUCTION 
Preface
At the brink of the new millennium neuroscience has become one of the great frontiers 
of science and the progress that has been made in the last decades in understanding the 
biology of the neurological disorders is extraordinary. Indeed, the significant advances 
in the fields of basic neuroscience give new approaches to the basic pathogenic 
mechanisms of nervous system disorders and several of these approaches have changed 
our understanding of their pathophysiology and hence their treatment.
Neurological diseases affect the qualities that make the lives o f human beings so 
special and distinct. Among these diseases, the autoimmune peripheral neuropathies 
have attracted the interest and enthusiasm of researchers from different scientific 
disciplines. Immune responses have been postulated to be involved in the pathogenesis 
of autoimmune peripheral neuropathies and glycolipids have been shown to play a 
central role in autoimmune processes affecting the nervous system. The human nervous 
system not only expresses large quantities of glycolipids but also contains glycolipid 
structures that are absent or less frequent in other organs. These molecules are thus 
potential antigenic targets for circulating autoantibodies in autoimmune nervous system 
disorders. Autoimmune peripheral neuropathies cover a set of clinical syndromes in 
which idiopathic neuropathy causes acute, subacute or chronic weakness affecting 
peripheral nerves. Our understanding of the pathogenic mechanisms leading to these 
clinical syndromes is growing rapidly through advances in epidemiology, microbiology, 
and immunology. A list of some neuropathies that have been reported to be associated 
with antiglycolipid antibodies is presented in the following Table 1:
20
Table 1 Antiglycolipid autoantibodies in neuropathies
C lin ic a l sy n d r o m e G ly c o lip id  a n tib o d y  r e a c tiv ity R e fe r e n c e s
A cu te  d em y elin a tin g  G uillain-B arrd  
syn d rom e (A ID P )
A cu te  pure m otor axon al G u illa in -  
Barre syn d rom e (A M A N )
A cu te  m otor-sen sory  axonal 
G u illa in -B arre synd rom e (A M S A N )
IgG, IgM  and IgA an tib od ies to 
G M 1, G D la , L M 1, G T la , 
G M lb , G M 2, su lfa tid e , and  
other g ly c o lip id s
(Ilyas et al. 1988; M cK hann et al. 1993; Y uk i et al. 
1993d ; V isser  et al. 1995; R ees , G regson  & H u gh es  
1995a; R ees et al. 1995b ; H afer-M ack o  et al. 1996; 
H ahn 1998; H o et al. 1999; H u gh es et al. 1999; 
R aida et al. 2 0 0 0 )
M iller F ish er synd rom e (M F S ), acute  
oropharyngeal palsy , and 
B ic k e s ta f f  s 
brainstem  en cep h a litis
IgG an tib od ies to G Q lb  and 
G T la
(C hiba et al. 1992; C hiba  et al. 1993; Y uk i et al. 
1993a; Y uki et al. 1993b; W illison  et al. 1993c; 
O'Leary e ta l .  1996; W illison  et al. 1997)
M u ltifoca l
m otor n europathy (M M N )
IgM an tib od ies  to GM 1 and 
related G al((31-3)G alN A c  
bearing g ly c o lip id s
(Freddo et al. 1986; Pestronk et al. 1988a; Pestronk  
et al. 1988b; Pestronk et al. 1990; Santoro et al. 
1990; Krarup et al. 1990; Pestronk 1991; L ange et 
al. 1992: G riffin  1994: K in sella  et al. 1994; W olfe  et 
al. 1997)
C hronic axonal and d em yelin a tin g  
p red om in an tly  sen sory  neuropathy
IgM an tib od ies to  su lfa tid e (Ilyas et al. 1992a: van den B erg et al. 1993; Lopate 
et al. 1997a)
C hronic large fibre pred om in an tly  
sen sory  n europathy w ith  ataxia
M on oclon a l IgM an tib od ies to 
g a n g lio s id es  con ta in in g  
N c u N A c (a 2 -8 )N e u N A c  
ep itop es
(Ilyas et al. 1985; Freddo et al. 1986: Y ou n es-  
C henn ou fi et al. 1992; D aun e et al. 1992; Y uki et al. 
1992a: W illison  et al. 1994; Latov 1994; D alak as & 
Q uarles 1996: W illison  et al. 1996; K usunoki et al. 
1996b: O'Leary & W illison  1997)
N eu rop athy  a ssoc ia ted  w ith  IgM  
g am m op ath y
M on oclon a l IgM  an tib od ies to 
SG PG , SG L PG , M A G , P0. 
su lfa tid e, and g a n g lio s id es
(L atov et al. 1980; Braun, Frail &  L atov 1982; Ilyas 
et al. 1984; Ilyas et al. 1985; V ital et al. 1989; K yle  
&  D yck  1993; N ob ile -O ra z io  et al. 1994; Pestronk et 
al. 1994a; Latov 1995; van den B erg  et al. 1996; 
R opper & G orson 1998)
Insu lin -d ep en d en t and n on -in su lin -  
d ep en d en t d iab etes m ellitu s
G a n g lio sid es. su lfa tid e (B uschard  et al. 1993; S h igeta  et al. 1997)
Antiglycolipid antibodies have been extensively studied in patients with neuropathy 
associated with IgM paraproteinemia. It appears clear from clinical, electrophysiological
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and experimental data, that the target glycolipid or glycolipid epitope for the IgM is 
related to the type of neuropathy, purely sensory or predominantly sensory or uniquely 
motor. About half of the patients with peripheral neuropathy and IgM monoclonal 
gammopathy have serum antibodies reacting with the myelin-associated glycoprotein 
(MAG), which shares an oligosaccharide epitope (HNK-1) with the peripheral nerve 
protein Po, a sulfated glucuronyl paragloboside (SGPG), and its related sulfated 
glucuronyl lactosaminyl paragloboside (SGLPG). This epitope is also present in human 
natural killer cells. It seems that there is a close correlation between the sensory 
demyelinating neuropathies and the presence of anti-MAG and anti-SGPG antibodies. 
Also, anti-GDlb IgM monoclonal antibodies have been found in sensory 
ganglionopathies or chronic large fibre sensory neuropathies with ataxia, and strong 
evidence supports the pathogenic role of the anti-GDlb ganglioside antibody in this 
neuropathy.
Guillain-Barre syndrome (GBS) is another autoimmune neuropathy that has been 
studied by several research groups. The term GBS defines a recognisable clinical entity 
that is characterised by rapidly evolving symmetrical limb weakness, loss of tendon 
reflexes, sensory signs and variable cranial nerve involvement and autonomic 
dysfunction. GBS is the most common cause of acute neuromuscular paralysis in 
developed countries. GBS has undergone considerable revision in recent years with the 
addition of axonal GBS (AMAN-acute motor axonal neuropathy, and AMSAN-acute 
motor and sensory axonal neuropathy) to the traditional view of acute inflammatory 
demyelinating polyradiculoneuropathy. Several glycolipid antigens, including GM1, 
LM1, GM lb, GM2, GTla, GDI a, and sulfatide have been found to be immune targets in 
GBS and its subgroups. Since Campylobacter jejuni infection often precedes the
22
disease, it has been proposed that this infection may be involved in the initiation of the 
antiglycolipid response.
Moreover, it seems clear that the IgG anti-GQlb antibody is associated with the 
syndrome of acute ophthalmoplegia, areflexia and ataxia defined as Miller Fisher 
syndrome (MFS). Anti-GQlb antibody has also been demonstrated in serum from GBS 
patients with ophthalmoplegia and from patients with acute paralysis of extraocular 
muscles, suggesting that the anti-GQlb antibody might be of pathogenic importance in 
an immune-mediated extraocular muscle paresis. Also, the antiglycolipid reactivity in 
sera from patients with chronic inflammatory demyelinating polyradiculopathy (CIDP), 
a chronic form of GBS is another issue of investigation.
The role of antiglycolipid antibodies in multifocal motor neuropathy (MMN), a newly 
recognised chronic neuropathy that has clinical features in common with both CIDP and 
lower motor neuron disease, has been extensively investigated. The diagnostic hallmark 
of MMN is the electrophysiological demonstration of persistent localised motor 
conduction block. Although the pathogenesis of MMN has not been elucidated, there is 
increasing evidence for an autoimmune mechanism. Anti-GMl antiganglioside antibody 
has been the most extensively studied antigen and its clinical significance and its 
potential pathogenic role are controversial. Another common antigen found in several 
neurological disorders is sulfatide, sulfated galactosylceramide. Sulfatide is also a 
potential antigen in insulin and non-insulin-dependent diabetes mellitus, a disease where 
late complications are neuropathy and retinopathy.
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CHAPTER ONE: GANGLIOS1DES AND PERIPHERAL NERVOUS SYSTEM
1. Distribution and biochemistry of gangliosides
Knowledge of basic biochemistry of gangliosides is important in understanding their 
physiological significance and their implication in many current areas of interest in 
autoimmune peripheral neuropathies. Glycosphingolipids are amphipathic components 
of plasma membranes of all vertebrate cells and they also occur in intracellular 
membranes of the secretory and endocytotic pathways, e.g., in the Golgi, endosomal and 
lysosomal membranes (Marks, Marks & Smith 1996; Voet & Voet 1995). They are 
widely distributed in nervous tissue, particularly in the outer leaflet of the plasma 
membrane, where they contribute to cell surface carbohydrates.
Gangliosides are a family of sialic acid containing glycosphingolipids (Svennerholm 
1963; Svennerholm 1994; Marks et al. 1996; Voet & Voet 1995). Gangliosides show 
great molecular diversity with numerous novel minor components and are composed of 
lipid and carbohydrate moiety (Svennerholm 1956; Svennerholm & Raal 1961; Ledeen 
1985). The lipids are a group of biologically important compounds related more by their 
physical than by their chemical properties. In the body, lipids serve as an efficient 
source of energy, and, also, as a thermal insulator in the subcutaneous tissues and around 
certain organs, including the nervous system. They have the common property o f being 
relatively insoluble in water and nonpolar lipids act as electrical insulators allowing 
rapid propagation of depolarisation waves along myelinated fibres. The fat content of 
nerve tissue is particularly high. Carbohydrates are widely distributed in animals having 
both structural and important metabolic roles. The sugar glucose is the most significant 
carbohydrate. The simplest type of sugar is a monosaccharide - a single sugar unit. 
Monosaccharides may be joined together to form disaccharides, trisaccharides, 
tetrasaccharides, and polymers or polysaccharides. Glycosphingolipids contain a fatty
24
acid, the alcohol sphingosine, and carbohydrate. The major glycolipids found in animal 
tissue are glycosphingolipids. They contain ceramide and one or more sugars. The two 
simplest are galactosylceramide and glycosylceramide. Galactosylceramide is a major 
glycosphingolipid of nervous system, but it is found in relatively low amounts 
elsewhere. Galactosylceramide can be converted to sulfogalactosylceramide (classic 
sulfatide), which is a major component of peripheral nerve myelin and an autoantigen in 
predominantly sensory neuropathies (Willison 1994).
Ganglioside comprise at least one sialic acid residue. Sialic acid is a generic term for 
N-acetylneuraminic acid, usually abbreviated to NeuNAc or NANA. The sialic acid(s) 
are linked to the internal or terminal galactose of an oligosaccharide core composed of 
up to four sugars with the following sequence: ceramide-glucose-galactose-N- 
acetylgalactosamine-galactose (Ledeen 1985; Willison 1994). Ceramide is the lipid 
moiety in ganglioside molecules, a fatty acid linked to a long base chain, sphingosine. 
Ceramide is synthesised in the endoplasmic reticulum. First, the aminoacid serine, 
following activation by a combination with pyridoxal phosphate, combines with 
palmitoyl-CoA to form 3-ketosphinganine. This is converted to dihydrosphingosine in a 
reductive step utilising NADPH. Dihydroceramide is formed by a combination with 
acyl-CoA followed by desaturation to form ceramide (Voet & Voet 1995). There is 
evidence that ceramide may act as a lipid mediator (second messenger), activating a 
protein kinase and opposing some of the actions of diacylglycerol. The acyl group is 
represented frequently by long-chain saturated or monoenoic acids (Voet & Voet 1995). 
Gangliosides are synthesised from ceramide by a stepwise addition of activated sugars 
and a sialic acid, usually N-acetylneuraminic acid. Gangliosides have an amphipathic 
structure because they contain polar groups. The lipid moiety represents the 
hydrophobic or water-insoluble part of the molecule that is embedded into the
25
membrane. This anchors the hydrophilic or water-soluble carbohydrate moiety to the 
outer surface of the membrane. The carbohydrate portion of gangliosides is a series of 
two or more sugars with at least one sialic acid. The sialic acid(s) are attached to the 
internal or the terminal galactose of the oligosaccharide chain (Svennerholm 1956; 
Svennerholm & Raal 1961; Svennerholm 1994).
Glycosphingolipids are inserted into the membrane lipid bilayer as is illustrated in the 
following Figure 1, which also indicates the structure of several carbohydrate chains in 
the commonly occurring glycosphingolipids. The ceramide group is contained within 
the lipid bilayer, with the sphingosine and fatty acid hydrocarbon chain parallel to and 
interacting with the fatty acyl chains of the sphingolipids. The carbohydrate group 
projects out from the surface of the bilayer, interacting with the surrounding water 
(Montgomery et al. 1996).
C  ^  G I u c o s e
| | G a I a c i o s e
N - a c e t y I g a I a c t o s a in i n e
N - a c e i y  In e u r a m  i n i c a c i d
Fig. 1 Insertion and orientation of glycosphingolipids in the membrane lipid bilayer. 
The ceramide group is inserted between phospholipids, and the carbohydrate projects 
into the extracellular fluid. The carbohydrate chains of different kinds of 
glycosphingolipids vary in number and type of monosaccharide residues.
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2. Terminology of gangliosides
The problems in the nomenclature of gangliosides arise from the complexity of the 
carbohydrate moiety of these compounds. The systematic names of the oligosaccharides 
linked to the hydrophobic portion, namely ceramide, are very cumbersome and they 
cannot be used for oral communication. Today, the code system, suggested by 
Svennerholm, is generally accepted (Svennerholm 1963; Svennerholm 1994). 
According to his suggestion gangliosides are named with the following method: G 
stands for ganglio; M, D, T, and Q refers to the number of sialic acids residues (mono-, 
di-, tri-, and quad-, respectively); arabic numerals and lower case letters refers to the 
sequence of migration in thin layer chromatography (TLC).
The older methods of separation and identification of lipids, based on classic chemical 
procedures of crystallisation, distillation, and solvent extraction, have now been largely 
supplanted by chromatographic procedures. TLC is particularly useful for the separation 
of the lipid moiety of gangliosides (Svennerholm 1963). The migration of gangliosides 
in TLC depends upon their oligosaccharide core and the number of attached sialic acids. 
Small gangliosides migrate more slowly than gangliosides with a longer oligosaccharide 
core and more sialic acids. For example, GM1 ganglioside (that has an oligosaccharide 
core consisted of four sugars, Cer-Glc-Gal-GalNAc-Gal) migrates more slowly than the 
three sugar oligosaccharide GM2 ganglioside (Cer-Glc-Gal-GalNAc). On the other hand 
GDlb runs ahead of GTlb, which runs ahead of GQlb, as they contain two, three, and 
four sialic acids respectively (Willison 1994).
There are four major gangliosides of the ganglio- series in the brain tissue (GM1, 
GDla, GDlb, GTlb) (Svennerholm 1956; Svennerholm & Raal 1961; Pestronk 1991; 
Svennerholm 1994; Willison 1994). They each contain the same four sugar chain, but 
vary in the number of sialic acids; GM1 with one, G D la with two, G Dlb with two, and
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GTlb with three. One ganglioside not found in peripheral neurons is GM4, 
sialosylgalactosylceramide, which appears to be a marker for myelin and 
oligodendrocytes of the CNS (Ledeen 1985). Numerous minor gangliosides in brain, 
nerve, and myelin have been described.
All antiglycolipid antibodies associated with neuropathy react with epitopes located 
on the carbohydrate region of glycolipid molecules. Because the carbohydrate structures 
are frequently present on several different glycolipids, glycoproteins and other 
carbohydrate composed molecules, such as bacterial lipopolysaccharides, there is 
considerable possibility for shared reactivity (Willison 1994). As an example, the 
Gal(pl-3)GalNAc epitope found on GM1 ganglioside is also present on asialo-GMl and 
GDlb, and the complete GM1 structure is present on Campylobacter jejuni 
lipopolysaccharide (Yuki et al. 1993c; Aspinall et al. 1994; Moran 1997; Hahn 1998; 
Sheikh et al. 1998b). Also, autoantibodies reacting with the sulfated glucuronic acid 
epitope on SGPG reacts with similar epitopes on many other glycoproteins of nerve 
tissue including the myelin associated glycoprotein (MAG) and the peripheral nerve 
compact myelin protein Po (Braun et al. 1982; Burger et al. 1990; Pestronk et al. 1994a; 
van den Berg et al. 1996).
3. Ganglioside storage disease in Clinical Neurology
Many neurological disorders have been associated with gangliosides. A block at the 
various intermediate stages of ganglioside metabolism causes the accumulation of the 
specific gangliosides within the nervous system and other tissue (Sandhoff & 
Conzelmann 1984; Marks et al. 1996; Voet & Voet 1995). Their excessive storage is 
responsible for the pathophysiology and clinical features of these diseases, and its 
identification on biopsy specimens is a useful screening procedure.
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Tay-Sachs disease, or infantile GM2 gangliosidosis, is the prototype for the 
ganglioside storage diseases; it is caused by a severe deficiency of hexosaminidase A 
(Sandhoff & Conzelmann 1984; Marks et al. 1996; Voet & Voet 1995) The patient 
presents between the third and sixth month of life with marked irritability and 
hyperacusis; by the age of six months weakness and hypotonia become evident, 
followed by progressive blindness, deafness, seizures, and spasticity; death occurs before 
the age of three years in these children (Evans et al. 1991). Also, juvenile GM2 
gangliosidosis, adult-onset GM2 gangliosidosis, and Sandhoffs disease, which is 
phenotypically similar to Tay-Sachs disease, are all GM2 gangliosidoses (Sandhoff & 
Conzelmann 1984). GM1 gangliosidosis (Kohlschutter 1984) is an autosomal recessive 
disorder caused by a deficiency of lysosomal acid beta galactosidase. The severity of 
this disease correlates with the degree of enzyme deficiency. In addition to the above the 
distribution of gangliosides is affected in Niemann-Pick disease, a group of disorders 
caused by sphingomyelinase deficiency (Sandhoff & Conzelmann 1984; Evans et al. 
1991; Marks et al. 1996).
Gangliosides are also involved in other disorders. For instance, an experimental 
autoimmune multiple sclerosis-like disease was induced in rabbits after immunisation 
with gangliosides (Konat et al. 1982). Moreover, exogenous ganglioside injections can 
be immunogenic, triggering an IgG anti-GMl anti-ganglioside antibody response, 
resulting in acute axonal Guillain-Barre syndrome (Ilia et al. 1995). On the other hand, a 
number of studies have found increased titres of anti-ganglioside antibodies in the sera 
and cerebrospinal fluid of patients with multiple sclerosis, even though the significance 
of these findings is unclear (Sadatipour, Greer & Pender 1998). Also, experimental 
allergic peripheral neuritis was observed in the peripheral nerves of animals by 
immunising them with gangliosides (Nagai et al. 1976).
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4. Functions and therapeutic effects of gangliosides
The functional roles of gangliosides are still poorly understood. They have been 
implicated in a variety of molecular mechanisms of important biological phenomena of 
the nervous system (Nagai 1995). Gangliosides are the most specific lipids of neuronal 
membranes (Svennerholm 1994; Ledeen 1985). Gangliosides of the central nervous 
system undergo characteristic changes during the stages of brain development, short­
term stimulation and long-term thermal adaptation. At the very early stages of brain 
development the less polar mono- and disialo- gangliosides are synthesised followed 
later by biosynthesis of the more polar ones. Short-term light, electrical stimulation and 
extreme temperature conditions affect the metabolism of gangliosides (Pankkezhum & 
Brewer 1990). An abundance of literature suggests that exogenous administration of 
gangliosides could enhance neurite outgrowth and recovery from injury (Karpiak 1984; 
Toffano et al. 1984; Roisen et al. 1984; Tsuji et al. 1988; Riggot & Matthew 1997).
Many authors suggest the possible use of gangliosides as a therapeutic agent for the 
treatment of many neurological problems (Pankkezhum & Brewer 1990). Initially, 
ganglioside mixtures were not considered immunogenic when administered parenterally 
(Asbury 1994), but subsequent reports suggested that exogenous ganglioside injections 
can elicit immune mediated side effects triggering a strong IgG GM 1 antibody response 
(Ilia 1995). The therapeutic effects of gangliosides have been well documented by 
several investigators in in vitro studies. In experimental animals, gangliosides have 
shown a considerable capacity to repair and regenerate damaged peripheral or central 
nervous tissue (Ceccarellk Aporti & Finesso 1976). Several studies have extended the 
therapeutic role of gangliosides to diseases such as diabetic neuropathy (Horowitz 1984; 
Hallett et al. 1984; Naarden et al. 1984). Gangliosides were administered in several 
clinical trials in the treatment of acute stroke and amyotrophic lateral sclerosis, although
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without therapeutic effect (Hallett et al. 1984; Hoffbrand et al. 1988). The effect of 
GM1 ganglioside on the amplitude of the electroencephalogram, neurologic function and 
histology has been studied in chronic middle cerebral artery occlusion in cats 
(Komatsumoto et al. 1988) and also, GM1 ganglioside has been tested in patients with 
Parkinson’s disease (Schneider et al. 1995). Some of these data give promising results 
with clear benefits for some patients, although the therapeutic potential o f gangliosides 
needs further extensive investigation (Abraham, Abraham & Wynn 1984; Fedele, 
Crepaldi & Battistin 1984; Schneider et al. 1995).
5. Involvement of gangliosides in biological interactions
Gangliosides have been associated with Ca++ interactions (Milani et al. 1992). Ca++ 
ions have been implicated in the initiation and propagation of neuronal activity and they 
play a central role in the release of neurotransmitter from nerve terminals. Also Ca++ 
ions regulate many other stages of neuronal activity, such as interaction of the 
neurotransmitter with the postsynaptic membrane, axoplasmic flow, and axonal growth 
(Kandel 1991). Ganglioside micelles have been reported to bind Ca++ with a high 
affinity and this may have physiological significance in synaptic transmission. For 
example, blocking ganglioside activity by antibody, toxin or competition may block 
synaptic transmission (Pankkezhum & Brewer 1990). So far there is not sufficient 
evidence to establish the involvement of gangliosides in neural transmission and 
extensive studies in this direction are necessary.
Another important role of gangliosides is their interaction with neuroactive substances 
and enzymes. It has been suggested that gangliosides act as receptors for serotonin 
(Woolley & Gommi 1965), and they also can bind LSD, tryptamine, ergometrine, 
morphine, naloxone, chloropromazine, tubocurarine, colchicine, tetanus toxin.
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botulinium toxin, and bilirubin (Pankkezhum & Brewer 1990). The inhibitory effect of 
gangliosides on Na+ /K+ ATPase of guinea pig brain microsomal fraction (Pankkezhum 
& Brewer 1990) was reported long ago. Gangliosides have been shown to bind 
specifically to calmodulin (Higashi, Omori & Yamagata 1992), and influence the 
activity of various types of protein kinases (Ca++ -calmodulin-dependent, Ca++ - 
phospholipid-dependent, cAMP-dependent and Ca++ -independent forms) and, also, 
they can interact with Mg++ - and Ca++ - ATPases (Fukunaga, Miyamoto & Soderling 
1990; Guerold et al. 1992; Higashi & Yamagata 1992). So, gangliosides may contribute 
to neuronal activity through their effects on ion channels and ion pumps (LoPachin et al. 
1993).
Wieraszko and Seifert suggested the involvement of gangliosides in cholinergic 
transmission in the striatum; rat brain striatal slices, treated with neuroaminidase from 
Vibrio cholerae abolished synaptic transmission within 90 min (Wieraszko & Seifert 
1984). The injection of exogenous neuraminidase into frog spinal cord segments caused 
a significant increase of motorneuron activity in the corresponding spinal nerve, and 
moreover neuroaminidase treatment increases the amplitude of postsynaptic potentials in 
fish optic tectum (Romer & Rahmann 1979). In rat hippocampal slices, GM1 seems to 
be implicated in synaptic transmission as it can be reduced by GM1 specific probes such 
as GM1 antiserum, cholera toxin, and neuroaminidase from Arthrobacter urecifaciens 
(Wieraszko & Seifert 1986). Exogenously added gangliosides delay the action of 
ruthenium red which blocks synaptic transmission in rat hippocampal slices (Wieraszko 
1986). In addition, gangliosides have been shown to influence the effect of anaesthetics 
on membranes (Harris et al. 1984; Harris & Groh 1985). Gangliosides are likely to be 
involved in the uptake of choline, and ganglioside-protein complexes may serve as 
choline binding sites and carriers (Massarelli et al. 1982; Ferretti & Borroni 1984). The
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presence of gangliosides in both presynaptic and postsynaptic membranes could explain 
their possible functional involvement in synaptic transmission (Pankkezhum & Brewer 
1990).
6. Gangliosides and bacterial toxins
Because of their structural diversity, gangliosides have been implicated in various cell 
recognition and signalling phenomena (Pankkezhum & Brewer 1990; Willison 1994; 
Nagai 1995). Many bacteria adhere to and colonise their hosts through production of 
toxins, which are often proteins that can bind to receptors on cell membranes (Willison 
& Kennedy 1993; Fishman, Pacuszka & Orlandi 1993). Some of these toxins frequently 
use gangliosides or cross-reactive glycoproteins as their cell surface receptors (Fishman 
et al. 1993; Holmgren 1994). When injected into the nervous system, cholera toxin 
produced a similar pattern of neuropathological lesions to those induced by anti-GMl 
antibodies (Schwerer et al. 1986).
6a. GM1 ganglioside, the membrane receptor for cholera toxin
It is now known that the GM1 ganglioside is the specific and only natural biological 
receptor for cholera toxin; this was first suggested by van Heyningen et al (van 
Heyningen et al. 1971), who observed that crude preparations of gangliosides inactivated 
choleragen. Since then several groups showed that ganglioside GM1 was the most 
potent inhibitor of toxin binding and action (Cuatrecasas 1973a; Cuatrecasas 1973b; 
Holmgren 1981; Fishman 1982). Cholera toxin is a protein with two types of subunits: a 
single '■‘heavy” subunit of molecular weight (MW) 28,000 non covalently attached to a 
58,000-MW aggregate of "‘light” subunits. The “light” subunits are responsible for cell 
binding (B subunits) and the “heavy” subunits for the direct toxic activity (A subunit) of
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cholera toxin (Lonnroth & Holmgren 1973; van Heyningen 1974; Holmgren 1981; 
Holmgren 1994). The binding receptor within the GM1 ganglioside (Figure 2) is the 
sequence Gal(31-3GalNAc(31-4(NeuAca2-3)Gal (Holmgren, Lonnroth & Svennerholm 
1973; Holmgren 1994).
Ceramide-Glucose-Galactose- N-Acetylgalactosamine-Galactose 
(Acyl- |
sphingo- NeuAc
sine)
or
Cer-Glc-Gal-GalNAc-Gal
NeuAc
Fig. 2 GM1 ganglioside, a monosialoganglioside, the receptor in human intestine for 
cholera toxin.
6b. Gangliosides and other than CT bacterial toxins
Toxins produced by strains of Campylobacter jejuni and Escherichia coli can bind to 
GM1 ganglioside and variably to other gangliosides and glycoproteins (Fishman et al. 
1993). Certain strains of E. coli produce a heat-labile enterotoxin (LT) which is similar 
in size to choleragen and is composed of A and B subunits which appear to be 
structurally and antigenically similar to the subunits of choleragen (Holmgren 1994). LT 
can be inactivated by GM1 ganglioside, although it is unclear if GM1 ganglioside is the 
native or only receptor for LT (Fishman et al. 1993). It is established that 
Campylobacter jejuni is a frequent preceding infection in GBS associated with anti- 
GM1 IgG Ab. Campylobacter jejuni strains contain cell wall lipopolysaccharides cross­
reactive with GM1 ganglioside (Yuki et al. 1993c; Aspinall et al. 1994; Willison 1994).
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Tetanus toxin is the neurotoxin produced by Clostiridium tetani (van Heyningen 
1968). Tetanus toxin seems to mediate its neurotoxic effect 011 the peripheral and 
central nervous system by blocking the release of neurotransmitter from inhibitory 
presynaptic membranes. Some studies demonstrated the interaction between tetanus 
toxin and gangliosides (van Heyningen 1968; Fishman 1982). Tetanus toxin binds with 
high affinity to G Qlb and GTlb gangliosides, less well to GDlb, and with low affinity 
to G D la and monosialo-gangliosides (Fishman 1982).
Also, Clostiridium botulinium toxin causes a disease similar to Miller Fisher 
syndrome but affecting all neuromuscular junctions (Willison & Kennedy 1993). Since 
the anti-GQlb antibody is strongly linked to MFS (Chiba et al. 1992; Chiba et al. 1993; 
Yuki et al. 1993b; Willison et al. 1993c), it is likely that the toxin and the anti-GQlb Ab 
bind to the same GQlb (or GQlb cross-reactive) receptor which is particularly highly 
concentrated in ocular nerves (Chiba et al. 1997). The similarities between botulism and 
MFS substantiate the role of anti-GQlb antibodies in the syndrome of ophthalmoplegia, 
ataxia and areflexia (Willison & Kennedy 1993).
7. Gangliosides in central and peripheral nervous system
Some studies have demonstrated that peripheral nervous system myelin contains a 
significantly high concentration of glycosphingolipid antigens, that may be targets for 
immunoglobulins detected in patients with several peripheral neuropathies 
(Svennerholm et al. 1994). The immunoglobulins from these patients have been found 
to react with specific sites in glycolipid molecules, and antigens of the patients’ 
autoantibodies can be separated into several groups correlated with their clinical 
conditions (Table 1). Therefore, there is considerable interest in elucidating the 
characteristic and specific composition of glycolipids in the nervous tissue.
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Schwann cells in the peripheral nervous system (PNS) develop plasma membrane 
processes that spirally ensheath neuraxons in segments between nodes of Ranvier 
(intemodes). In the central nervous system (CNS) oligodendrocytes play a similar role. 
Compared to unmyelinated axons, the fatty insulated sheath surrounding the axons of 
myelinated fibres is essential for the high speed conduction of action potentials. 
Cholesterol, complex phospholipids and glycophospholipids form the lipid bilayer, 
comprising about 70% of the dry weight of both CNS and PNS myelin (Schwartz 1991). 
The glycolipids galactocerebroside (GalC) and galactosulfatide (sGalC) are typical 
major myelin classes, together with galactoglyceride (GalDG) and gangliosides. These 
components are assembled with myelin-specific membrane proteins, the most abundant 
of which are the integral membrane proteins proteolipid protein (PLP) in the CNS and Po 
in the PNS and the myelin basic protein (MBP), with myelin-associated glycoprotein 
(MAG) as a minor component (Schwartz 1991). One ganglioside not found in 
peripheral nerves is GM4, sialosylgalactosylceramide, which appears to be a marker for 
myelin and oligodendrocytes of the CNS of mammals and other vertebrates (Ledeen 
1985; Chiba et al. 1997). Also, the glycolipid antigens of peripheral nerve differ from 
those of CNS; large proportions of lactotetraose and lactohexaose gangliosides and 
sulfoglucuronyl glycosphingolipids are found in PNS myelin, which occur only in 
negligible amounts in CNS myelin (Svennerholm et al. 1994).
Peripheral nerves usually consist of both motor and sensory nerve fibres. The 
ganglioside composition of the peripheral nervous system might be of great importance 
in understanding the autoimmune mechanisms in peripheral neuropathies. Ganglioside 
analysis of human motor and sensory nerves revealed that ceramide composition of 
sensory nerve GDla, GDlb, and GM1 differed apparently from those in the motor 
nerve; sensory nerve gangliosides contained a larger amount of long-chain fatty acids in
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the gangliotetraose gangliosides than motor nerve (Ogawa-Goto et al. 1990; 
Svennerholm et al. 1994). Furthermore, the predominant ganglioside in the human 
peripheral nervous system myelin, both for motor and sensory nerves is LM1 
(sialosylneolactotetraosyl ceramide) (Ogawa-Goto et al. 1992; Chiba et al. 1997). 
Sialosyl-nLc6Cer and disialosyl-nLc4Cer, GD3, GM3, and GDlb are detected as 
common components of the two nerve myelins (Ogawa-Goto et al. 1992). The same 
study showed that the content of GM1 ganglioside in the motor nerve myelin was higher 
than that in the sensory nerve myelin (Ogawa-Goto et al. 1992), in contrast with the 
results reported by Svennerholm et al. (Svennerholm et al. 1994).
Moreover, the frequent association of anti-GQlb antibodies with diseases 
characterised by ophthalmoparesis (Chiba et al. 1992; Chiba et al. 1993; Willison et al. 
1993c; Yuki et al. 1993a; Yuki 1993b; Yuki 1996a) correlates with the abundant 
expression of GQlb ganglioside in the paranodal regions of the extramedullary portions 
of all three cranial nerves involved in oculomotion (Chiba et al. 1997). Ganglioside 
composition of the human cranial nerves showed higher proportion of GQlb ganglioside 
in all three nerves (Illrd, IVth, and Vlth) that control the ocular muscles involved in the 
ocular movement as compared with the other cranial nerves (Chiba et al. 1997). This 
finding may support the role of serum anti-GQlb antibody in the pathogenic 
mechanisms of ophthalmoplegia in MFS and GBS.
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Table 2 Chemical structure o f  glycolipids o f  biological interest (Svennerholm 1994)
Glycolipid  
nom encla tu re
C arbohydrate  sequence
G M 4 N e iiA c a 2 -» 3 G a ip  1 -» C era m id e
G M 3 N eii A c a 2 - > 3 G a ip 1 —>4G lcP 1 -» C e ia m id e
G M 2 GaIN A cp  l- > 4 ( N e u A c a 2 - » 3 )  G a ip i-» C e r a m id e
GM1 G alp  1 ->  3 G a lN A cP  1 -» 4 ( N e u A c a 2 -» 3 )  G aip  1 - » 4 G lc p  1 -^ C eram id e
G M l b N e u A c a 2 - » 3 G a ip i - »  3 G a lN A c p i-» 4  G a ip i-> 4 G lc p i-> C e r a m id e
G D3 N e u A c a 2 -» 8  N e u A c a 2 -» 3 G a ip  1 -> 4 G lc p  1 -* C era m id e
G D2 GaIN A cp  1 - » 4 ( N e u A c a 2 -» 8 N e u A c a 2 - > 3 )  G aip  1 -> 4 G lc p  1 -> C eram id e
G D l a N e u A c a 2 -» 3 G a ip  1 -> 3 G a lN A c p  1 -» 4 (N e u A c c c 2 -> 3 )  G aip  1 -» 4 G lc P  1 -» C era m id e
G D l b G aip  1 -> 3 G a lN A c P  1 -» 4 ( N e u A c a 2 - » 8 N e i iA c a 2 - » 3 ) G aip  1 -> 4 G lcP  1 -» C era m id e
G T3 N eiiA ccx2 -»  8 N e u A c a 2 -»  8 N e u A c a 2 -> -3 G a ip i-> 4 G lc p i-» C e r a m id e
G T l a N e u A c a 2 —> 8 N e u A c a 2 —>3G aip 1 —»3G alN A cp  1 - » 4 ( N e u A c a 2 -> 3 ) G aip  1 —>4G lcP 1 —^ Ceram ide
G T l b N e u A c a 2 -> 3 G a ip  1 —»3G alN  A cp  I -> 4 (N e i iA c a 2 —> 8 N e u A c a 2 —>3) G aip  1 -> 4 G lc p  1 -^ C eram id e
G T l c G aip  1 -> 3 G a lN  A cp  1 - » 4 ( N e u A c a 2 -» 8 N e u A c a 2 - » 8 N e u A c a 2 - » 3 )  G aip  I —»4G lcp  1 -^ C eram id e
G Q l b N e u A c a 2 H » -8 N e iiA ca 2 -> 3 G a ip  l- » 3 G a lN A c p i -> -4 (N e iiA c a 2 - » 8 N e u A c a 2 -» 3 )  
G aip  1 -» 4 G lc P  1 -^ C eram id e
G Q l c N e u A c a 2 -» 3 G a ip  1—»3G alN A cP  1—» 4 (N e u A c a 2 -> 8 N e u A c a 2 —» 8 N e u A c a 2 -> ’3) 
Gal p I —>4G lcP 1 -^ C eram id e
Glycosyl-ceram ide G lc p i -> C eram id e
Galactosyl-ccram idc G a ip i-> C e r a m id e
Globosid e G aIN A cP 1 —» 3 G a la  1 -> 4  G alp  1 -» 4 G lc p  1 -> C eram id e
Paraglobosid e G alp  I —>4G alN A cP  1 —>3G alp 1 -h>4G1cP 1 -> C eram id e
LK1
Sulfoglucuronyl  
neolactote trao  
sylceramid e (SG PG )
3-su lfa teG lcU  A p  I -^ 3 G a ip  1 -> 4 G a lN  A cp  1 —>3Gal P 1 -» 4 G lc p  1 -^ C eram id e
Abbreviations: Gal=galactose, Glc=glucose, GalNAc=A-acetylglucosamine,
GlcNAc=A-acetylglucosamine, NeuAc=ALacetylneuraminic acid. Terms within 
brackets () represent a branching point in the molecule.
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CHAPTER TWO: PERIPHERAL NEUROPATHIES - AN OVERVIEW
1. A brief anatomic view of the peripheral nervous system
The nervous system is divided into central nervous system (CNS) and peripheral nervous 
system (PNS). The CNS includes the brain and spinal cord and the PNS consists of the 
cranial and spinal nerves and their associated ganglia. There are 12 pairs of cranial 
nerves, which leave the brain and pass through foramina in the skull, and 31 pairs of 
spinal nerves, which leave the spinal cord and pass through intervertebral foramina in 
the vertebral column. Each spinal nerve is connected to the spinal cord by the anterior 
and posterior roots, which are bundles of nerve fibres carrying nerve impulses away 
from and to the CNS, respectively. The anterior root contains efferent nerve fibres that 
go to the skeletal muscle (motor fibres) and their cells lie in the gray matter of the 
anterior horn of the spinal cord. The posterior root consists of afferent fibres that carry 
information about sensations of touch, pain, temperature, and vibration to the central 
nervous system (sensory fibres) and their cell bodies are situated in a spindle-shaped 
enlargement of the posterior root called the spinal ganglion or dorsal root ganglion 
(DRG). The spinal nerves contain a mixture of motor and sensory fibres. Similarly, 
some of the cranial nerves are composed of afferent nerve fibres (olfactory, optic, and 
vestibulo-cochlear), others are composed of efferent fibres (oculomotor, trochlear, 
abducent, accessory, and hypoglossal), and the remainder contains both afferent and 
efferent fibres (trigeminal, facial, glossopharyngeal, and vagus).
The peripheral nervous system is generally considered to begin at the nerve root or 
exit zones of the spinal cord (and at the Obesteiner-Redlich junctions for the cranial 
nerves) and to extent distally to the peripheral motor or sensory endings. Structures also 
included in the peripheral nervous system are portions of the postganglionic autonomic 
fibres that lie outside of the spinal cord and brainstem, the autonomic ganglia and the
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postganglionic fibres. Another way of describing the peripheral nervous system is that 
which is synonymous with the distribution of the Schwann cells. Nevertheless, the 
intraspinal portion of the central processes of the primary sensory neurons, the cell 
bodies of the motor neurons and the proximal portion of their axons and the 
preganglionic autonomic neurons lie within the central nervous system and therefore, are 
protected by the blood brain barrier. The dorsal root ganglia are barrier free structures. 
These anatomic facts have major implications for the distribution of disease and 
selective vulnerabilities of neural elements that make up the peripheral nervous system 
(Kahle 1986; Gardner & Bunge 1993).
2. Basic microscopic anatomic considerations of nerve fibres
Nerve fibres are surrounded by connective tissue, which is subdivided into endoneurium, 
perineurium, and epineurium. The endoneurium forms the supporting structure found 
around individual axons within each fascicle. The perineurium consists of collagenous 
tissue, which binds each fascicle with elastic fibres and mesothelial cells. This layer 
rather provides a diffusion barrier to regulate intrafascicular fluid. The epineurium, 
composed of collagen tissue, elastic fibres, and fatty tissue, tightly binds individual 
fascicles together.
The nerve trunks contain myelinated and unmyelinated fibres. All axons in the 
peripheral nervous system (PNS) and central nervous system (CNS), both myelinated 
and nonmyelinated, are surrounded by, or ensheathed in, accessory or satellite cells. In 
the PNS, these are the Schwann cells and in the CNS, the oligodendrocytes. Although 
important anatomical, biochemical, and morphological differences occur in the nerve 
fibres of the PNS and CNS, the fundamental structure of central and peripheral 
myelinated fibres, and their electrophysiological characteristics, are essentially similar.
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In the myelinated fibres of the PNS, the Schwann cell is spirally wrapped around the 
axon forming a multilayered membrane specialisation, the myelin sheath. The nodes of 
Ranvier are located at junctions between adjacent Schwann cells and represent myelin- 
free fibre segments. The internodes are the long fibre segments corresponding to the 
extension of one Schwann cell. But whereas in the PNS a single satellite cell ensheathes 
each myelinated axon between one node and the next, in peripheral non-myelinated 
nerves, many axons are ensheathed by a single Schwann cell. In myelinated fibres of the 
CNS, a single oligodentrocyte may ensheath 30-50 internodes. One consequence of this 
arrangement is that in some pathological conditions, the death of a single myelin- 
forming cell in the periphery affects only one internode, whereas in the CNS many 
internodes are destroyed (Thomas, Berthold & Ochoa 1993).
3. Composition and molecular organisation of the myelin membrane
A detailed analysis of the biochemical properties and organisation of myelin components 
is required in order to understand the immunopathogenic aspects of peripheral 
neuropathies. The biochemical composition of myelin is simple, having a high 
proportion of lipids and relatively few individual protein components.
The major protein in mature peripheral protein is the Po glycoprotein, which 
represents more than 50% of the total membrane protein. CNS lacks Po protein, which is 
truly specific for peripheral nerve myelin. Analysis of myelin membranes indicates the 
presence of two other basic proteins designated Pi and P2 which account for a further 15- 
20% of the membrane protein. However, these proteins are not specific for peripheral 
nerve because they are also expressed in the CNS. Most of the other quantitatively 
minor peripheral nerve myelin proteins, such as myelin-associated glycoprotein (MAG), 
are probably also common to both peripheral and central myelin. Po and MAG are
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members of the immunoglobulin superfamily. In comparison to Po protein, less is 
known about the functions of P| and P2 proteins in peripheral nerve myelin. The Pi 
basic protein is identical to the CNS myelin basic protein (MBP), which is the major 
CNS autoantigen responsible for inducing experimental allergic encephalomyelitis 
(EAE). EAE has been extensively investigated because of its similarities to multiple 
sclerosis. The P2 basic protein is unrelated to MBP and its function within the PNS 
myelin remains unclear. Immunocytochemical analyses have shown that P2 protein is 
concentrated within the cytoplasmic domains of the PNS myelin sheath rather than in 
compact internodal myelin and P2 basic protein is believed to play a metabolic rather 
than structural role in peripheral nerve myelin. Of the remaining proteins MAG, present 
in both PNS and CNS myelin, is a highly glycosylated transmembrane glycoprotein 
concentrated in the periaxonal and outer regions of the peripheral nerve myelin sheath.
In addition to the proteins discussed so far, PNS myelin contains a number of other 
minor proteins, which may be highly specific for the PNS and may be considered as 
potential antigen targets in autoimmune peripheral neuropathies. On the other hand, the 
importance of PNS myelin lipids and in particular glycolipids as autoantigenic targets in 
human autoimmune neuropathies has been extensively recognised. The major myelin 
lipids are cholesterol, ethanolamine glycerophosphatide, sphingomyelin, and 
galactocelebroside. Ethanolamine plasmalogens, serine choline glycerophosphatides, 
and sulfatide are also present in smaller amounts. More importantly PNS myelin 
contains several different gangliosides that have been implicated in the pathogenesis of 
GBS and antibody-mediated polyneuropathy. The extracellular display of the sialyated 
oligosaccharide core of gangliosides makes them potential target antigens for pathogenic 
autoantibodies in neurological diseases (Brostoff et al. 1972; Trapp, McIntyre & Quarles 
1979; Norton & Cammer 1984; Schwartz 1991; Thomas et al. 1993).
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4. Physiology of nerve conduction
Ion channels are an important class of membrane glycoproteins that govern the flow of 
ions across the membranes (Siegelbaum & Koester 2000). In nerve fibres they control 
the rapid changes that occur in the generation of membrane action potentials. Channels 
can be distinguished from each other on the basis of their ion selectivity and the factors 
that determine their opening and closing, or gating. Various ion blockers, toxins and 
drugs can influence the activity of ion channels. Also, ion channels are important targets 
in various diseases. Myasthenia gravis, Lambert-Eaton syndrome and acquired 
neuromyotonia are thought to be autoimmune neurological disorders resulting from the 
actions of specific antibodies against ion channels (Vincent, Lily & Palace 1999). With 
the increasing understanding and detailed knowledge of ion channel function it seems 
likely that other diseases due to channel dysfunction will be identified and new 
pharmacological therapies will be developed.
Nerve cells are capable of self-generation of electrochemical impulses at their 
membranes and they can transmit signals along the membranes, so they are “excitable'5 
cells. The membrane potential of large nerve fibres when they are not transmitting nerve 
signals is about -90  millivolts (mV). That means, the potential inside the fibre is 90 mV 
more negative that the potential in the interstitial fluid on the outside of the fibre. This 
potential is due to the sodium-potassium pump which actively transports sodium to the 
outside of the fibre and potassium to the inside (three Na+ ions to the outside for each 
two K+ ions to the inside causing the negative charge inside the cell membrane). The 
sodium-potassium pump also causes the different concentration gradients for sodium 
and potassium across the resting nerve membrane. The contribution of the potassium 
and sodium diffusion through the nerve membrane and the continuous pumping by the
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electrogenic Na+ - K+ pump are the most important factors that give the normal resting 
membrane potential of -90  mV.
Nerve signals are transmitted by rapid changes in the membrane potential, which are 
called action potentials. At the time of depolarization stage, the opening of sodium 
channels makes membrane very permeable to sodium ions, allowing tremendous 
numbers of sodium ions to flow to the interior of the axon causing the potential to rise 
rapidly from -90  mV in the positive direction. The depolarization process travels along 
the entire extent of the nerve fibre and the transmission of depolarization gives rise to a 
nerve impulse. The increase Na+ influx into the cell produces the rising phase of the 
action potential. The falling phase of the action potential is caused by the subsequent 
closing of the Na+ channels, which reduces the Na+ influx into the cell, and by the 
opening of voltage gated K+ channels, which allows increased K+ efflux from the cell. 
This rapid diffusion of potassium ions to the exterior re-establishes the normal negative 
resting potential and the membrane is repolarized. Voltage-gated channels are opened 
when the membrane potential is near the action potential threshold. They open in an all- 
or-none fashion, and when open, they permit a pulse of current to flow with a variable 
duration but constant amplitude. At the juncture between each two successive Schwann 
cells along the axon, i.e. the area of the node of Ranvier, ions can still flow easily 
between the extracellular fluid and the nerve membrane, while along the myelin sheath 
the ions flow is considerably decreased. Thus, action potentials can occur only at the 
nodes of Ranvier.
In myelinated axons the action potential is conducted from node to node (saltatory 
conduction) instead of continuous propagation that occurs in ummyelinated fibres. In 
other words, electrical current flows through the surrounding extracellular fluid and 
through the axoplasm from node to node, exciting successive nodes one after another
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and the nerve impulse jumps down the fibre. Saltatory conduction is of important value 
for myelinated nerve fibres, because this mechanism increases the conduction velocity of 
nerve impulse transmission and conserves energy for the axon (Guyton 1991; Ganong
1993).
Intemodal capacitance and conductance decrease with increasing myelin thickness 
and myelinated fibres fulfil all the conditions required for maximal conduction velocity. 
The demyelinated or remyelinated fibres have an increased capacitance and conductance 
due to thinner myelin sheaths; so, more local current is lost to charge the capacitors and 
by leakage through the internodal membrane, and the demyelinated axons 
characteristically have conduction failure, decrease velocity, and temporal dispersion. 
The impairment of nerve conduction by demyelination is considerable. In humans, 
myelinated sensory fibres conduct up to a maximum of 87m/sec, and motor axons 
conduct between 5 and 10% slower. In contrast, in mammalian unmyelinated axons, the 
conduction velocity of the nerve impulses is of the order of lm/sec; it varies in 
proportion to the square root of the fibre diameter (Koester 1991; Thomas et al. 1993).
5. Properties of multifibre nerve trunks - The compound nerve action potential
Because of the practical difficulty of isolating single mammalian fibres, most of the 
electrical data on such fibres come from studies of the extracellularly recorded 
compound nerve action potential, resulting from simultaneous activation of all or some 
of the population of fibres comprising the nerve tract. The compound nerve action 
potential is merely the algebraic sum of individual fibres action potentials. With 
subthreshold stimuli, none of the nerve fibres are stimulated and no response occurs. 
When the stimuli are of threshold intensity, axons with low thresholds depolarise. As 
the intensity of the stimuli is increased, the axons with higher threshold fire and the
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electrical response increases proportionately until the stimulus is strong enough to excite 
all the fibres of the nerve. The stimulus that results in excitation of all axons is the 
maximal stimulus, and further application of greater supramaximal stimuli produces no 
further increase in the size of the obtained action potential.
Mammalian nerve fibres are divided into three groups: A, B, and C; the A group is 
further subdivided into a , P, y, and 8 fibres. The A and B fibres are all myelinated, 
whereas the C fibres are unmyelinated. Because of the relations between conduction 
velocity, diameter, and threshold the A fibres are the largest and also have the lowest 
threshold. The B fibres cannot be distinguished from small A fibres either histologically 
or in terms of conduction velocity because both groups have similar diameters. C fibres 
can be easily distinguished from either A and B fibres because they are all unmyelinated 
and of small diameter and hence of very slow conduction velocity. In the following 
Table 3, the various fibre types are listed with their functions, diameters and conduction 
velocities (Ganong 1993).
Table 3 Nerve fibre types in mammalian nerve
F ib r e  ty p e F u n ctio n F ib r e  D ia m e te r  (p m ) C o n d u c t io n  V e lo c ity  (m /s)
A a Proprioception: so m a tic  m otor 12-20 7 0 -1 2 0
P T ou ch , pressure 5 -1 2 3 0 -7 0
Y M otor to m u sc le  sp in d les 3-6 15-30
8 Pain, co ld , touch 2-5 12-30
B P regan glion ic  au ton om ic <3 3-1 5
C D o rsa l r o o t Pain, tem perature, som e  
m ech an orecep tors. re Ilex 
resp on ses
0 .4 -1 .2 0 .5 -2
S y m p a th e t ic P o stg a n g lio n ic  sym p ath etics 0 .3 -1 .3 0 .7 -2 .3
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6. Neuropathological aspects
It is important in the study of a peripheral neuropathy to recognise the underlying 
pathological nature of the condition because it influences subsequent management. In 
general, there are three basic pathological processes by which peripheral nerve fibres are 
affected:
-Wallerian degeneration 
-segmental demyelination, and 
-axonal degeneration
6a. Wallerian degeneration
This is the response when nerve axons are interrupted. Motor and sensory loss in the 
distribution of the transected fibres occurs immediately, the axon and the myelin 
disintegrate distally to the site of transection, conduction fails, and recovery is slow and 
incomplete. Denervation atrophy occurs in muscles to which the motor nerve fibres 
have been interrupted. Although Wallerian degeneration is usually caused by physical 
or mechanical injury of nerve fibres, nerve trunk ischaemia can produce focal axonal 
damage and distal Wallerian degeneration stems from widespread pathological processes 
affecting small vessels and capillaries of the size of vasa nervorum. Multifocal nerve 
trunk ischaemia in systemic vasculitis, is a frequent basis for multiple mononeuropathy 
(mononeuropathy multiplex) encountered clinically (Bosch & Mitsumoto 1991; Asbury
1994).
6b. Segmental demyelination
This pathological process implies breakdown of myelin sheath or the myelin-producing 
Schwann cells with preservation of axonal continuity. Conduction block is the hallmark
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of segmental demyelination. In practice this occurs most commonly in immune 
mediated inflammatory demyelinating neuropathies and rarely in hereditary disorders of 
Schwann cell myelin metabolism. Myelin damage can be produced experimentally by 
myelinotoxic agents such as diphtheria toxin and chronic lead intoxication. The 
physiological expression of segmental demyelination is conduction block, resulting in 
the clinical deficits of motor weakness and sensory loss. Block can occur with a lesion 
restricted to a single node of Ranvier. This is because sodium channels are highly 
concentrated at the axon membrane at the nodes of Ranvier, whereas the membrane of 
the intemodal regions contains potassium channels that stabilise the membrane potential, 
thus reducing excitability. Nerve conduction studies can provide confirmation of 
demyelination. As a rule, demyelination is likely when conduction velocities of motor 
and sensory nerves are reduced to less than 70% of normal. Other electrodiagnostic 
features of demyelinating polyneuropathies are temporal dispersion and 
desynchronization of compound evoked potentials and prolonged distal latencies and 
late responses.
In current clinical practice, conduction block is usually accepted when the amplitude 
or the area of an evoked action potential, recorded through surface electrodes, is reduced 
with proximal stimulation, compared with the response to distal stimulation and in the 
absence of temporal dispersion. The extent of the reduction has been put at 20% to 60% 
in published papers. Several articles have emphasised the problems caused by temporal 
dispersion, which not only can lead to prolongation of the evoked action potential, but 
can also cause cancellation of the negative phase of one motor unit action potential by 
the positive phase of another, as a result of desynchronization. This can reduce the 
amplitude or the area of the compound muscle action potential, which can be 
misinterpreted as evidence of conduction block. Temporal dispersion and phase
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cancellation must be excluded as a cause of reduction. Conduction block is not found in 
axonal disorders or primary lesions of nerve cell bodies. Recovery from segmental 
demyelination can be rapid and dramatic, because all that is required is remyelination of 
those sites that are demyelinated and blocked (Lafontaine et al. 1982; Cornblath et al. 
1991; Bosch & Mitsumoto 1991; Parry & Sumner 1992; Oh, Kim & Kuruoglu 1994).
6c. Axonal degeneration
This pathological process involves distal axonal breakdown, resembling Wallerian 
degeneration, presumably due to metabolic derangement within the neurons. The myelin 
sheath breaks down concomitantly with the axon in a pattern that starts at the most distal 
part of the nerve and progresses towards to the cell body, hence the term dying-back 
neuropathy. The distinction between Wallerian degeneration and axonal degeneration 
may not always be evident, even histologically, but the processes are quite different. 
Wallerian degeneration implies transection of otherwise healthy nerve fibres, but axonal 
degeneration results from systemic metabolic disorders and toxins. Electrodiagnostic 
features of axonal degeneration are striking decreases in the amplitudes of nerve and 
muscle compound action potentials with minor degrees of slowing of conduction 
velocity. When explored by electromyography, the distal muscles show acute or chronic 
changes of denervation. Recovery from axonal degeneration may be delayed and often 
incomplete (Bosch & Mitsumoto 1991; Asbury 1994).
7. Clinical symptoms and signs in peripheral neuropathies
Peripheral neuropathy is defined as the condition in which there is deranged function 
and structure of peripheral motor, sensory, and autonomic neurons. The numerous and 
varied neuropathic symptoms and signs are usually a mixture of sensory, motor and
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autonomic disturbances. Damage to motor nerve fibres either by demyelination or 
axonal degeneration causes weakness of the affected muscles. Muscle cramps, 
fasciculations and muscle atrophy are all manifestations of motor neuron dysfunction. 
Tendon reflexes are reduced due to the muscle weakness, and may disappear completely 
if there is co-existing damage to the large sensory group la axons from muscle spindles. 
Sensory disturbances can be categorised as those resulting from the involvement of 
small or large sensory fibres. They frequently co-exist. Among the many varied 
positive sensory symptoms affecting the small sensory fibres are those of burning 
dysesthesias and paresthesias, usually painful. Hypoesthesia to pin prick and thermal 
stimuli is another frequent finding on sensory examination. The prominent sign of large 
fibre neuropathy is sensory ataxia. On examination, reduced vibration and position 
sense are present, together with areflexia and disturbances in balance particularly in the 
dark or with eyes closed (positive Romberg's test). Autonomic dysfunction may present 
with a variety of symptoms and signs (hypotension, anhidrosis or hyperhidrosis, 
hypothermia, cardiac dysrythmias etc.) and is characteristically associated with Guillain- 
Barre syndrome, amyloidosis, diabetes, porphyria, and certain familiar sensory and 
autonomic neuropathies (Bosch & Mitsumoto 1991; Thomas & Ochoa 1993).
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CHAPTER THREE: NEUROPATHIES ASSOCIATED WITH ANTI-
GLYCOCONJUGATE ANTIBODIES
Introduction
It is well established that the majority of peripheral nerve myelin proteins are 
immunogenic, and antibodies specific for MAG, MBP, Po, and P2 have been extensively 
studied. Demyelinating activity has been observed after animal immunisation with 
peripheral nerve tissue or myelin and this activity implies either immunoglobulin or cell 
mediated immune attack following recognition of antigenic determinants exposed on the 
outer surface of the myelin sheath (Saida et al. 1978; Hahn, Gilbert & Feasby 1980). In 
the rabbit the major target antigen for the demyelinating antibody response is the major 
myelin glycolipid galactocylceramide (GC). Sera from patients with GBS also contain 
reactive autoantibodies that recognise peripheral nerve glycolipids (Ilyas et al. 1988). 
These antibodies can initiate demyelination, either in vivo after intraneural injection 
(Harrison et al. 1984), or in vitro in myelinating cultures o f peripheral nerve (Koski 
1990). These antibodies recognise a number of different carbohydrate epitopes on 
myelin glycolipids (Quarles, Ilyas & Willison 1984).
Gangliosides are important carbohydrate determinants for autoimmune activity and 
many forms of peripheral neuropathy with a suspected autoimmune basis are associated 
with serum antibodies against gangliosides. Multifocal motor neuropathy (MMN) and 
Guillain-Barre syndrome including its variant Miller Fisher syndrome (MFS) are two 
characteristic examples of antiganglioside antibodies associated syndromes. MMN and 
motor forms of Guillain-Barre syndrome are associated with anti-GMl IgM and IgG 
antibodies respectively; ataxic neuropathies (including the CANOMAD phenotype - 
chronic ataxic neuropathy, ophthalmoplegia, monoclonal IgM protein, cold agglutinins
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and disialosyl antibodies (Willison et al. 1996)), and Miller Fisher syndrome are 
associated with anti-GQlb IgM and IgG antibodies respectively.
1. Neuropathies associated with paraproteinemia
The association between monoclonal gammopathy and peripheral neuropathy is now 
well recognised (Kelly 1985; Kyle & Dyck 1993; Nobile-Orazio et al. 1994; Latov 1995; 
van den Berg et al. 1996; Ropper & Gorson 1998). Some common disorders of the 
peripheral nervous system are closely connected with the presence of excessive amounts 
of an abnormal immunoglobulin in the blood. These peripheral neuropathies are termed 
paraproteinemic neuropathies and electrophoresis or the more sensitive immunofixation 
test can detect the abnormal paraprotein (Kyle 1992; Kyle & Dyck 1993).
Approximately 10% of patients with idiopathic peripheral polyneuropathy are of this 
type and the anomalous blood immunoglobulins are usually monoclonal (termed M 
protein or M spike) as they are the product of a single clone of plasma cells (Latov
1995). If such a paraprotein is identified in the serum or the urine of a patient with 
neuropathy, haematological studies, including bone marrow aspiration, skeletal survey 
and bone scan, and appropriate tissue biopsies may be done to determine whether the 
monoclonal gammopathy is associated with an underlying lymphoproliferative disorder. 
The main diseases that may be considered are primary amyloidosis, multiple myeloma, 
osteosclerotic myeloma, Waldestrom's macroglobulinemia, cryoglobulinemia, non- 
Hodgkin's lymphoma, Castleman's disease and related lymphatic diseases, and chronic 
leukaemias (Kyle & Dyck 1993; Latov 1995; Ropper & Gorson 1998). Frequently, none 
of these are found and the patient is considered as having a monoclonal gammopathy of 
undetermined significance (MGUS), and the associated neuropathy is labelled MGUS 
neuropathy (Kyle & Dyck 1993; Latov 1995; Chalk 1997).
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Neuropathies associated with IgM M-proteins are distinguished from those with IgG 
or IgA M-proteins because of evidence for the pathogenicity of IgM M-proteins. IgG or 
IgA monoclonal gammopathies are associated with neuropathy in patients with 
osteosclerotic myeloma or the POEMS syndrome (polyneuropathy, organomegaly, 
endocrinopathy, monoclonal protein, and skin changes). The neuropathy in 
Waldestrom's macroglobulinemia is similar to MGUS IgM neuropathy. Amyloid or 
cryoglobulinemia neuropathies can occur with IgM, IgG or IgA M-protein. In some 
patients with non-malignant IgG or IgA monoclonal gammopathy malignant disease may 
develop, mostly myeloma, after some years. In the majority of patients the IgM M- 
protein shows autoantibody activity that reacts with oligosaccharide determinants of 
glycolipids and glycoproteins in peripheral nerve (Kyle & Dyck 1993). The incidence of 
this type of neuropathy is estimated to be between 1 to 5 per 10000 adult population. 
Patients typically present with a slowly progressive distal and symmetrical sensory or 
sensorimotor neuropathy that usually affects the anus and then the legs. Cranial nerves 
and autonomic function are normal. Many patients have a predominantly sensory 
neuropathy. A few patients may present with a mainly motor neuropathy characterised 
by rapid progression with profound weakness. The examination of cerebrospinal fluid 
(CSF) usually shows increased protein concentration (Kyle & Dyck 1993).
Myelin-associated glycoprotein (MAG) is a minor protein (glycoconjugate) 
component of nerve and is central to understanding the paraproteinemic neuropathies. 
In 1980, Latov et al. reported a patient with severe demyelinating neuropathy and high 
levels of monoclonal IgM kappa immunoglobulin that bound to peripheral nerve myelin. 
Immunosuppressive therapy resulted in clinical improvement and significant reduction 
of circulating monoclonal antibodies (Latov et al. 1980). The constituent to which the 
IgM immunoglobulin bound was later shown to be MAG, a specific glycoprotein
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component of myelin (Braun et al. 1982). Soon after, in patients with paraproteinemia 
and peripheral neuropathy it was observed that the IgM that bound to MAG might also 
bind to gangliosides (Ilyas et al. 1984) and that monoclonal IgM kappa from a patient 
with a long-standing progressive sensory polyneuropathy bound to polysialosyl 
gangliosides but did not react to MAG (Ilyas et al. 1985).
One year later, Freddo et al. reported a patient with an IgM lambda dysproteinemia 
and a progressive weakness of all four extremities, normal sensation and absent reflexes 
diagnosed as lower motor neuron disease; the monoclonal immunoglobulin from this 
patient bound avidly to GM1 and GDlb and asialo-GMl gangliosides (Freddo et al. 
1986). Since then, many more patients have been identified (Willison et al. 1993b; 
Brindel et al. 1994; Herron et al. 1994; Oka et al. 1996). Thus the question was raised 
that gangliosides might be potential autoantigens or could act as tissue specific binding 
sites for monoclonal proteins.
MAG is concentrated in periaxonal Schwann-cell membranes and paranodal loops of 
myelin and acts as an adhesion molecule for interactions between the Schwann cells and 
the axons. Its unique structure consists of five immunoglobulin-like domains and a 
carbohydrate epitope. In approximately one-half of patients with IgM M-protein and 
neuropathy, the M-protein binds to a carbohydrate determinant that is shared by the 
proteins myelin-associated-glycoprotein (MAG), the main Po glycoprotein of myelin and 
peripheral myelin protein-22 (PMP-22), and several complex glycosphingolipids (Braun 
et al. 1982; Burger et al. 1990; Pestronk et al. 1994a; van den Berg et al. 1996). Of these 
complex glycosphingolipids the best characterised are sulfoglucuronylparagloboside 
(SGPG) and sulfoglucuronyl lactosaminyl paragloboside (SGLPG), which are present in 
both myelin and axon in peripheral nerve (Yu et al. 1990). The same determinant is also
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recognised by the mouse monoclonal antibody HNK-1, which shows a higher affinity 
compared with most of the human antibodies (Burger et al. 1990).
The majority of patients with anti-MAG IgM activity have a slowly progressive, 
predominantly sensory, demyelinating neuropathy, whereas patients with unknown IgM 
reactivity do not have an homogeneous pattern of neuropathy, suggesting that variable 
pathogenic mechanisms may implicated in the later group (Nobile-Orazio et al. 1994). 
Recent studies suggest that the neuropathy associated with anti-MAG and anti-SGPG 
antibodies are more heterogeneous than was previously thought, and that although most 
of these antibodies react with both MAG and SGPG, some may react with MAG or 
SGPG alone (van den Berg et al. 1996).
The relationship between anti-MAG autoantibodies and neuropathy is generally 
accepted (Griffin 1994; Latov 1994; van den Berg et al. 1996), but the precise role of the 
monoclonal protein in the immunopathogenesis of the neuropathy remains to be 
elucidated (Wolfe et al. 1997). Electrophysiological studies show demyelinating 
features with slowed nerve conduction velocities and prolonged distal latencies (Kelly 
1990). Pathological studies of biopsed nerves in patients with high titres of anti-MAG 
antibodies display pronounced demyelination, loss of myelinated fibres, widening of the 
myelin lamellae, and deposits of IgM and complement on the myelin sheaths (Trojaborg 
et al. 1995). Abnonnal widening of myelin lamellae is almost pathognomonic for 
patients with anti-MAG antibodies (Vital et al. 1989; Steck & Kappos 1994). Passive 
transfer of patients’ serum intraneurally into cats’ median and ulnar nerves (Willison et 
al. 1988) and sciatic nerve (Hays et al. 1987; Trojaborg et al. 1989) induces 
demyelination. Immunofluorescence studies demonstrated deposition of the injected M- 
protein on the surface of the myelin sheath, implying that the M-protein showed 
reactivity with epitopes of myelin (Hays et al. 1987).
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The experimental study by Tatum showed the capacity of IgM anti-MAG antibodies 
to produce demyelination and the characteristic wide-spacing of myelin in chickens and 
proved that this type of neuropathy is an antibody-mediated disease (Tatum 1993). In 
all these instances the case for pathogenic activity of IgM antibodies directed against 
MAG and other glycosphingolipids including gangliosides is better recognised than for 
other antigens and for IgG and IgA antibodies (Ropper & Gorson 1998). Despite the 
debate about the precise pathogenic role of the paraprotein, therapeutic reduction of 
antibody titres is associated with clinical improvement (Latov 1995; Notermans 1996; 
van den Berg et al. 1996; Chalk 1997).
2. Monoclonal gammopathy of undetermined significance
Two thirds of patients with paraproteinemic neuropathy have what has been termed 
"monoclonal gammopathy of undetermined significance". MGUS was once considered 
benign, but it is now known that a number of patients (approximately 20%) will develop 
in time a malignant plasma-cell disorder, usually multiple myeloma (Kyle 1992; Kyle & 
Dyck 1993; Ropper & Gorson 1998). Epidemiological evidence suggest that the 
prevalence of MGUS is higher in patients with idiopathic neuropathy than in those with 
an identifiable cause of the neuropathy and the incidence of neuropathy is higher in 
patients with monoclonal gammopathy than in the general population (Notermans 1996).
These polyneuropathies affect usually but not exclusively, men over 50 years of age. 
The symptomatology in patients includes foot numbness, paresthesias, imbalance, and 
gait ataxia that progress over a period of months. Large diameter sensory fibres are most 
affected (joint position, vibration, and touch). Weakness of the distal muscles of the 
legs with atrophy occurs as the disease advances. Only a small minority of the patients 
has a pure motor disorder resembling motor neuron disease. Neuropathy associated with
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MGUS is typically a predominantly demyelinating disorder or mixed with findings of 
demyelination and axonal loss, but a pure axonal type of neuropathy with distinct 
clinical and electrophysiological features has been described (Gorson & Ropper 1997). 
Although IgG is the most common class of paraprotein in patients with MGUS, in those 
with neuropathy the most frequent type of immunoglobulin is IgM (60 percent), 
followed by IgG (30 percent) and IgA (10 percent) (Ropper & Gorson 1998). Finally, 
anti-GMl antibody levels are rarely raised in MGUS and probably play a minor or no 
role in the pathogenesis of these conditions (Finsterer et al. 1996).
3. Guillain-Barre syndrome and autoimmunity
The importance of antiglycolipid antibodies in the pathogenesis of GBS and other 
diseases of the peripheral nervous system with suspected autoimmune basis is indicated 
by the fact that they have been a field of intensive study over the past years (Ilyas et al. 
1988; McFarlin 1990; Yu et al. 1990; Pestronk 1991; Ropper 1992; Griffin 1994; Latov 
1994; Komberg & Pestronk 1995; Rees et al. 1995b; Baumann et al. 1998; Fredman 
1998; Hahn 1998). In particular, many forms of peripheral neuropathy are associated 
with increased levels of activated T cells in the peripheral blood, have circulating 
antimyelin autoantibodies, and respond well, in some cases, to plasma exchange or 
intravenous immunoglobulin infusions (Dalakas 1995). However, the aetiology of these 
diseases remains obscure, and although prodromal infections have been reported to play 
an important role, other factors such as vaccination or surgery are also reported to trigger 
some of these diseases (Amason & Soliven 1993). To date, there is increasing evidence 
that antimyelin autoantibody activity may be involved in their pathogenesis. The 
presence of demyelinating autoantibodies that recognise peripheral nerve myelin 
glycolipids has been demonstrated in sera of patients with GBS. In some cases a
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decrease in autoantibody titre correlates with the patient’s clinical improvement, 
suggesting that the antibody is possibly involved in the pathogenesis of the disease (Ilyas 
et al. 1988).
So far, experimental and clinical studies of the inflammatory demyelinating 
neuropathies demonstrate that very different pathogenic mechanisms may be responsible 
for the initiation of the autoimmune attack to the nerve. Experimental animal models 
emphasise the role of the T cell response, whereas clinical studies also indicate the 
involvement of antimyelin autoantibodies. For antibody-mediated demyelination, the 
target epitopes of the myelin membrane must be accessible to the circulating antibodies 
and other substances and the blood nerve barrier must be disrupted. Once these minimal 
requirements are met, the demyelination will be mediated by antibody-induced 
activation of complement or by an antibody-dependent cell-mediated cytotoxic response. 
In contrast, in the case of T cell-mediated disease the endoneurial presence of antigen- 
presenting molecules is required. Since endoneurial inflammation is the hallmark of 
AIDP, demyelination might be the consequence of the inflammatory mediators secreted 
by activated macrophages or of direct cytotoxicity by T cells (Arnason & Soliven 1993; 
Hughes et al. 1999). The association of GBS with prodromal infections may suggest 
that a pathogen may be involved in the initiation of an autoimmune response, but further 
detailed studies of the immune response in human peripheral neuropathies are necessary 
to clarify the understanding in these diseases.
An autoimmune pathogenesis for GBS was first suggested after the demonstration that 
rabbits immunised with peripheral nerve tissue develop an inflammatory demyelinating 
disease of the peripheral nervous system, experimental allergic neuritis (EAN) 
(Waksman & Adams 1955). This experimental disease (EAN) is considered the in vivo 
model of GBS, with similar clinical features and inflammatory lesions. EAN appears to
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be predominantly cell-mediated and can be induced by lymphocytes from sensitised 
animals but not by serum; autoreactive T cells that recognise specific peripheral nerve 
myelin proteins are responsible for the inflammatory demyelinating pathology in EAN 
(Waksman & Adams 1955). However, whether such an autoreactive T cell plays an 
active role in the pathogenesis of GBS is still unclear.
Indeed, there is increasing evidence implicating antimyelin autoantibody activity in 
the pathogenesis of GBS. GBS is considered an acute immune-mediated peripheral 
neuropathy in which an immune response following an infection is directed against 
components of peripheral nerve. The presence of demyelinating autoantibodies has been 
demonstrated in the sera of patients with GBS. Autoantibody responses against 
peripheral nerve myelin glycolipids are also involved in the pathogenesis of certain 
neuropathies associated with IgM gammopathies. An antibody mediated animal model 
o f EAN can also be induced in rabbits by immunisation with galactocerebroside, the 
major myelin glycolipid (Saida, Saida & Dorfman 1979). EAN can be induced in the 
Lewis rat by immunisation with peripheral nerve homogenate, bovine peripheral nerve 
myelin, myelin basic proteins Po and P2 , and neutrogenic peptides (synthetic peptides 
derived from P2) (Hartung, Stoll & Toyka 1993).
Campylobacter jejuni infection has been recognised as a frequent prodromal event in 
GBS and is associated with the generation of serum antibodies to gangliosides that can 
bind to specific gangliosides epitopes in peripheral nerves and cross-react with 
carbohydrate antigens in bacterial polysaccharides (Latov 1994; Oomes et al. 1995; van 
der Meche & van Doom 1995; Yuki 1997; Sheikh et al. 1998a; Sheikh et al. 1998b). 
Both the demyelinating form and the recently identified axonal GBS can follow 
Campylobacter jejuni infection frequently associated with demonstrable anti-ganglioside 
antibodies (Hahn 1998). However, the in vivo model of GBS (EAN) cannot be induced
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in the Lewis rats by Campylobacter jejuni, also, immunisation with gangliosides does 
not produce EAN in the Lewis rats, and the addition of gangliosides to the immunogen 
does not alter this experimental disease (Ponzin et al. 1991).
In other species, immunisation with gangliosides has been more successful. Rabbits 
immunised with GM1 developed electrophysiological conduction block and Gal(bl- 
3)GalNAc deposition at the nodes of Ranvier in the sciatic nerve but not clinical 
symptoms (Thomas et al. 1991), while rabbits immunised repeatedly with GDlb 
ganglioside developed a sensory ataxia with loss of dorsal root ganglion cells (Kusunoki 
et al. 1996b). One of 8 rabbits immunised with Campylobacter jejuni isolated from a 
Chinese patient with the acute motor axonal neuropathy (AMAN) form of GBS 
developed axonal neuropathy. Feeding the same Campylobacter jejuni isolate to 
chickens led to paralysis in 33 of 100 chickens. In the same study sciatic nerve histology 
showed Wallerian degeneration and only occasional paranodal demyelination. Also, 
several fibres had intra-axonal macrophages (Li et al. 1996). The pathologic changes 
were similar to AMAN in humans and this study represents the most direct animal 
model of GBS following Campylobacter jejuni infection, although it needs to be 
investigated more extensively.
4. The anti-ganglioside antibody in lower motor neuron syndromes 
4a. History and clinical observations
Increased titres of antiganglioside antibodies reacting with GM1, GDlb, and asialo-GMl 
ganglioside were first reported in a patient with a lower motor neuron syndrome without 
conduction block, but with a serum IgM monoclonal gammopathy (Freddo et al. 1986). 
In this report the association of the motor neuropathy with an autoantibody directed
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against a neural antigen suggested that the disease may be immune mediated and that 
patients with IgM M protein and motor syndrome may form a distinct clinical syndrome.
Two years later Pestronk et al. described two patients with multifocal conduction 
block in motor but not in sensory fibres and high titres of anti-GMl anti-ganglioside 
antibodies (Pestronk et al. 1988b). The initial diagnosis was a lower motor neuron form 
of amyotrophic lateral sclerosis. Both patients had progressive asymmetrical weakness 
in the hands with fasciculations. Upper motor neuron or bulbar signs were absent. 
Sensory examination was normal. The patients did not show improvement with 
corticosteroid treatment and the titres of the antibodies remained high during this 
treatment. However they showed significant improvement and the antibody titre was 
reduced after treatment with cyclophosphamide. This report underscored the fact that 
some patients diagnosed as having lower motor neuron forms of amyotrophic lateral 
sclerosis may have had a motor neuropathy with serum antibodies to GM1 ganglioside, 
which is immune mediated and treatable (Pestronk et al. 1988b).
In fact, in the past, numerous cases of pure motor syndromes without signs of upper 
motor neuron involvement or types of focal weakness and atrophy such as monomelic 
amyotrophy that occasionally persisted for decades, were usually considered variants of 
amyotrophic lateral sclerosis (Parry & Clarke 1988; Pestronk et al. 1988b; Kaji et al. 
1992; Kornberg & Pestronk 1995; Parry 1996). These studies described the cardinal 
features of this condition: insidious onset, male preponderance, asymmetrical wasting 
and weakness usually confined to the upper limbs, slow progression of the disease and 
lack of involvement of the cranial nerves, cerebellum, brainstem, or sensory system 
suggesting that the focus of the disease was on cell bodies in the ventral horn (Riggs, 
Schochet & Gutmann 1984; Gourie-Devi, Suresh & Shankar 1984).
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Since the first full description of this disease subsequent studies appeared, reporting 
patients with increased titres of monoclonal or polyclonal IgM anti-GMl antibodies and 
motor neuropathy or motor neuron disease syndromes (Pestronk et al. 1988a; Pestronk et 
al. 1990; Santoro et al. 1990; Sadiq et al. 1990; Krarup et al. 1990; Lange et al. 1992; 
Kaji et al. 1992; Adams et al. 1993; Kinsella et al. 1994; Chaudhry et al. 1994; Pestronk 
et al. 1994b). Nerve conduction studies in these patients showed blockade of nerve 
impulses along the course of motor fibres suggested that the motor axon in peripheral 
nerve, rather than the cell body in spinal cord is the primary focus of the disease. These 
reports suggest that either conduction block or serum antibodies to GM1 ganglioside 
could be useful markers in the diagnosis and management of lower motor neuron 
syndromes (Pestronk et al. 1988a; Pestronk et al. 1990; Sadiq et al. 1990; Kinsella et al. 
1994; Komberg & Pestronk 1994).
Patients with immune-mediated motor neuropathies typically have slow progressive 
weakness with muscular atrophy. The weakness is frequently asymmetric and involves 
the arms more than the legs; more often it begins distally and its distribution is usually 
multifocal, localised within the territory of the individual peripheral nerves. With long- 
existing disease, muscle atrophy becomes more generalised and symmetrical with axonal 
loss. Deep tendon reflexes are often preserved in the affected areas in the early phase 
but they reduce with the course of the disease. Fasciculations and cramps may be 
present in the disease, and also bulbar signs may occasionally be present. The average 
age of onset is in the fifth decade with a range of 20 to 70 years. The symptoms of the 
patients may progress slowly for periods of up to 20 years. Conduction studies 
frequently show one or more areas with conduction block in motor nerves, although 
sometimes motor conduction could be normal. Sensory signs or abnormal sensory 
conduction are typically absent and cerebrospinal fluid protein is usually normal. At
present the suggested diagnostic criteria for this newly recognised clinical entity 
(multifocal motor neuropathy) include progressive lower motor neuron weakness, 
multifocal motor demyelination with motor conduction block and normal sensory 
responses on electrodiagnostic testing. The asymmetry of the weakness and the loss of 
tendon reflexes with relatively strong muscles are two useful clinical features. The 
presence of elevated antiglycolipid antibodies is not an essential criterion for the 
diagnosis of the disease, although they are present in approximately 50 - 70% of patients 
with the clinical and electrophysiological picture of MMN (Pestronk et al. 1990; 
Kinsella et al. 1994; Chaudhry et al. 1994; Parry 1996; Griffin et al. 1996a; Pestronk et 
al. 1997; Wolfe et al. 1997). In patients where the electrodiagnosis and clinical 
evaluation are inconclusive, a high anti-GMl antibody titre may be useful in supporting 
the diagnosis of MMN. Security of diagnosis is an important issue because patients with 
MMN can improve remarkably to intravenous immunoglobulin administration as a first 
line of treatment, or alternatively to cyclophoshamide, whereas MMN does not respond 
to plasmapheresis or corticosteroids (Pestronk et al. 1989; Nobile-Orazio et al. 1993; 
Azulay et al. 1994; van der Meche & van Doom 1997; Dalakas 1999).
MMN was previously not distinguished from chronic inflammatory demyelinating 
polyradiculopathy (CIDP) (Lewis et al. 1982; Parry & Clarke 1988; Kaji et al. 1992). 
There is still some controversy as to whether MMN and CIDP represent distinct or 
overlapping disorders (Lewis et al. 1982). However clinical, electrophysiological, and 
immunological data suggest that the differences between these two diseases are more 
prominent than the similarities. In CIDP proximal symmetrical weakness, the remitting- 
relapsing course of the disease, sensory symptoms, and increased protein concentration 
in the majority of patients distinguish this clinical entity from MMN (Pestronk 1991; 
Lange et al. 1992; Griffin 1994; Kinsella et al. 1994; Kaji et al. 1994; Chaudhry et al.
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1994; Taylor et al. 1996; Parry 1996; Ho et al. 1999). Also, anti-GMl antibody is not 
often found in CIDP (Kornberg & Pestronk 1995; Melendez-Vasquez et al. 1997; Case 
Records of the Massachusetts General Hospital (Case 13-1998) 1998) and patients with 
MMN show an extremely poor response to corticosteroids (with less than 3% of reported 
patients responding) (Pestronk et al. 1990; Chaudhry et al. 1994; Saperstein et al. 1999). 
Sensory abnormalities in MMN are unusual (Krarup et al. 1990; Adams et al. 1993; 
Parry 1996). The clinical, histopathological, and electrodiagnostic hallmarks suggest 
selective involvement of motor fibres (Kaji et al. 1994). However, some studies have 
demonstrated that MMN is not an exclusively motor abnormality, although it seems to 
be so with relation to clinical and electrophysiological criteria. The pathological process 
in MMN appears also to affect sensory fibres frequently, albeit to a lesser degree than 
motor fibres (Ho et al. 1999).
The first report of a multifocal demyelinating neuropathy with persisting conduction 
block was published by Lewis et al. in 1982. Their patients showed motor and sensory 
symptoms and they have been considered to represent the first described cases of MMN, 
although the authors regarded this type of neuropathy as a CIDP variant (Lewis et al. 
1982). Recently, a new type of multifocal motor neuropathy with involvement of 
sensory nerves has become known as the Lewis-Sumner syndrome or multifocal 
acquired demyelinating sensory and motor neuropathy (described by the acronym 
MADSAM (Saperstein et al. 1999)). Patients with this disorder appear to have 
important differences from those with MMN: shorter duration of symptoms, abnormal 
nerve conduction studies showing multifocal motor and sensory conduction block, 
definite sensory abnonnalities including pathological features of prominent sensory 
nerve demyelination, high incidence of elevated CSF protein, no elevated titres of anti- 
GMl antibodies, and good response to corticosteroids (Saperstein et al. 1999). As to
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whether this clinical disorder represents a distinct nosologic entity is a matter of 
controversy. Multifocal acquired demyelinating sensory and motor neuropathy is 
thought to be distinct from MMN syndrome, and may represents a variant of CIDP 
(Saperstein et al. 1999) but some authors believe that it is premature to draw such 
definite conclusions (Parry 1999).
4b. The clinical significance of anti-GMl antibodies
The clinical significance of anti-GMl antibodies is still debated (Sadiq et al. 1990; 
Lange et al. 1992; Adams et al. 1993; Parry 1994; Kinsella et al. 1994; Lange & 
Trojaborg 1994; Taylor et al. 1996; Parry 1996). Antibodies to GM1 and other 
gangliosides have been described in a wide variety of neurologic and non-neurologic 
disorders. Antibodies to GM1 and asialo-GMl have been found in the sera of patients 
with multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and even in 
patients with crania] trauma and cerebrovascular accidents or normal controls (Endo et 
al. 1984; Willison et al. 1993a; Lange & Trojaborg 1994; Taylor et al. 1996; Salih et al. 
1996; Matsuki et al. 1999; Hashimoto 1999). Some reports describe the occurrence of 
anti-GMl antibodies in patients with ALS, motor neuron syndromes with gammopathy 
or thyroid abnormalities, cervical spondylosis simulating ALS, other motor neuropathies 
and CIDP (Pestronk et al. 1988a; Lamb & Patten 1991; Willison et al. 1993a; Taylor et 
al. 1996). The possibility that anti-GMl antibodies might be useful in the diagnosis of 
ALS was considered initially, but at the present time they do not play a role in either 
diagnosis or treatment decisions in ALS (Griffin et al. 1996a). Although anti-GMl 
antibodies are not necessary for the diagnosis of MMN, it is important to realise, 
however, that testing for anti-GMl antibodies is useful when a treatable motor 
neuropathy is suspected but is difficult to distinguish from ALS (Wolfe et al. 1997).
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Whether anti-GMl antibodies are primarily or secondarily associated with neural tissue 
damage or whether they represent significant indicators of autoimmune reactivity is not 
yet clearly known.
4c. Antecedent infections, neurological disease and antibodies to gangliosides
The relationship between preceding infections and antibodies against GM1 ganglioside 
has been extensively investigated. Guillain-Barre syndrome is an acute demyelinating 
disease of the peripheral nervous system with accompanying rise in CSF albumin while 
the cell count remains normal (Honavar et al. 1991; Ropper 1992; Amason & Soliven 
1993; van der Meche & van Doom 1995). The classical syndrome is usually an acute 
monophasic neuropathy that usually affects the motor, sensory and autonomic nerves 
(van der Meche & van Doom 1995; Hughes & Rees 1997). The symptoms are usually 
symmetrical and more marked in the lower limbs and the paralysis appears to ascend. 
The advancing disease may involve the cranial nerves, especially the facial nerves, and 
in almost 25% of patients the disease affects the respiratory muscles, so that ventilatory 
support is necessary (Hughes & Rees 1997; Hahn 1998). Typically the progressive 
phase lasts up to three weeks and by definition must last no longer than 4 weeks. 
Although its cause and pathogenesis remain unknown, the neurological symptoms are 
preceded by clinical signs and symptoms of infection 1 -3 weeks before the neuropathy 
(Ropper 1992; Amason & Soliven 1993; van der Meche & van Doom 1995).
The clinical picture of GBS is usually produced by an acute inflammatory 
demyelinating polyradiculoneuropathy, but recently a specific subgroup, separable from 
poliomyelitis and demyelinating GBS. with distinctive clinical, electrophysiological and 
laboratory findings has been recognised that is due to acute axonal neuropathy 
(McKhann et al. 1993; Yuki 1994; Feasby 1994; Visser et al. 1995; Hafer-Macko et al.
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1996; Powel & Myers 1996; Hahn 1997; Hughes & Rees 1997; Feasby & Hughes 1998; 
Hahn 1998; Ho & Griffin 1999). The distinctive clinical pattern of acute motor axonal 
Guillain-Barre syndrome (AMAN) is characterised by a more rapid onset of paralysis, an 
earlier nadir, an initially predominant distal weakness, no sensory involvement, and a 
sparing of the cranial nerves. The affected patients have significantly high titres of anti- 
GMl antibodies with no electromyographic evidence for demyelination, and the disease 
often follows a gastro-intestinal illness usually caused by prodromal Campylobacter 
jejuni infection (Visser et al. 1995).
GBS with severe axonal degeneration involving motor nerves has also been reported 
in association with anti-GDI a antiganglioside antibody, which may play a significant 
role in the pathogenesis of AMAN (Yuki et al. 1992b; Yuki et al. 1993d; Carpo et al. 
1996; Lugaresi et al. 1997; Ho et al. 1999). Moreover, recently IgG anti-GalNAc-GDla 
antibody has been reported to be a possible marker of this pure motor axonal variant of 
GBS and must be tested together with anti-GMl in order to diagnose AMAN (Ang et al. 
1999; Kaida et al. 2000). Hyperreflexia has been described in some patients with 
AMAN and anti-GMl antibodies (Kuwabara et al. 1999). Autopsy studies have shown 
Wallerian-like degeneration of motor fibres (McKhann et al. 1993). Patients with 
AMAN seem to respond better to intravenous immunoglobulin than to plasma exchange 
(Visser et al. 1995).
At present the Guillain-Barre syndrome should be considered to be pathologically 
heterogeneous, with a primary demyelinating variant, which is most common in North 
America and Europe, a primary axonal motor variant, described in northern China, and a 
rare primary axonal sensory and motor variant (Case Records of the Massachusetts 
General Hospital (Case 39-1999)1999). The variability in the clinical spectrum of GBS 
may be caused by different pathogenic mechanisms (Kuwabara et al. 1998b; Sheikh et
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al. 1998b), although at the present time this seems to have no significant importance in 
determining the therapeutic approaches for the management of GBS (Hadden et al.
1998). The high effectiveness of intravenous immunoglobulin has been proven in 
clinical trials and its efficacy appears to be equal to or, in some aspects, superior to 
plasmapheresis (van der Meche, Schmitz & the Dutch Guillain-Barre study group 1992; 
Plasma exchange/Sandoglobulin Guillain-Barre syndrome study group 1997; Hadden et 
al. 1998; Dalakas 1999).
Campylobacter jejuni has been identified as an important cause of prodromal 
infection in GBS (Yuki et al. 1990; Gregson et al. 1993; Mishu et al. 1993; Oomes et al. 
1995; van der Meche & van Doom 1995; Rees et al. 1995b; Jacobs et al. 1996; Hughes 
& Reesl997; Nishimura et al. 1997; Feasby & Hughes 1998; Hahn 1998; Jacobs et al. 
1998; Sheikh et al. 1998b; Case Records of the Massachusetts General Hospital (Case 
39-1999)1999), and patients with recent Campylobacter jejuni infection had antibody to 
GM1 ganglioside (Gregson et al. 1993; Oomes et al. 1995; Rees et al. 1995a; Jacobs et 
al. 1996; Yuki et al. 1997; Hahn 1998; Hao et al. 1998; Jacobs et al. 1998). The 
frequency of anti-GMl antibody associated GBS in different series varies from 2% to 
30% (Ilyas et al. 1988; Yuki et al. 1990; Nobile-Orazio et al. 1992; van den Berg et al. 
1992; Gregson et al. 1993; Rees et al. 1995a; Jacobs et al. 1996; Hughes & Rees 1997; 
Nevo & Pestronk 1997; Feasby & Hughes 1998; Hao et al. 1998; Kuwabara et al. 
1998b). Some studies have confirmed the association between Campylobacter jejuni 
infection, IgG antibodies to GM1 ganglioside and severe axonal degeneration with poor 
prognosis in patients with the AMAN form of Guillain-Barre syndrome (Gregson et al. 
1993; Yuki 1994; Oomes et al. 1995; van der Meche & van Doom 1995; Rees et al. 
1995b; Jacobs et al. 1996; Hahn 1997; Hughes & Rees 1997; Nevo & Pestronk 1997; 
Jacobs et al. 1998), although other studies suggest that the presence of anti-GMl
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antibody is not necessarily a marker of poor prognosis (Rees et al. 1995a; Kuwabara et 
al. 1998a; Dalakas 1999; Case Records of the Massachusetts General Hospital (Case 39-
1999)1999).
The molecular mimicry between GM1 ganglioside and Campylobacter jejuni 
lipopolysaccharides isolated from patients with GBS may play a key pathogenic role in 
the production of antiganglioside antibodies and the development of the GBS (Latov 
1994; Oomes et al. 1995; van der Meche & van Doom 1995; Yuki 1997; Sheikh et al. 
1998a; Sheikh et al. 1998b). It has been shown that GM 1-oligosaccharide structure is 
present in the lipopolysaccharide of Campylobacter jejuni (Yuki et al. 1993c; Aspinall et 
al. 1994; Moran 1997; Halm 1998; Sheikh et al. 1998b). Although the mechanism of 
molecular mimicry remains an issue of controversy (Jacobs et al. 1997a), the association 
of specific gangliosides with distinct forms of GBS lends support to this notion.
The IgG anti-GTla antibody may be associated with the pharyngeal-cervical-brachial 
variant or oropharyngeal palsy in GBS and can further contribute in diagnosis of this 
variant of GBS (Koga et al. 1998; Koga et al. 1999). Also LM1 (Ilyas et al. 1992b) and 
GM lb (Kusunoki et al. 1996a) gangliosides are immune antigenic targets in GBS, but 
their possible pathogenic effect remains unknown.
Certain micro-organisms apart from Campylobacter jejuni have been associated with 
particular autoantibodies: Cytomegalovirus is associated with GM2 ganglioside (Irie et 
al. 1996; Jacobs et al. 1998), although the role of anti-GM2 antibody in the development 
of Cytomegalovirus-related GBS is unknown (Hahn 1998; Yuki & Tagawa 1998; 
Khalili-Shirazi et al. 1999). More recently Mori et al. reported a patient with an axonal 
GBS associated with anti-GMl antibodies after Haemophilus influenzae infection. 
Using ELISA inhibition studies and cytochemical staining of the bacteria strain they 
postulated that H. Inflmnzae has a Gal(|31-3)GalNAc epitope which is shared by GM1
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or G D lb gangliosides. They suggest that the syndrome could occur because of a crossed 
immune reaction between a component of the bacterium and the axolemma of the motor 
nerves, as has been speculated in Campylobacter jejuni-related GBS (Mori et al. 1999b).
4d. In vitro and in vivo studies on anti-GMl antibodies
The pathogenic relationship between autoimmune peripheral neuropathies and 
antiganglioside antibodies is still a matter of great controversy (Latov 1994; Hahn 1998; 
Kaji & Kimura 1999). Nevertheless, abundant clinical and epidemiological observations 
support the notion of a pathogenic role for these antibodies (Table 1). However, as 
described above, antibodies to GM 1 and other gangliosides have been found in a variety 
of neurologic and non-neurologic autoimmune conditions. In addition, a wide variety of 
electrophysiological and morphological studies on anti-GMl antibodies have shown 
divergent findings.
Experimental conduction block was described in demyelination induced by topical 
application of anti-galactocerebroside serum (Lafontaine et al. 1982), and after 
intraneural injection of anti-galactocerebroside (Saida et al. 1979; Sumner et al. 1982) or 
anti-MAG antibodies (Hays et al. 1987; Willison et al. 1988; Trojaborg et al. 1989). 
Intraneural injection of anti-GMl serum from a patient who had motor neuron disease 
and multifocal motor conduction block into rat sciatic nerve produced acute conduction 
block with significant fall in the amplitude ratio and deposits of immunoglobulin were 
observed at the nodes of Ranvier (Santoro et al. 1992). Similar studies using intraneural 
injection into rat tibial nerve showed that anti-GMl sera obtained from patients with 
MMN produce conduction block and demyelination, whereas, in the same study, 
injection of sera with high titres of anti-GMl obtained from patients with spinal
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muscular atrophy did not produced block and pathological analysis did not showed 
demyelination (Uncini et al. 1993).
In contrast, Harvey et al. (Harvey et al. 1995) failed to induce conduction block after 
intraneural injection into rat tibial nerves of immunoglobulin fractions with high titres of 
anti-GMl IgG or IgM antibodies from patients with Guillain-Barre syndrome or MMN. 
In the same study, histological examination of the injected nerves did not show 
demyelination despite the binding of the anti-GMl antibody to the nodes of Ranvier. 
Similarly, antisera against GM1 have previously failed to induce demyelination after 
injection into rat sciatic nerves, in contrast to the marked demyelination produced by 
anti-galactocerebroside and anti-Po sera (Hughes et al. 1985).
In similar studies, immunisation of rabbits with GM1 ganglioside has been reported to 
induce electrophysiological abnormalities, mild axonal degeneration and 
immunoglobulin deposits at the nodes of Ranvier (Thomas et al. 1991). Axonal 
degeneration and conduction block was observed after intraneural injection of the B 
subunit of cholera toxin (CT-B) into sciatic nerves of rats in which anti-CT-B antibodies 
were previously generated by immunisation with the B subunit of CT, which avidly 
binds to GM1 ganglioside (Wirguin et al. 1995). The study implies that CT binds to 
GM1 both at the nodal gap and paranodal myelin (Corbo et al. 1993) and complement 
activation by immune complexes may damage the myelin sheath and axons at the nodes 
of Ranvier, producing both conduction block and demyelination. In another study using 
mouse phrenic nerve-hemidiaphragm preparation multifocal motor neuropathy sera 
containing anti-GMl antibodies blocked nerve conduction at distal motor nerves, but 
also, multifocal motor neuropathy anti-GMl negative sera produced similar results 
(Roberts et al. 1995), suggesting that anti-GMl antibodies may are not exclusively the 
cause of conduction block.
In numerous immunohistological studies using anti-GMl ganglioside sera (Freddo et 
al. 1986; Gregson et al. 1991; Harvey et al. 1995; Kusunoki et al. 1997) and monoclonal 
antibodies (O' Hanlon et al. 1996; Molander et al. 1997; O' Hanlon et al. 1998), binding 
to peripheral nerve structures, including nodes of Ranvier has been convincingly 
demonstrated (Santoro et al. 1990; Santoro et al. 1992; Adams et al. 1993; Nardeli et al. 
1994; Hafer-Macko et al. 1996; Paparounas et al. 1999).
Also, incubation of an isolated nerve preparation in vitro with anti-GMl antibodies 
produced acute conduction block of myelinated nerve fibres in excised and desheathed 
rat sciatic nerves (Arasaki et al. 1993). However, in a more recent study the same 
authors observed conduction block with IgM antibodies whereas IgG antibody failed to 
block myelinated nerve conduction (Arasaki et al. 1998), suggesting a difference in 
action between IgG and IgM antibodies. Takigawa et al. (Takigawa et al. 1995) found 
that anti-GMl antibody increased the potassium current elicited by step depolarisation, 
and in the presence of active complement blocked sodium channels irreversibly, 
suggesting that anti-GMl antibodies block sodium channels, causing conduction block 
(Waxman 1995). However these data have recently been challenged in a study in which 
the application o f the same sera with high titres of anti-GMl antibody did not cause 
conduction block or block sodium channels (Hirota et al. 1997). It was therefore 
concluded that the physiological action of the antibody alone is insufficient to explain 
conduction block in human disorders. More recently, as discussed later in this thesis, 
Paparounas et al. showed that anti-GMl antibodies can bind to the nodes of Ranvier, and 
activate the complement cascade without causing acute conduction block in vitro 
(Paparounas et al. 1999). This also suggests that antiganglioside antibodies do not act as 
a primary blocker of sodium channels.
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5. The role of anti-GQlb antibody in autoimmune neuropathies
5a. Anti-GQlb antibody: an immunological marker for Miller Fisher syndrome
Over the last years there has been an extensive discussion related to the role of anti- 
G Qlb antibodies in the pathogenesis of Miller Fisher syndrome. The syndrome of total 
external ophthalmoplegia, severe ataxia and loss of tendon reflexes was first reported in 
three patients by M. Fisher; he noticed that the cause of this syndrome was obscure but 
the rise in the protein of the cerebrospinal fluid in the late stages of the disease indicated 
a close relation to the Guillain-Barre syndrome, and since then the MFS has been 
described as an unusual variant of Guillain-Barre syndrome with benign prognosis 
(Fisher 1956).
The first report involving the antiganglioside antibodies in the pathogenesis of MFS 
was published in 1992. Chiba et al. found increased serum anti-GQlb IgG activity in all 
six patients with MFS in the early phase of the illness. The titre of the antibody reduced 
with time. They suggested an association between anti-GQlb antibodies and MFS, 
emphasising that this antibody could be a possible immunological marker of great 
clinical significance in this syndrome (Chiba et al. 1992). Since then several studies 
have found increased anti-GQlb antibodies titres in Miller Fisher syndrome with the 
immunoglobulin being of IgG class rather than IgM; the antibody titre decreased with 
the clinical course of the illness (Chiba et al. 1993; Yuki et al. 1993b; Willison et al. 
1993c; Jacobs et al. 1995; Yuki 1996a; Carpo et al. 1998; Suzuki et al. 1998; Schwerer 
et al. 1999).
5b. The link of anti-GQlb antibody with acute ophthalmoplegia
Some studies have shown that anti-GQlb IgG antibody is related to the severity of the 
cerebellar-like ataxia of the syndrome (Yuki et al. 1993b). Selective staining of the
human cerebellar molecular layer by serum IgG anti-GQlb antibodies from patients with 
Miller Fisher syndrome or Guillain-Barre syndrome with ophthalmoplegia and ataxia 
give further evidence that anti-GQlb antibody is related with ophthalmoplegia and 
ataxia in MFS and similar syndromes, and supports the hypothesis for a central origin of 
the ataxia in MFS (Kornberg et al. 1996). In contrast, a number of studies suggest the 
close correlation between anti-GQlb IgG antibody and acute ophthalmoplegia in typical 
Miller Fisher syndrome, in atypical (without ataxia) Miller Fisher syndrome with 
ophthalmoplegia, or Bickerstaffs brainstem encephalitis, and in Guillain-Barre 
syndrome with ophthalmoplegia (Chiba et al. 1993; Yuki 1996a; Goffette et al. 1998; 
Suzuki et al. 1998), or isolated ophthalmoplegia (Yuki, Koga & Hirata 1998; Radziwill 
et al. 1998). Some authors recommend that diseases which show external 
ophthalmoplegia, should be labelled as "IgG anti-GQlb antibody syndrome" (Yuki 
1996a), and this proposal is supported by the fact that the anti-GQlb antibody activity 
reflects the severity of the patients’ symptoms, especially ophthalmoplegia (Mizoguchi 
1998). Extensive investigations including large numbers of patients have confirmed the 
close association of IgG anti-GQlb antibody with both ataxia and ophthalmoplegia 
(Kusunoki, Chiba & Kanazawa 1999). In contrast, other reports suggest that anti-GQlb 
IgG antibody is not necessarily associated with ophthalmoplegia. They presented 
patients with acute oropharyngeal palsy (O'Leary et al. 1996), acute demyelinating 
polyradiculoneuropathy (Mizoguchi et al. 1997) or Miller Fisher-like syndrome (Mori et 
al. 1999a) with high titres of anti-GQlb IgG antibody activity without ophthalmoplegia.
Immunohistochemical studies have shown staining in the paranodal regions of the 
extramedullary portions of the human oculomotor, trochlear and abducens nerves; such 
an accumulation of GQlb epitope was not present in the other cranial nerves or in the 
peripheral and central nerve tissues examined (Chiba et al. 1993). The same authors
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more recently (Chiba et al. 1997) investigated the ganglioside composition of all the 
human cranial nerves. They found a significantly higher percentage of GQlb 
ganglioside in the optic, and all three ocular motor nerves than in all the other cranial 
nerves.
5c. Anti-GQlb antibody and neuromuscular transmission
Recent electrophysiological evidence has revealed that sera from patients with Miller 
Fisher syndrome who were anti-GQlb positive cause a transient rise in miniature end 
plate potential frequency, followed by transmission block, in the mouse phrenic nerve- 
hemidiaphragm preparation; this suggests that the GQlb antibody is likely to cause a 
disturbance of acetylcholine release from motor nerve terminals (Roberts et al. 1994). 
Clinical electrophysiological recordings in anti-GQlb positive patients with tetraparesis 
suggest that motor nerve terminal block was the cause of weakness and thus the anti- 
GQlb antibody may be the blocking factor (Uncini & Lugaresi 1999). Plomp et al. have 
recently published the effects of anti-GQlb antibody on mouse neuromuscular junctions 
in vitro; they found that the antibody binds at neuromuscular junctions, inducing a 
massive quantal release of acetylcholine from nerve terminals, and blocks 
neuromuscular transmission, an effect that closely resembles the action of the paralytic 
neurotoxin a-latrotoxin at the mouse neuromuscular junctions. The report strongly 
suggests that anti-GQlb antibodies, in conjunction with activated complement 
components, are the principal pathophysiological factors of motor symptoms in MFS 
(Plomp et al. 1999).
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5d. Molecular mimicry and anti-GQlb antibody
In some anti-GQlb IgG antibody positive sera, additional anti-GTla IgG antibody 
activity has been detected (Chiba et al. 1993); this indicates that anti-GQlb and anti- 
G Tla antibodies cross-reacted with each other's antigen, suggesting that the same IgG 
antibody bound to both antigens, which are structurally similar (Chiba et al. 1993; 
Willison et al. 1997). Cross-reactivity of anti-GQlb IgG antibody with surface epitope 
on Campylobacter jejuni strains from patients with Miller Fisher syndrome supports the 
hypothesis of molecular mimicry between bacteria and neural tissue (Jacobs et al. 1995; 
Yuki 1997; Neisser et al. 1997; Jacobs et al. 1997a; Hahn 1998; Yuki & Miyatake 1998; 
Ohtsuka et al. 1998a).
5e. Benign brainstem encephalitis and anti-GQlb antibody
The nosological condition with which Miller Fisher syndrome has clinical similarities is 
Bickerstaffs brainstem encephalitis. Bickerstaff described 8 patients who had a clinical 
syndrome of gradual onset with almost total paralysis of all motor function originating in 
the brainstem, but without cardiac or respiratory abnormality; the syndrome is 
accompanied by mild pyramidal and long-tract sensory disturbances with severe 
drowsiness. All these patients had a prodromal infection. Seven patients had a dramatic 
total recovery without neurological sequelae. He characterised it as a grave syndrome 
but with benign prognosis (Bickerstaff & Cloake 1951; Bickerstaff 1957). Whether 
Miller Fisher syndrome and Bickerstaffs encephalitis are distinct diseases is a matter of 
controversy. Whether the lesions responsible for the clinical findings of these diseases 
are in the peripheral or central nervous system is a matter of disagreement as well 
(Phillips, Stewart & Anderson 1984; Al-Din 1987; Taphoorn et al. 1989; Yaqub et al.
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1990; Petty et al. 1993; Al-Din et al. 1994; Urushitani, Udaka & Kameyama 1995; Miwa 
et al. 1995).
Interestingly, sera taken from patients with Bickerstaffs brainstem encephalitis with 
ophthalmoparesis have increased titres of anti-GQlb IgG antibody during the acute 
phase of the syndrome (Yuki et al. 1993a; Yuki 1995; Yuki 1996a; Shimokawa et al. 
1998). The antibody titres decrease during the clinical course of the disease. These 
findings suggest that a common autoimmune mechanism is likely in Miller Fisher 
syndrome and Bickerstaffs encephalitis and that both illnesses possibly represent a 
distinct disease with a wide spectrum of symptoms, which include ophthalmoplegia and 
ataxia. Plasmapheresis has been suggested as a successful treatment in Miller Fisher 
syndrome and in Bickerstaffs brainstem encephalitis with anti-GQlb IgG antibody 
(Yuki 1995; Yuki 1996a; Shimokawa et al. 1998). Immunoadsorption using the 
tryptophan-immobilized polyvinyl alcohol gel column is a new alternative type of 
plasmapheresis in these illnesses (Yuki 1996b; Tagawa, Yuki & Hirata 1998; Ohtsuka et 
al. 1998b).
6. Sensory neuropathy with antibodies to GDlb and disialosyl gangliosides 
6a. Clinical implications
Monoclonal IgM antibodies that reacted with GDlb and disialosyl gangliosides were 
first reported in a patient with a predominantly sensory ataxic demyelinating neuropathy 
associated with paraproteinemia. The monoclonal IgM reacted strongly with GDlb and 
other gangliosides containing disialosyl groups, such as GTlb, GD3, and GD2, but not 
with GM1, GM3, GDI a, and MAG (Ilyas et al. 1985). Since then several patients have 
been described with predominantly sensory neuropathy and elevated titres of IgM or IgG 
antibodies with activity against disialosyl residue (Younes-Chennoufl et al. 1992; Daune
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et al. 1992; Yuki et al. 1992a; Willison et al. 1993b; Willison et al. 1994; Brindel et al. 
1994; Herron et al. 1994; Wicklein et al. 1997).
All patients had a large-fibre neuropathy with areflexia and most had gait ataxia and 
elevated CSF protein levels. In most cases the neuropathy was demyelinating, but also 
mixed, axonal and demyelinating, has been described in some patients (Latov 1995). 
Also, antibodies against G Dlb ganglioside have been found in many patients with motor 
neuron syndromes and mixed sensorimotor neuropathies where the IgM antibody also 
recognises GM1 or other gangliosides without disialosyl groups (Latov 1994).
6b. Experimental studies on anti-GDlb antibodies - Immunoreactivity against 
dorsal root ganglion neurons and sensory neuropathy
Anti-GM l/GDlb IgM M-immunoglobulins from patients with motor neuron syndromes 
can bind presynaptically to neuromuscular junctions in guinea pig gastrocnemius muscle 
(Schluep & Steck 1988), and moreover can destroy human spinal cord neurons co­
cultured with muscle (Heiman-Patterson et al. 1993). Sera from patients with a 
clinically pure sensory ataxic neuropathy containing high titres of IgM anti-disialosyl 
antiganglioside antibodies (reacting against GDlb, GD3, GTlb, GQlb, GM3, and GDI a 
but not against GM1) showed cytoplasmic staining in about 80% of human dorsal root 
ganglion cells. This study suggests that the immunostaining of dorsal root ganglion 
neurons is likely to be due to the reactivity with GDlb ganglioside (Oka et al. 1996).
Also, other important studies have revealed cytotoxic effects of GDlb antibody that 
appear to be destructive to ganglionic neurons in vitro; sera from patients with acute 
relapsing sensory neuropathy and high titres of monoclonal IgM antibody recognising 
disialosyl groups of gangliosides produced cell death of rat dorsal root ganglion neurons
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in cultures (Ohsawa et al. 1993). Interestingly, the cell damage occurred without the 
addition of complement (Ohsawa et al. 1993).
Willison et al., using a monoclonal antibody cloned from a patient with an IgM 
paraproteinemic neuropathy which was reactive with GDlb, GTlb, G Qlb and GT3 
gangliosides, demonstrated immunolocalization to the dorsal root ganglia, and to motor 
nerve terminals, muscle spindles, myelinated axons and nodes of Ranvier in rodent 
tissue (Willison et al. 1996). Moreover they showed that this antibody can cause 
neurophysio logical effects by impairing nerve excitability and reducing neurotransmitter 
release in the phrenic nerve-hemidiaphragm preparation (Willison et al. 1996). 
Kusunoki et al., using two mouse monoclonal antibodies each monospecific to GM1 and 
G Dlb gangliosides, found that the GDlb bound to neurons in dorsal root ganglia and 
sympathetic ganglia, and some parts of the peripheral myelin, mainly to paranodal areas, 
whereas no significant immunoreactivity was observed with GM1 antibody (Kusunoki et 
al. 1993). Furthermore, GDlb is localized to dorsal root ganglia neurons and to 
paranodal myelin of human peripheral nerve, and these places could be the binding sites 
for anti-GDlb antibodies (Kusunoki et al. 1997).
G D lb ganglioside shares with GM1 the Gal ((31-3) GalNAc epitope, whereas the 
NeuNAc (a2-8) NeuNAc moiety is present only in the G D lb structure (Dalakas & 
Quarles 1996). It is likely that when IgM immunoglobulin recognises the Gal ((31-3) 
GalNAc epitope of GM1 and GDlb gangliosides, patients present with a motor 
neuropathy (Freddo et al. 1986; Corbo et al. 1993). In contrast, if IgM reacts with 
epitopes containing disialosyl groups found only in the GD1 b structure there is clinically 
a sensory neuropathy.
The report by Kusunoki et al. that immunisation of rabbits with GDlb ganglioside can 
cause sensory ataxic neuropathy resembling the human disease was the first study in
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which an animal model for autoimmune neuropathy was induced by sensitisation with 
ganglioside. High anti-GDlb antibody titre and the absence of inflammatory 
lymphocytic infiltration suggested an antibody-mediated pathogenic process (Kusunoki 
et al. 1996b). In the same study pathological analysis showed axonal degeneration in the 
dorsal column of the spinal cord, in the dorsal roots, and sciatic nerve; some of the nerve 
cell bodies in the dorsal root ganglia had degenerated and disappeared (Kusunoki et al. 
1996b). In a more recent study the same investigators immunised increased numbers of 
rabbits with GDlb and confirmed the induction of sensory ataxic neuropathy in more 
than one-half of them. Moreover, they found that IgG antibody monospecific to GDlb 
may be crucial to induce this experimental neuropathy, whereas antibodies that react 
with both G D lb and GM1 by binding to the terminal Gal-GalNAc residue may be of no 
importance in pathogenesis (Kusunoki et al. 1999). The primary sensory neurons that 
mediate proprioceptive sensation depend mainly on neurotrophin-3, which is particularly 
essential for the survival and maintenance of large sensory neurons in the dorsal root 
ganglion (Chen et al. 1999). Each neurotrophin has its receptor and trkC is the preferred 
receptor for neurotrophin-3 (Chen et al. 1999). Hitoshi et al. studied the expression of 
trkC in dorsal root ganglia of experimentally diseased rabbits after immunisation with 
GD lb ganglioside and found markedly reduced expression of trkC in dorsal root ganglia 
of affected rabbits in the acute phase. This suggested that the G Dlb antibody-mediated 
down-regulation of trkC expression could be important in the pathogenesis of this 
experimentally induced sensory ataxic neuropathy (Hitoshi et al. 1999).
Despite the strong evidence supporting the pathogenic role of anti-GDlb antibody in 
inducing sensory ataxic neuropathy further studies are needed to elucidate thoroughly 
the pathophysiological mechanisms and the immunopathological aspects of this 
antibody-mediated autoimmune neuropathy. Finally, the convincing evidence that
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GDlb antibody is causally related to the development of sensory ataxic neuropathy is 
very encouraging, and improves the prospects that future therapies will successfully 
inactivate or remove the antibody (Dalakas & Quarles 1996; Quarles & Dalakas 1996; 
O'Leary & Willison 1997).
7. Predominantly sensory neuropathy and anti-sulfatide antibodies
Increased titres of circulating monoclonal or polyclonal IgM antibodies to sulfatide have 
been reported in a variety of chronic axonal and demyelinating polyneuropathy 
syndromes (Ilyas et al. 1992a; Lopate et al. 1997a; Ferrari et al. 1998), associated with a 
predominantly sensory neuropathy (van den Berg et al. 1993; Latov 1995; Lopate et al. 
1997a). Immunocytochemical studies have shown that the antibodies bound to the 
surface of rat dorsal root ganglia neurons (Quattrini et al. 1992; Nardeli et al. 1995); 
other studies demonstrated the presence of IgM antibody and complement product C3d 
bound to myelin sheath, suggesting that pathological changes in some types of 
demyelinating neuropathy associated with antisulfatide antibodies are complement 
mediated (Ferrari et al. 1998). In several other studies the antisulfatide antibody cross 
reacted with MAG (Ilyas et al. 1992a; van den Berg et al. 1993), and patients had a 
sensorimotor neuropathy with demyelination, widened myelin lamellae, and deposits of 
IgM on myelin sheaths (Latov 1995). Passive transfer in new-born rabbits of anti­
sulfatide antibodies from a patient has produced demyelinating nerve lesions resembling 
the patient’s polyneuropathy (Nardeli et al. 1995). Also, sera from patients with insulin- 
dependent diabetes mellitus (IDDM) were anti-sulfatide positive and sulfatide as an 
antigen may be involved in the pathology of IDDM, being an immunological marker of 
this disorder (Buschard et al. 1993). In addition, serum autoantibodies against sulfatide 
were detected in non-insulin-dependent diabetes mellitus (NIDDM) patients with
diabetic neuropathy, so that autoimmune mechanisms may play a role in this type of 
neuropathy (Shigeta et al. 1997).
The role of anti-sulfatide antibodies in the pathogenesis of neuropathy is still 
unknown (van den Berg et al. 1993). Sulfatide is a common glycolipid of the spinal 
cord and peripheral nerve tissue, and is highly enriched in myelin (van den Berg et al. 
1993). Recent studies suggest that anti-sulfatide antibody related polyneuropathy 
syndromes do not appear to constitute a distinct syndrome with specific clinical, 
electrophysiological, histopathological, and antibody binding findings (van den Berg et 
al. 1993). Some patients seem to have a predominantly axonal sensory neuropathy, 
while others present with severe demyelinating sensorimotor neuropathy (van den Berg 
et al. 1993). It is likely that the antisulfatide antibodies differ in their fine specificity, 
binding sites and cross-reactivity. Maybe these parameters could determine the 
particular clinical syndromes and, also, explain the heterogeneity of anti-sulfatide 
antibody associated neuropathy. Thus in predominantly axonal sensory neuropathy, 
binding may occur to sensory axons whereas in patients with demyelinating neuropathy, 
antibodies may be directed against the sulfatide in myelin (Lopate et al. 1997a; Lopate et 
al. 1997b). Moreover the predominant sensory disturbances in these patients may be 
explained by antibody binding to dorsal root ganglia (Quattrini et al. 1992), although 
recent studies have found that IgM anti-sulfatide antibodies show several different tissue 
binding patterns in the peripheral and central nervous systems and no strong binding to 
structures in dorsal root ganglia (Lopate et al. 1997b).
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PART TWO -  THE STUDY
Introduction
In the first two chapters of this study we attempted to clarify the electrophysiological 
effect of anti-ganglioside antibodies on nerve conduction. For this purpose we used two 
different isolated nerve preparations: a) the mouse sciatic nerve preparation, where the 
greater part of this work was conducted and b) the rabbit sural nerve preraration, a pure 
sensory nerve from another animal species. Subsequently, in the immunohistochemistry 
chapter we investigated the immunoglobulin and complement deposition at the nodes of 
Ranvier following in vitro incubation of mouse sciatic nerve teased fibres with anti- 
ganglioside IgM antibodies. Finally, we completed this study by examining the 
physiological effect of antibody on neuromuscular transmission with the aid of mouse 
phrenic nerve-hemidiaphragm preparation.
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CHAPTER ONE: ELECTROPHYSIOLOGICAL EFFECT OF ANTIBODIES 
AGAINST GANGLIOSIDES ON MOUSE SCIATIC NERVE PREPARATION
A. Method and materials
1. Anti-ganglioside antisera and monoclonal antibodies
Sera were collected from patients with autoimmune neuropathies and normal controls 
and stored at -70°C until use (as approved by the Southern general Hospital NHS Trust 
Ethics Committee). Screening for anti-ganglioside antibodies using a panel of 
gangliosides comprising GM1, GM2, GM3, GDI a, GalNAc-GDla, GDlb, GD3, GTla, 
GTlb and GQlb, was perfonned by ELISA (enzyme-linked immunoabsorbent assay) 
and thin layer chromatography overlay (Willison et al. 1996). We studied nine samples 
of human sera or plasma (see Table 4) positive for anti-ganglioside antibodies taken 
from the following groups of patients: a) three patients with multifocal motor 
neuropathy that showed anti-GMl IgM antibody reactivity; b) three patients with 
paraproteinemic and anti-disialosyl IgM antibodies; c) three patients with Guillain-Barre 
syndrome or Miller Fisher syndrome and anti-GMl or GQlb IgG antibodies. We also 
examined three monoclonal IgM anti-GMl antibodies cloned from peripheral blood 
lymphocytes of MMN patients with elevated titres of anti-GMl antibody (Paterson et al. 
1995). In order to maintain experimental consistency throughout these studies, a single 
human normal control serum, which did not contain anti-ganglioside antibodies, was 
used as a source of complement and confirmed as having classical pathway (CH50 = 1 2 0  
units/ml) and alternate pathway (CH50 =71 units/ml) complement levels within the 
normal ranges. Immunoassay studies of these sera were perfonned by Mrs J Veitch in 
the Neuroimmunology Laboratory, Southern General Hospital.
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Table 4 Binding properties and origin o f anti-ganglioside antibodies
Code Diagnosis Ab class Ganglioside binding profile (titre)
GM1 GM2 GDlb G Q lb
GA MMN IgM 1/17000 1/35000 neg neg
JW MMN IgM 1/12800 neg 1/7400 neg
PS MMN IgM 1/1000 neg 1/800 neg
CH PPN IgM Neg neg 1/100,000 1/450,000
VP PPN IgM Neg neg 1/120,000 1/170,000
BK PPN IgM neg neg 1/1300 >1/5000
MI GBS IgG >1/5000 neg >1/5000 neg
JY GBS IgG 1/1600 1/1400 1/600 neg
AS MFS IgG Neg neg neg 1/3300
Monoclonal antibodies*
W ol MMN IgM 9100 neg 1700 neg
Sml MMN IgM 6500 neg neg neg
Bol MMN IgM 1200 neg 250 neg
neg signifies reactivity undetectable; MMN = multifocal motor neuropathy; PPN = 
paraproteinemic neuropathy; GBS = Guillain-Barre syndrome; MFS = Miller Fisher 
syndrome; Ab = antibody. *Titre is expressed as the reciprocal of the antibody 
concentration that gave half maximal binding.
2. Electrophysiological recordings from mouse sciatic nerve
Male BALB/c mice (weighing 25-30g) were killed by inhalation of carbon dioxide, 
according to United Kingdom Home Office guidelines. A 5-7 cm length of sciatic
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nerve, comprising proximal and distal regions was dissected out and desheathed under a 
dissecting microscope (x50). The preparation was then mounted into a recording 
chamber consisting of three cylindrical compartments of 1ml capacity each (Figure 3).
Fig. 3 Diagram of the recording chamber.
Electrical isolation between the compartments was achieved using vaseline. The two 
external compartments were filled with physiological buffer 154mM NaCl, 5mM KC1, 
1.25mM M gCf, l l mM  glucose, 5.46mM HEPES (Ar-[2-hydroxyethyl]piperazine-Nl-[2- 
ethanesulfonic acid]), 1.8mM CaCE, pH 7.4; the central compartment (volume=lmL) 
contained the test reagents. Before each experiment the solution was saturated with 
100% O2 for 30mins. Standard extracellular recording techniques were employed to 
record compound nerve action potential events. Pellet type silver electrodes were 
dipped into each of the compartments of the recording chamber with stimulation taking 
place between the central and one of the external compartments. Recordings were 
obtained from the central pool. The ground electrode was dipped into the central pool. 
A Grass S48 stimulator was used to supply electrical impulses (0.4Hz, 0.04msec 
duration) supramaximally via a stimulus isolation unit, model SIU 5A (Grass Instrument 
Co., Quincy, Mass., USA). Signals were amplified with a CED 1902 transducer, 
digitised by an analogue-digital converter CED 1401 and analysed with a 
microcomputer program (Dempster 1988).
In each experiment the amplitude, latency, rise time, and threshold of the obtained 
action potentials were measured. Before the addition of test compounds, the sciatic 
nerve preparation was incubated in physiological buffer for 45 min under constant 
supramaximal stimulation to demonstrate viability in the preparation and consistency in 
the recordings. All test solutions were dialysed against physiological buffer at pH 7.4. 
Osmotic pressure was maintained at 320±10 mOsm/kg. The pH and osmotic pressure 
were re-checked at the beginning and end of all recordings since in preliminary 
experiments we noted markedly deleterious effects of high and low pH and osmolarity 
on the physiological stability of the preparation. All test sera and plasma, including the 
normal serum used as a source of supplementary complement, were diluted 1:10 in 
physiological buffer. Monoclonal anti-GMl antibodies and normal human IgM were 
diluted in physiological buffer and used at a concentration of 20pg/ml. Cholera toxin B 
subunit (Sigma C9903) a high affinity ligand for GM1 (Holmgren 1981) was used at 
20pg/ml, and the sodium channel blockers saxitoxin (STX) and tetrodotoxin (TTX) at
0.5nM and lpg/m l concentration, respectively.
All the experiments on ensheathed nerve and the initial experiments on desheathed 
nerve were carried out at a room temperature (RT) of 20+2°C. In later experiments, one 
anti-GQlb IgM (CH) and one anti-GMl IgG (MI) sera were tested after changing 
temperature conditions, and also two anti-GMl sera (GA and JW) were studied at 37°C, 
maintained using a circulating constant temperature bath. Nerves were incubated with 
test sera for 180-240mins, with supplementary normal serum as a fresh source of active 
complement being applied for a further 90-120mins. In the later experiments performed 
at 37°C, fresh serum was applied together with the two anti-GMl sera from the start of 
the experimental recordings. Electrophysiological studies were performed with the 
operator blinded to the nature of the test compound.
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The data are presented as mean ± standard error mean. All measurements were 
normalized according to the control values at time 0 min, without the presence of anti- 
ganglioside antibody. Statistical significance was tested with non-parametric statistics 
(Mann -  Whitney’s test) andX2 test as appropriate. All analyses were performed using 
Minitab 10.5 for Windows statistical package.
B. Results
1. Pitfalls that can influence the electrophysiological recordings
In early electrophysiological recordings on ensheathed and desheathed mouse sciatic 
nerve preparations the reproducibility of some experiments was doubtful; we found 
acute conduction block after the application of patients' sera or plasmas and we 
hypothesized that it was due to a direct effect of anti-ganglioside antibody activity. 
However, we observed similar changes in nerve action potentials with the preparation 
incubated only with physiological salt solution, and also we recorded acute conduction 
block after the application of other normal control compounds.
Initially, we were unable to give a satisfactory explanation of these contradictory 
results and we tried to identify and elucidate those factors and parameters that could 
influence the stability and consistency of the electrophysiological recordings. We 
performed a significant number of experiments with control and anti-ganglioside 
compounds and we found that several factors can affect and alter the experimental 
process and give incorrect results. Only after having identified these factors, were we 
able to achieve good reproducibility of the experiments and trustworthiness of the 
recordings. In the next pages, we briefly discuss these observations.
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la . High osmolarity and changes in bath pH can induce negative effects on 
compound nerve action potential in vitro
In preliminary experiments we observed that some time after the antibody application, a 
progressive decrease in the amplitude of the action potential occurred. This was more 
apparent with some samples, in particular with some batches of monoclonal antibodies 
(Figure 4A shows such an extreme example). When we checked the osmotic strength of 
the bathing solution before and after the antibody application, we found that it was 
considerably higher compared to normal osmolarity of the physiological salt solution 
used (Normal osmolarity: 320±10 mOsm/kg; Table 5). We also obtained similar results 
with some control compounds (Figure 4B). In order to look at the effects of high 
osmolarity reagents on nerve conduction, we removed a part of the volume (1 OOpJL) of a 
hypertonic solution and substituted it with an equal amount of normal osmolarity control 
compound; then, an increase in nerve action potential was observed (Figure 5A, and 
Table 5). As expected, the application of normal isotonic compounds did not influence 
the real physiological effect of STX solution which was of normal osmolarity (Figure 
5B). We assumed that the high osmotic pressure of test compounds and solutions can 
produce acute conduction block and, in subsequent experiments, the osmolarity of 
bathing solutions was maintained at 320±10 mOsm/kg.
We also observed that significant changes in pH of bathing solutions and compounds 
(Table 5) can alter the electrophysiological recordings (Figures 6A, 6B, 7, and 8), and in 
all later experiments the pH was at 7.4 level, checked at the beginning and end of 
recordings.
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Fig. 4 Effect of high osmotic strength compounds on the amplitude of action potentials 
of desheathed mouse sciatic nerve preparation. Arrows signify the time of application 
of Bo3 anti-GMl antibody (Fig. 4A, n=2), and normal human IgM (Fig.4B, n=2). The 
final osmolarities were 776mOsm/Kg and 885 mOsm/Kg respectively. Points are mean 
values and SEM are indicated by error bars unless they were smaller than symbols.
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Fig. 5 Removal (arrows) of 100 pL of the bathing solution (1/10 of the total bath 
volume) and application (arrows) of 100 pL normal human serum of normal osmolarity 
can reverse the conduction block induced by high osmolarity Cholera toxin B subunit 
(Fig. 5A, and Table 5), but does not influence the physiological effect of normal 
osmolarity saxitoxin (STX) solution (Fig. 5B). Total bath volume=lmL.
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Fig. 6 Effect of pH=9.4 on the amplitude of desheathed mouse sciatic nerve action 
potential. The pH of physiological salt solution before application of test compounds 
was 7.4. Arrows signify the time of application of Bol anti-GMl IgM antibody (Fig. 
6A, n=2), and normal human IgM (Fig. 6B, n=2). SEM are indicated by error bars 
unless they were smaller than symbols.
Fig. 7 Acid pH (7 .4  - 4 .6)
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Fig. 7, 8 Incubation of desheathed mouse sciatic nerve in different acid and alkaline 
physiological buffers. For each pH value a different preparation was used, and each 
preparation was exposed to a different pH for 15 min.
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Table 5 Osmolarities and pH  changes o f bathing solutions before and after application 
of some monoclonal anti-ganglioside antibodies (Bol, Bo3, Sml, Wol) and control 
compounds
Sample Values before application of test reagents 
(physiological buffer)
Values at end of experiments 
(after application of test reagents)
Osmolarity pH Osmolarity pH
Bol 318 mOsm/kg 7.4 322 mOsm/kg 9.4
Bo3 324 mOsm/kg 7.4 776 mOsm/kg 7.3
Sm l 325 mOsm/kg 7.4 538 mOsm/kg 7.2
W ol 310 m Osm/kg 7.4 472 m Osm/kg 7.6
Human IgM 
(1st sample)
328 mOsm/kg 7.4 885 mOsm/kg 7.7
CTb subunit 312 m Osm/kg 7.4 515 m Osm/kg 7.4
Human IgM
(2nd sample)
320 m Osm/kg 7.4 344 mOsm/kg 9.4
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lb . Additional experimental factors that can affect nerve fibres physiology in vitro
In some experiments, even though we have controlled the osmotic pressure and the pH 
of used solutions, we observed progressive reduction in action potentials amplitude 
leading to acute conduction block and we regarded that as a true effect of anti- 
ganglioside antibody containing sera. The following Figure 9 shows such an example.
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Fig. 9 Progressive reduction of nerve action potential 15 min after the nerve set up and 
antibody application, although osmolarity and pH were at normal levels (representative 
experiments n=3. Osmolarity was 320±10 mOsm/Kg and pH=7.4 and they were 
checked at the beginning and at the end of the experiments).
Because of poor reproducibility in our findings, we suspected that other factors, apart 
from osmotic strength and pH, could affect the stability of the preparation and so the 
reliability of our results.
i) Poor electrical isolation can cause conduction block
As has been described in method, the preparation was mounted into a recording chamber 
consisting of three cylindrical compartments (Figure 3); the central compartment 
communicated with each of the extreme ones by means of a small groove and electrical 
isolation between the compartments was achieved using vaseline on these grooves.
implitude
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Impaired electrical isolation among the experimental bath compartments can influence 
the experiment and give conduction block as Figure 10 shows. Therefore, care was 
taken to achieve hermetically sealed bath compartments.
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Time (min)
Fig. 10 Impaired electrical isolation (creating small pores among the recording chamber 
compartments) can lead to acute conduction block (n=2).
ii) Stretch of the nerve and conduction block
Figure 11 shows the result of nerve stretching in the amplitude of the obtained action 
potentials in ensheathed and desheathed preparations. Stretch of the nerve during the 
dissection can damage or traumatize nerve fibres and, especially, clumsy desheathment 
of the nerve can eliminate the viability of the preparation.
A. Ensheathed nerve B. D esheathed nerve
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Fig. 11 Effect of stretching on ensheathed (n=2) and desheathed (n=2) nerves (slight 
pulling of nerve fibres during the dissection).
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iii) Dry nerve and conduction block
It was important to keep all the length of the nerve in moist environment throughout the 
experiment. In preliminary experiments with anti-ganglioside antibody or control 
solutions, we observed that it was not sufficient to cover with vaseline only the two 
narrow grooves of the experimental chamber but also the very small portions of the 
nerve at the edges of each groove. Figure 12 depicts this important detail, which, if 
overlooked, could lead to a dry nerve and progressive conduction block.
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Fig. 12 The dissected nerve has to be kept in moist environment and even a short 
period of exposure into dry conditions can change the elctrophysiological recordings 
(n=2).
iv) Pressure on chamber grooves and conduction block
Moreover, we observed that during the nerve placement in to experimental bath it was 
important to press gently the two square glass coverslips, which were placed at the top 
of each vaseline and nerve-containing groove. Even minor pressure can traumatize the 
nerve fibres into the narrow grooves of the chamber and produce progressive decrease in 
the amplitude of the obtained action potentials (Figure 13).
2 0 -
1 0 -
amplitude
o
0 30  60  90  120  15 0  180  2 1 0
Time (min)
Fig. 13 Pressure on glass coverslip in experimental chamber can damage the nerve 
fibres into small bath grooves and lead to conduction block. Arrow signifies the time of 
application of excessive pressure (n=3).
v) Experimental instability the first 30-45 min
Finally, in preliminary experiments, immediately after the nerve set up and during the 
first 30 to 45 min of recordings we often observed a gradual increase in the amplitude of 
the electrophysiological recordings (Figure 14). Thus, before the addition of test 
compounds, the preparation was incubated for up to 45 min under constant 
supramaximal stimulation in order to demonstrate consistency in the recordings.
Time (min)
Fig. 14 Before the addition of test compounds, during the first 30-45 min of the 
experiment an increase in nerve action potential was observed. Consistency in
160-1
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1 3 0 -
amplitude in en sh ea th ed  nerve  
amplitude in d esh ea th ed  nerve
3 0 -20-10-0
0 5 10 15 20  25  30 35  40  45  50 55  60  65  70
recordings could be achieved after this “stabilization” period.
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2. Ensheathed nerve 
2a. Control experiments
In electrophysiological recordings from mouse ensheathed sciatic nerve, we first 
performed a significant number of control experiments:
- with physiological salt solution (Figure 15),
- with normal human serum, which did not contain anti-ganglioside antibodies (Figure 
16),
- with normal guinea pig serum as a source of complement (Figure 17), and
- with pentoglobin (commercially prepared normal human IgM) (Figure 18).
The data are summarized in Table 6.
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Fig. 15 Electrophysiological recordings performed at RT on ensheathed mouse sciatic
nerve exposed to physiological salt solution (n = 4). SEM are indicated by error bars
unless they were smaller than symbols.
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Fig. 16 Electrophysiological recordings perfonned at RT on ensheathed mouse sciatic 
nerve exposed to normal human serum (n = 4). SEM are indicated by error bars unless 
they were smaller than symbols.
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Fig. 17 Electrophysiological recordings perfonned at RT on ensheathed mouse sciatic
nerve exposed to normal guinea pig serum as a source of complement (n = 4). SEM are
indicated by error bars unless they were smaller than symbols.
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Fig. 18 Electrophysiological recordings perfonned at RT on ensheathed mouse sciatic 
nerve exposed to nonnal human IgM (n = 4). SEM are indicated by error bars unless 
they were smaller than symbols.
Finally, we tested the effects of tetrodotoxin (TTX), a sodium channel blocker and 
the anti-GQlb IgM serum that obtained from a patient with PPN (CH).
2b. Conduction block induced by TTX
Nerves treated with TTX showed acute conduction block of the compound nerve action 
potentials. In 45 min the amplitude of the compound nerve action potentials was 
decreased in about 90%; also, a significant prolongation of the latency was observed; the 
rise time was equally reduced and an increase to the stimulus threshold was noticed 
(Figure 19 and Table 6).
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Fig. 19 Electrophysiological recordings perfonned at RT on ensheathed mouse sciatic 
nerve exposed to sodium channel blocker tetrodotoxin (TTX: n = 2). SEM are indicated 
by error bars unless they were smaller than symbols.
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2c. The effect of anti-GQlb IgM antibody
The application of anti-GQlb anti-ganglioside serum did not produce conduction block 
in three hours of recording at room temperature (Figure 20 and Table 6). No significant 
changes in amplitude, latency, rise time, and stimulus threshold of the recorded nerve 
action potentials were documented.
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Fig. 20 Electrophysiological recordings performed at RT on ensheathed mouse sciatic 
nerve exposed to anti-GQlb IgM serum from a patient with PPN (CH: n = 5). SEM are 
indicated by error bars unless they were smaller than symbols.
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Table 6 Electrophysiological parameters recorded from the ensheathed mouse sciatic
nerve at room temperature
SAMPLE AMPLITUDE (mV) LATENCY (ms) RISE TIME (ms) THRESHOLD (V)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
CONTROL MATERIALS
PSS (n=4) 4.4±l .9 101.312.7 0.910.1 96.913.1 0.910.1 111.417.5 3.310.2 100.010.0
NS (n=4) 0.9±0.2 102.214.4 1.110.3 96.711.6 1.110.2 96.712.5 3.210.2 98.311.7
NGPS
(n=4)
1.110.1 94.113.9 1.210.2 96.913.1 0.910.0 98.911.1 3.410.1 97.111.7
IgM (n=4) 1.2±0.1 97.913.3 1.110.3 93.312.7 1.210.2 102.015.0 3.810.2 95.911.9
TTX (n=2) 0.7±0.1 7.112.2 0.710.2 194.9138.4 0.710.2 39.3110.7 3.210.3 198.611.4
ANTI-GANGLIOSIDE SERUM
CH (n=5) 1.911.2 93.417.1 0.810.1 98.816.2 0.810.0 1 10.817.0 3.610.4 97.311.6
PSS = physiological salt solution; NS = normal serum; NGPS = normal guinea pig
serum; IgM = normal human IgM; TTX = tetrodotoxin.
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3. Desheathed nerve
3a. The effect of nerve desheathment on saxitoxin penetration
In early electrophysiological recordings from isolated ensheathed nerves during which 
no effects of anti-ganglioside antibody were observed we were concerned that antibody 
may be poorly penetrating. We compared the rate of onset of saxitoxin action (STX, a 
sodium channel blocking agent) in sheathed and desheathed nerve (Figure 21) and noted 
clear differences between the two preparations, indicating the nerve sheath acts as a 
significant mechanical diffusion barrier to small molecules delivered to the extraneural 
environment. Therefore, all subsequent incubations were carried out on desheathed 
nerve preparations.
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Fig. 21 Electrophysiological effect of saxitoxin (STX), a sodium channel blocker on 
sheathed (n=3) and desheathed (n=3) mouse sciatic nerves with the same concentration 
of STX (0.5 nM) of STX. Desheathed preparations were washed out after 12 min. SEM 
are indicated by error bars unless they were smaller than symbols.
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3b. Electrophysiological recordings at room temperature
1. Control experiments
We first applied fresh normal human serum (as a control for the test sera) to the 
preparation for periods up to 4hrs and observed no significant changes in any of our 
recorded parameters (Figure 22 and Table 7). Then we obtained similar results with the 
nerve exposed to normal human IgM (Figure 23 and Table 7). We also observed no 
effect with cholera B subunit, a high affinity multimeric ligand for GM1 ganglioside, 
applied under similar conditions (Figure 24 and Table 7).
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Fig. 22 Electrophysiological recordings at RT on desheathed mouse sciatic nerve
exposed to normal human serum (n = 4). SEM are indicated by error bars unless they
were smaller than symbols.
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Fig. 23 Electrophysiological recordings at RT on desheathed mouse sciatic nerve 
exposed to normal human IgM (n = 4). SEM are indicated by error bars unless they 
were smaller than symbols.
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Fig. 24 Electrophysiological recordings at RT on desheathed mouse sciatic nerve
exposed to cholera toxin B subunit (11 = 2). SEM are indicated by error bars unless they
were smaller than symbols.
Table 7 Electrophysiological parameters recorded from the desheathed mouse sciatic
nerve in control experiments
SAMPLE AMPLITUDE (mV) LATENCY (ms) RISE TIME (ms) THRESHOLD (V)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
NS (n=4) 2.0±0.1 99.4±1.4 0.9±0.2 98.5±1.5 0.8±0.1 95.4±3.1 3.5±0.1 98.6±1.4
IgM (11=4) 3.8±1.0 104.9±2.0 0 .9 ± 0 .1 I02.1±2.1 1.1±0.2 90.6±3.9 3.6±0.1 100.6±0.6
CT (n=2) 3.0±0.3 99.9±2.5 0.8±0.0 103.3±3.3 0.9±0.0 102.9±2.9 3.5±0.1 100.0±0.0
NS = normal serum; IgM = normal human IgM; CT = cholera toxin B subunit.
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2. Physiological effect of anti-GMl IgM sera
When we applied anti-GMl IgM containing sera obtained from three different MMN 
patients (GA, JW, PS), we again observed no significant changes from baseline levels 
of the amplitude of the compound nerve action potential, latency, rise time or stimulus 
threshold (Figures 25, 26, 27 and Table 8). In order to ensure sufficient complement 
was available (if required to induce an effect) we added a fresh source at 3 or 4 hrs for a 
further 90-120mins and again did not observed any changes in the recorded parameters.
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Fig. 25 Electrophysiological recordings at RT on desheathed mouse sciatic nerve
exposed to anti-GMl IgM serum from a patient with MMN (GA: n = 2). SEM are
indicated by error bars unless they were smaller than symbols.
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Fig. 26 Electrophysiological recordings at RT on desheathed mouse sciatic nerve 
exposed to anti-GMl IgM serum from a patient with MMN (JW: n = 6). SEM are 
indicated by error bars unless they were smaller than symbols.
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Fig. 27 Electrophysiological recordings performed at RT on desheathed mouse sciatic
nerve exposed to anti-GMl IgM serum from a patient with MMN (PS: n = 4). SEM are
indicated by error bars unless they were smaller than symbols.
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Table 8 Electrophysiological parameters recorded from the desheathed mouse sciatic 
nerve incubated with anti-GMl IgM  sera
SAMPLE AMPLITUDE (mV) LATENCY (ms) RISE TIME (ms) THRESHOLD (V)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% tim e 
zero)
GA (n=2) 3.3±0.9 120.6±0.7 0.8±0.2 100.010.0 1.310.1 88.512.8 3.710.0 98.611.3
JW (n=6) 5 .7± 2 .1 99.9±7.0 1.110.1 99.210.8 0.910.1 100.810.8 3.610.1 97.610.9
PS (n=4) 2.7±0.8 103.8± 3.1 0.610.0 100.010.0 0.710.0 90.216.2 3.010.1 96.112.3
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3. Physiological effect of anti-GQlb IgM sera
We studied the acute physiological effects of three anti-GQlb IgM containing sera 
obtained from three different patients with PPN (CH, VP, and BK). We used again 
normal human serum as a source of complement that applied for a further 90-120 mins. 
During the 4h of nerve incubation none of the measured parameters has again 
significantly changed (Figures 28, 29, 30 and Table 9).
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Fig. 28 Electrophysiological recordings at RT on desheathed mouse sciatic nerve
exposed to anti-GQlb IgM serum from a patient with PPN (CH: n = 10). SEM are
indicated by error bars unless they were smaller than symbols.
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Fig. 29 Electrophysiological recordings at RT on desheathed mouse sciatic nerve 
exposed to anti-GQlb IgM serum from a patient with PPN (VP: n = 3). SEM are 
indicated by error bars unless smaller than symbols.
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Fig. 30 Electrophysiological recordings at RT on desheathed mouse sciatic nerve
exposed to anti-GQlb IgM serum from a patient with PPN (BK: n = 4). SEM are
indicated by error bars unless they were smaller than symbols.
Table 9 Electrophysiological parameters recorded from  the desheathed mouse sciatic
nerve incubated with anti-GQlb IgM  sera
SAMPLE AMPLITUDE (mV) LATENCY (ms) RISE TIME (ms) THRESHOLD (V)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End of 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f  
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
CH (n=10) 2.9±0.3 103.312.5 0.910.1 94.512.8 0.910.0 92.013.7 3.710.3 99.910.7
VP (n=3) 2.5±0.3 95.513.9 0.710.1 89.815.1 0.710.0 90.113.8 3.210.1 102.112.1
BK (n=4) 3.411.4 97.912.1 0.710.1 100.010.0 0.710.1 91.113.6 3.010.1 104.714.7
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4. Physiological effect of IgG anti-GMl and anti-GQlb sera
Having not observed any acute physiological effect with IgM anti-ganglioside sera, we 
investigated the role of IgG anti-ganglioside sera under the same experimental 
conditions. We studied the acute effects of two different anti-GMl IgG antibodies 
obtained from two patients with GBS (MI, and JY) and a anti-GQlb IgG antibody from 
a third patient with MFS (AS). Again human serum was used as an additional source of 
complement and the nerve was incubated for 4 hrs. The IgG antibody did not induce 
any significant changes in the recording parameters (Figures 31, 32, 33 and Table 10).
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Fig. 31 Electrophysiological recordings at RT on desheathed mouse sciatic nerve
exposed to anti-GMl IgG antibody from a patient with GBS (MI: n = 4). SEM are
indicated by error bars unless they were smaller than symbols.
113
A. Amplitude
1 10-1 
100-  
90- 
80- 
70- 
60- 
50- 
40- 
30-
ant i-G M1 IgG  s e r u m  ( J Y )
90 120 150
Time (min)
180 210 240
1 10 
100-
B. Latency
i i i
an t i -G M 1 IgG s e r u m  (J Y )
90 120 150
Time (min)
180 210 240
C. Rise time
ant i-G M 1 Ig G  s e r u m  ( J Y )
0 30 60 90 120 150 180 210 240
Time (min)
1 1 0 -. 
1 0 0 - '
0 90" 
k. 80-
C 70-
o 60-
0 50-
s« 40-
D. Stimulus threshold
an t i-G M 1 IgG  s e r u m  ( J Y )
30 60 90 120 150 180 210 240
Time (min)
Fig. 32 Electrophysiological recordings at RT on desheathed mouse sciatic nerve 
exposed to anti-GMl IgG antibody from a patient with GBS (JY: n = 4). SEM are 
indicated by error bars unless they were smaller than symbols.
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Fig. 33 Electrophysiological recordings at RT on desheathed mouse sciatic nerve
exposed to anti-GQlb IgG antibody from a patient with MFS (AS: n = 4). SEM are
indicated by error bars unless they were smaller than symbols.
Table 10 Electrophysiological parameters recorded from the desheathed mouse sciatic
nerve incubated with anti-GMl and anti-GQlb IgG sera
SAMPLE AMPLITUDE (mV) LATENCY (ms) RISE TIME (ms) THRESHOLD (V)
Time zero
(absolute
values)
End o f 
incubation 
(% tim e 
zero)
Tim e zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% tim e 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
MI (n=4) 2.2±0.5 126.7±13.4 0 .7 ± 0 .1 96.7±3.3 1.1±0.1 8 4 .U 6 .6 3.6±0.1 99.3±0.7
JY (n=4) 3.4±0.7 87.7±9.9 0.7±0.0 98.2±1.8 0.7±0.1 99.2±2.8 3.3±0.2 100.0±0.0
AS (n=4) 2.4±0.3 103.9±5.1 0.6±0.0 96.1±3.8 1.0±0.1 96.0±2.6 4.5±0.3 99.5±0.5
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5. Physiological effect of anti-GMl monoclonal antibodies
In order to determine the acute electrophysiological effects of anti-ganglioside 
monoclonal antibodies we tested three different anti-GMl IgM monoclonal antibodies 
that came from three different patients with MMN (W ol, Sm l, and Bol). The 
monoclonal antibodies did not induce any acute significant effect on desheathed mouse 
sciatic nerve. Again all measured parameters (amplitude, latency, rise time, and 
stimulus threshold of the action potentials) remained without considerable alterations 
(Figures 34, 35, 36 and Table 11).
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Fig. 34 Electrophysiological recordings at RT on desheathed mouse sciatic nerve 
exposed to anti-GMl IgM monoclonal anti-ganglioside antibody from a patient with 
MMN (W ol: n = 2). SEM are indicated by error bars unless they were smaller than 
symbols.
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Fig. 35 Electrophysiological recordings at RT on desheathed mouse sciatic nerve 
exposed to anti-GMl IgM monoclonal anti-ganglioside antibody from a patient with 
MMN (Sml: n = 6). SEM are indicated by error bars unless they were smaller than 
symbols.
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Fig. 36 Electrophysiological recordings at RT on desheathed mouse sciatic nerve 
exposed to anti-GMl IgM monoclonal anti-ganglioside antibody from a patient with 
MMN (Bol: n = 4). SEM are indicated by error bars unless they were smaller than 
symbols.
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Table 11 Electrophysiological parameters recorded from  the desheathed mouse sciatic 
nerve exposed to anti-GMl IgM  monoclonal antibodies
SAMPLE AMPLITUDE (raV) LATENCY (ms) RISE TIME (ms) THRESHOLD (V)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
W ol (n=2) 3.1 ±0.2 98.3±0.7 0.7±0.0 100.0±0.0 0.6±0.0 100.0±0.0 2.7±0.2 100.0±0.0
Sml (n=6) 3.7±0.8 97.2±5.9 0 .7± 0 .1 101.2±1.2 0.7±0.0 101.1 ±4.5 3.6±0.4 100.8±0.6
Bol (n=4) 2.5±0.6 103.2±4.0 0 .6 ± 0 .1 92 .8±4 .1 0.9±0.2 91 ,6±3.7 3.3±0.2 99.3±0.7
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3c. Effect of temperature on anti-ganglioside antibody activity
1. Electophysiological recordings under different temperature conditions
So far, our results have not confirmed the hypothesis that anti-ganglioside antibodies 
could induce acute conduction block in vitro. We suspected that temperature may play 
an important role in antibody binding and affinity and decided to record at different 
temperature conditions. We tested two different anti-ganglioside sera: one anti-GQlb 
IgM from a patient with PPN (CH), and one anti-GMl IgG from a second patient with 
GBS (MI). In the first case we applied the antibody at RT for 1 hour, then we warmed 
up the preparation and we recorded at 37°C in the presence of complement (Figure 37 
and Table 12); in the second case the nerve was incubated for 1 h at 37°C with the IgG 
antibody, then the temperature was decreased and we recorded at RT after complement 
application (Figure 38 and Table 12). Despite that, none of these two antibodies 
produced conduction block.
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Fig. 37 Electrophysiological recordings at 37°C after incubation of desheathed mouse 
sciatic nerve at RT for lh  with complement. We tested anti-GQlb IgM serum (n=2, 
CH).
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Fig. 38 Electrophysiological recordings at RT after incubation of desheathed mouse 
sciatic nerve at 37°C for 1 h with IgG anti-GMl serum (MI) and complement (n=2).
Table 12 Electrophysiological parameters recorded from the desheathed mouse sciatic 
nerve under different temperature conditions
SA M P L E A M PL IT U D E  (mV) LA TEN C Y  (m s) R ISE  T IM E  (m s) T H R E S H O L D  (V)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End of 
incubation 
(% time 
zero)
CH (n=2) 5.3±0.4 99.814.3 0.6510.0 103.6+3.6 1.010.0 107.912.7 3.110.3 101.811.8
N S (n = l) 8.8 105.2 0.7 100.0 0.8 93.8 2.9 100.0
MI (n=2) 6.810.4 100.814 0.610.0 10010.0 0.810.1 107.117.1 2.710.3 108.318.3
NS (n = l) 4.0 97.6 0.5 100.0 0.7 100.0 2.9 103.5
NS = Normal serum.
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2. Electrophysiological recordings at 37°C
Having determined from immunofluorescence studies (see pages 133-145) that some 
anti-GMl antibodies possessed extensive nodal immunoreactivity with complement 
activation at 37°C, we obtained further electrophysiological recordings under these 
incubation conditions. We observed in preliminary experiments that nerve viability (as 
defined by electrophysiological stability of our recorded parameters) began to 
deteriorate after 4hrs at 37°C and we thus restricted our recording period to 3hrs, plus 45 
mins stabilization period prior to antibody and complement application. We examined 
the acute effects of two anti-GMl IgM containing sera (GA, and JW) that showed the 
highest immunoreactivity in teased fibres. Under these conditions, considered optimal 
in tenns of antibody binding for observing any potentially deleterious effects on nerve 
conduction in this experimental paradigm, we again observed no effects of anti-GMl 
antibody containing sera. During the time course described the amplitude, latency, rise 
time, and stimulus threshold of the recorded nerve action potentials showed no 
significant alteration (Figures 39, 40 and Table 13).
B . L a te n c y
30 60 90 120 150 180
T1 m e  (m in )
anti-GM1 IgM  serum  (GA)
60-
50-
40-
T im e (m in)
110-1
100-
90- 
80 - 
70- 
60 - 
50-
Rise tine
>nti-GM1 IgM  se r
T im e (m in)
1 1 o-
1 OO-' 
90- 
80-
S t im u lu s  t h r e s h o ld
anti-G M  1 IgM  serum  
norm al se rum  
60 90 120 150
Ti m e  ( m in )
Fig. 39 Electrophysiological recordings at 37°C on desheathed mouse sciatic nerve
exposed to anti-GMl IgM serum from a patient with MMN (GA). Points are means of 4
experiments. SEM are indicated by error bars unless they were smaller than symbols.
121
A. A m p litu d e B. L a ten cy
- anti-G M 1 IgM se rum  (J W )
• n orm a l se rum
—i----------------- 1----- 1------------1----------- 1-----------1
30 60 90 120 150 180
Tim e (m in) T im e (m in)
D. S t im u lu s  t h r e s h o ld
- a n ti-G M 1  Ig M  s e ru m  ( J W )  
n o rm a l s e ru m
—i-------------------1--------------------r ---------------1--------------------r —-----------1
30 60 90 120 150 180
T im e  (m in )
Fig. 40 Electrophysiological recordings at 37°C on desheathed mouse sciatic nerve 
exposed to anti-GMl IgM serum from a patient with MMN (JW). Points are means of 4 
experiments. SEM are indicated by error bars unless they were smaller than symbols.
Table 13 Electrophysiological parameters recorded at 37°C from the desheathed 
mouse sciatic nerve exposed to anti-GMl IgM sera from two patients
SA M P L E A M P L IT U D E  (m V) LA TEN CY  (m s) RISE T IM E  (m s) T H R E S H O L D  (V)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End of 
incubation 
(% time 
zero)
GA (n=4) 6 .1 ±0.6 92.7±4.8 0.3±0.2 100.0±0.0 1.1 ±0.2 100.0±0.0 3.4±0.1 100.0±0.0
JW  (n=4) 4.0±l .2 97.7±1.7 0.1 ±0.0 100.0±0.0 1.4±0.3 101.7±2.1 3.5±0.2 100.8±0.8
NS (n = l) 6.4 93.3 0.7 100.0 0.7 100.0 4.5 100.0
NS = nonnal serum.
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C. Discussion
The physiological role of anti-ganglioside antibodies in the pathogenesis of the 
peripheral neuropathies with which they are associated remains uncertain. It has yet to 
be firmly established whether their existence is related with the basic pathogenic 
mechanism or they are simply an associated epiphenomenon of the human autoimmune 
response. Although several reports have suggested that some peripheral neuropathy 
syndromes are immune mediated and anti-ganglioside antibodies are the responsible 
cause for these diseases other data have not confirmed that theory.
One arm of this study was to examine the acute physiological effects of anti-GQlb 
and structurally related disialosyl gangliosides on nerve conduction in vitro. It has been 
previously shown in electrophysiological studies using the mouse phrenic nerve- 
hemidiaphragm preparation in vitro that the motor nerve terminals appear to be 
important site for their action in producing muscle weakness at room temperature 
(Roberts et al. 1994; Willison et al. 1996; Plomp et al. 1999). Although an important 
site, the motor nerve terminal is unlikely to be the exclusive site of action for several 
reasons. Firstly, clinical electrophysiological data from affected patients with both the 
acute Miller Fisher syndrome and chronic sensory ataxic neuropathy associated with 
anti-disialosyl antibodies indicates that peripheral nerve demyelination can occur 
(Willison et al. 1993b; Herron et al. 1994; Jacobs et al. 1997b). Secondly, pathological 
studies on biopsy and post-mortem material have confirmed the peripheral nerve 
demyelination (Phillips et al. 1984). Thirdly, GQlb immunoreactive glycoconjugates 
have been shown in immunohistological studies with G Qlb and anti-disialosyl 
antibodies to be localized to peripheral nerve nodes of Ranvier, both in the human 
extraocular nerves (Chiba et al. 1993) and the mouse sciatic nerve (Willison et al. 1996).
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There are thus strong grounds for predicting that these antibodies might have 
pathophysiological effects in the in vitro mouse sciatic nerve model system.
The second arm of the study concerned the role of anti-GMl antibodies on nerve 
conduction. Clinical studies strongly support the view that there is an association 
between anti-GMl antibodies and motor nerve failure. In addition, immunohistological 
studies have demonstrated that GM1 is localized to peripheral nerve nodal regions 
(Ganser, Kirschner & Willinger 1983; Santoro et al. 1990; Gregson et al. 1991; Thomas 
et al. 1991; Corbo et al. 1993). However the relationship of the anti-GMl antibody to 
the pathogenesis of acute and chronic autoimmune peripheral neuropathies remains a 
matter of controversy and a wide variety of electrophysiological and morphological 
studies on anti-GMl antibodies have shown contradictory findings (Hughes et al. 1985; 
Thomas et al. 1991; Santoro et al. 1992; Arasaki et al. 1993; Uncini et al. 1993; Harvey 
et al. 1995; Takigawa et al. 1995; Roberts et al. 1995; Hirota et al. 1997).
Under the experimental conditions described here, we did not observed any acutely 
deleterious effect of anti-ganglioside antibodies on mouse ensheathed and desheathed 
sciatic nerve conduction. The experiments reported here were conducted after extensive 
preliminary studies aimed at creating a highly stable nerve preparation within the 
duration of the electrophysiological recordings. We described the negative effect that 
can exert changes of bath osmotic pressure and pH. Moreover, we found that great care 
had to be taken with the tissue desheathment and placement of the desheathed nerve in 
the recording bath in order to ensure a stable recording preparation; for this reason the 
stability of the preparation was always checked and monitored for 45 min prior to 
application of test compounds. We notice that a large number of experiments were 
rejected because they were not in keeping with those preconditions. We also repeated
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all experiments on mouse desheathed sciatic nerve preparation at least three occasions to 
accommodate any experimental variability.
In our study we used IgM and IgG anti-ganglioside antibodies and both failed to 
induce acute conduction block. Recently, Arasaki et al. (Arasaki et al. 1998) applied 
sera from 14 patients with AIDP, MMN, and CIDP to isolated lengths of rat sciatic 
nerve and found that 4 produced conduction block in some axons. The effect was 
complement dependent and authors suggest that it was associated with the presence of 
IgM antibodies to ganglioside GM1, although in the same study sera from other patients 
with IgM anti-ganglioside antibody activity did not produce conduction block and in an 
older report the same authors found acute conduction block with rabbit IgG anti- 
ganglioside sera (Arasaki et al. 1993). Our study indicates that it is unlikely that the 
type of the antibody (IgM or IgG) plays a crucial role in the production of conduction 
block or, in an other respect, we cannot support the concept that anti-ganglioside 
antibodies of only IgM or only IgG subclass are involved in the pathogenesis of 
autoimmune peripheral neuropathies.
Moreover, in order to ensure that we had not overlooked any electrophysiological 
abnormalities we re-investigated the 2 anti-GMl antibodies that showed the highest 
degree of binding to the majority of nodes (see pages 133-145). In these later 
experiments, incubations and recordings were conducted at physiological temperatures 
(37°C) under which antibody binding had been identified as maximal and complement 
activation would also be maximal. Even under these conditions, no effects were 
confirmed up to 3 hours incubation, after which time recordings were terminated 
because of the potential for non-specific deterioration in the viability of the preparation.
Ideally, prolonged electrophysiological recordings wouid have been conducted, 
particularly since our immunodeposition studies suggested that to observe full antibody
and complement fixation required overnight incubation, compared with the poorer and 
less consistent immunodeposition signals obtained after 3 hours incubation. However 
this was clearly not possible and a compromise position was thus reached. The study 
described here cannot provide evidence that anti-ganglioside antibodies play a critical 
role in the pathogenesis of autoimmune peripheral neuropathies. Moreover, our data are 
not in favour of the suggestion that anti-ganglioside antibodies may interfere or directly 
block sodium channels. Anti-ganglioside antibodies are not necessarily the cause in 
autoimmune peripheral neuropathies and maybe the presence of other unidentified 
factors plays a primary role in these disorders.
Our conclusion is that anti-ganglioside sera do not produce conduction block under 
carefully control conditions when applied locally to short nerve segments in vitro for 
small periods. Further studies are necessary to demonstrate whether anti-ganglioside 
antibodies have a key pathogenic role, on their own or in association with other 
undetermined factors in causing human autoimmune peripheral neuropathy syndromes. 
The significance of antibodies to gangliosides remains a challenging subject for further 
investigation.
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CHAPTER TWO: ELECTROPHYSIOLOGICAL EFFECT OF ANTI-
GANGLIOSIDE ANTIBODY ON RABBIT SURAL NERVE
Introduction
In the experiments described so far, we attempted to clarify the pathophysiological role 
of anti-ganglioside antibodies from many different aspects. The electrophysiological 
recordings from mouse sciatic nerve preparation clearly showed that these antibodies 
were without effect in this in vitro model. We decided to use rabbit sural nerve, a pure 
sensory nerve, in order to test the hypothesis that CANOMAD anti-ganglioside sera 
(Willison et al. 1996) might have some deleterious effects on sensory neurons. Rabbit 
may have different ganglioside composition at the nodes of Ranvier and more 
vulnerability to human complement than mouse. Also, several studies support the role 
of serum anti-ganglioside antibodies against GDlb and related gangliosides containing 
disialosyl moieties in the pathogenesis of autoimmune ataxic neuropathies (Ilyas et al. 
1985; Daune et al. 1992; Dalakas & Quarles 1996; O’Leary & Willison 1997). 
Moreover, rabbit has been proven vulnerable to anti-GDlb antibodies in sensory ataxic 
neuropathy model (Kusunoki et al. 1996b).
A. Method and materials
1. Anti-ganglioside serum
We examined the acute physiological effect of anti-GQlb and anti-GDlb IgM anti- 
ganglioside antibodies-containing serum from a patient who suffered from a chronic, 
large fiber sensory PPN (CH: see Table 4). This serum showed no detectable GM1 
or/and GM2 activity. As a source of complement and as a control compound we used 
the same human normal serum described in mouse sciatic nerve preparation, which did 
not contain anti-ganglioside antibodies.
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2. Electrophysiological recordings from desheathed rabbit sural nerve
Rabbits were killed according to United Kingdom Home Office guidelines. A 5-6 cm 
length of sural nerve (which originates from the union of the medial sural cutaneous 
branch of the tibial nerve and the sural communicating branch o f the common peroneal 
nerve below the popliteal space) was dissected out and desheathed under a dissecting 
microscope (x50). The preparation was then mounted into the same recording chamber 
used in mouse sciatic nerve preparation (Figure 3), and the physiological buffer solution 
that we used was of the same composition as previously described (see pages 84-87). 
We also followed exactly the same method of extracellular recording as in mouse sciatic 
nerve preparation and we controlled all conditions that could influence the reliability of 
our results, as it has already been described in the previous chapter. All the experiments 
were carried out at room temperature (RT) of 20±2°C. The preparation was incubated 
for 180 mins in the test serum and normal human control serum was applied the last 90 
mins of each experiment as a supplementary source of complement. Control serum, 
complement and patient’s serum were diluted 1:10 in physiological buffer. The sodium 
channel blocker, tetrodotoxin (TTX) was used at a concentration of 1 mg/ml. Finally, we 
perfonned the same analysis of the data as has been described in the previous chapter.
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B. Results
1. Acute conduction block induced by TTX
We first applied tetrodotoxin (TTX), which selectively blocks sodium channels, and we 
observed acute reversible conduction block in about 3 min (Figure 41).
Amplitude
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Fig. 41 Desheathed rabbit sural nerve treated with 1 mg/ml tetrodotoxin (TTX), a 
reversible sodium channel blocker (n=l). Arrow shows the start of the washout phase.
2. Physiological effect of IgM anti-GQlb and anti-GDlb serum
When we applied the patient’s serum containing GQlb and GDlb anti-ganglioside 
antibodies we noticed no significant changes in the amplitude, latency, rise time or 
stimulus threshold of the action potentials. When we added fresh normal human serum 
in order to ensure that sufficient complement was available, again we did not observed 
any changes in the recorded parameters (Figure 42 and Table 14).
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Fig. 42 Desheathed rabbit sural nerve recordings at RT. Exposure of the nerve to anti- 
GQlb and anti-GDlb IgM serum from a patient with PPN (CH). Points are means of 3 
experiments. SEM are indicated by error bars unless they were smaller than symbols.
Table 14 Electrophysiological parameters recorded at RT from the desheathed rabbit 
sural nerve exposed to anti-GQlb and anti-GDlb IgM  serum
S A M P L E A M PL IT U D E  (mV) L A TE N C Y  (ms) R ISE  T IM E  (m s) T H R E S H O L D  (V)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
Time zero
(absolute
values)
End o f 
incubation 
(% time 
zero)
CH (n=3) 3.0±l .2 110.9±12.6 0.5±0.2 9 6 .1 ±3.9 0.710.0 97.612.4 4.010.8 101.111.1
N S (n = l) 2 .1 106.3 0.9 95.8 0.6 100.0 3.9 100.0
NS = normal serum.
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C. Discussion
The recent literature about autoimmune peripheral neuropathies has been dominated by 
the discovery of antibodies to a wide variety of gangliosides. Clinical and 
electrophysiological data from affected patients have shown that serum antibodies 
against gangliosides may have a significant contribution in the pathogenic mechanism of 
some peripheral neuropathy syndromes. In particular, several reports have suggested an 
association between sensory neuropathy syndromes and antibodies which immunoreact 
with disialosyl gangliosides (Ilyas et al. 1985; Daune et al. 1992; Yuki et al. 1992a; 
Brindel et al. 1994; Dalakas & Quarles 1996). Also, it has been reported that IgM 
antibody recognizing B-series gangliosides including GQlb and GDlb causes cell death 
of rat dorsal root ganglion neurons and it has been proposed the anti-B-series 
ganglioside-directed antibody is the causal agent for the human sensory polyneuropathy 
(O hsaw aetal. 1993).
In addition, it is well established that the anti-GQlb antibody is the best example of a 
close association between antibodies to gangliosides and neuropathy and it is detected in 
the majority of patients with Miller Fisher syndrome (MFS) (Chiba et al. 1992; Chiba et 
al. 1993; Yuki et al. 1993b; Willison et al. 1993c; Jacobs et al. 1995; Yuki 1996a; Carpo 
et al. 1998; Suzuki et al. 1998; Schwerer et al. 1999). The anti-GQlb ganglioside 
antibody is highly specific for this syndrome of acute sensory ataxic neuropathy with 
ophthalmoplegia (MFS), and it is not found in normal sera. The only other cases in 
which it is found are patients with related conditions, which might share the same 
pathogenic mechanism, as the acute oropharyngeal palsy variant of GBS (O' Leary et al.
1996) and the benign brain stem encephalitis (Yuki et al. 1993a). Strong evidence 
supporting a pathogenic role for anti-GQ 1 b antibody comes from the demonstration that 
ganglioside G Q lb is particularly abundant in the ocular motor nerves (Chiba et al. 1993;
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Chiba et al. 1997). However, the clinical and neurophysiological findings in Fisher 
syndrome do not match entirely with the distribution of G Q lb ganglioside (which is not 
present in high quantities in the lower cranial nerves that may be affected in atypical 
MFS whereas its concentration is high in optic nerves that are not affected (Chiba et al. 
1997)). In some studies sera positive for anti-GQlb antibody have been found to impair 
neuromuscular transmission in the mouse phrenic nerve-hemidiaphragm model at room 
temperature (Roberts et al. 1994; Plomp et al. 1999), although MFS sera without any 
detectable anti-GQlb activity have also been shown to block evoked quantal release at 
mouse neuromuscular junction (Buchwald et al. 1998b). On the other hand the anti- 
GDlb ganglioside antibody has been proven to cause sensory ataxic neuropathy in 
rabbits due to antibody-mediated damage to the sensory neurons in the first reported 
animal model for autoimmune neuropathy mediated by anti-ganglioside antibody 
(Kusunoki et al. 1996b).
In this study we examined the acute physiological effect of the anti-GQlb and the 
structurally related anti-GDlb ganglioside antibody on a pure sensory nerve preparation 
for several reasons. Firstly, it has been reported that the anti-GQlb antibodies are 
associated with selective and more severe damage of sensory nerves (Jacobs et al. 
1997b), and the GDlb epitope is present on dorsal root ganglion neurons and paranodal 
myelin (Kusunoki et al. 1993; Oka et al. 1996; Willison et al. 1996; Kusunoki et al.
1997). Secondly, studies on human peripheral nerve tissues have demonstrated the 
differences in biochemical composition, content and concentration of gangliosides 
between motor and sensory nerves which may explain the variations in peripheral nerve 
disorders (Ogawa-Goto et al. 1990; Ogawa-Goto et al. 1992; Svennerholm et al. 1994). 
Thirdly, electrodiagnostic and pathological studies from affected patients with sensory 
neuropathy syndromes and anti-disialosyl antibodies have suggested the selective
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vulnerability of sensory nerve fibers (Dalakas 1986; Willison et al. 1993b). Fourthly, it 
is well recognized that sensory and motor axons exhibits ion channels with different 
properties and this diversity may explain the regional and selective immune attack in 
different types of peripheral polyneuropathies (Waxman 1995). Moreover, we selected 
rabbit sural nerve because rabbit nodes of Ranvier contain a set of ionic channels that 
are very similar to those in human nodes as it has proven with voltage-clamp methods 
(Schwarz, Reid & Bostock 1995). The tested antibody came from a patient who 
suffered from chronic paraproteinemic neuropathy with predominantly sensory rather 
than motor symptoms.
Our study described here did not reveal any changes on recorded electrophysiological 
parameters within the 3 hours time frame. The IgM anti-GQlb and anti-GDlb 
antibodies failed to exert any acute dysfunction on sensory neurons conduction and 
these results are in keeping with the previous study on mouse sciatic nerve preparation. 
Also, these negative results failed to give an in vitro support of the suggested pathogenic 
importance of disialosyl antibodies in autoimmune sensory polyneuropathies. 
Moreover, we failed to confirm that these antibodies in the presence of complement 
could block sodium channels, as has been postulated (Waxman 1995), compared with 
the acute block induced by the tetrodotoxin (TTX). Despite our negative results, we 
remain in favour of the view based on collective data from clinical studies that these 
antibodies are likely to be pathogenic in vivo. Moreover, more extensive studies than 
the in vitro electrophysiological model described here will be necessary to convincingly 
elucidate the role of these antibodies in causing conduction block.
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CHAPTER THREE: IMMUNOHISTOCHEMICAL STUDY OF ANTI-
GANGLIOSIDE ANTIBODIES
A. Method and materials
1. Immunofluorescence studies on mouse sciatic nerve preparations
Male BALB/c mice (15-20 g) were sacrificed by exposure to carbon dioxide and the 
sciatic nerves were dissected and desheathed as for the electophysiology preparation 
described above. The nerves were incubated overnight at RT or at 37°C in 0.1 ml of 
pre-oxygenated physiological buffer containing the experimental sera or monoclonal 
antibodies. In preliminary studies we found that incubation for up to 4 hours was 
insufficient to achieve equilibration in antibody binding and produced antibody binding 
and complement fixation with high inter-experimental variability; we therefore 
performed overnight incubations to compensate for this effect. We tested three different 
anti-GMl monoclonal antibodies (W ol, B ol, Sm l; 20 pg/ml), two different red cell 
eluate preparations (RCE, prepared on red cell affinity columns as described in Willison 
et al., (Willison et al. 1996)) with anti-GQlb IgM activity (CH, VP; 20 pg/ml), and 
three different plasmas with activity against GQlb (BK; diluted 1:10), GM1 (PS; diluted 
1:10) or GM1/GM2 (GA; diluted 1:50). The active antibodies in each preparation were 
IgM (see Table 4). We used normal human serum as both a serum control (at the 
appropriate dilution) and a source of complement (diluted 1:10). Samples were coded 
and studied blind. After the incubation period, the nerves were subjected to three 15 
min washes with clean buffer, and then teased out into bundles containing as few fibres 
as possible, using fine syringe needles. The separated fibres were allowed to air dry 
onto 3-aminopropyltriethoxysilane coated slides before use or storage at -20°C. To 
identify immunoglobulin and complement deposits on the fibres, the slides were 
incubated for 1 hour at 4°C in PBS containing 10% lamb serum, 0.3% rhodamine-
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labelled anti-human IgM antibody (Southern Biotechnology Associates; diluted 1:300), 
and either a fluorescein-labelled antibody to the C3c complement activation product 
(C3c; Dako) or 0.1% fluorescein-labelled cholera toxin B subunit (CT; Sigma). The CT 
was used to help identify Schwann cell architecture, especially the paranodal regions 
that stain strongly. The slides were again rinsed in cold PBS before being mounted in 
Citifluor antifade (Citifluor Products, Canterbury, UK), ringed with nail-vamish to 
minimise drying and stored at 4°C in the dark prior to viewing. Controls consisting of 
second antibody alone were run in parallel with every staining batch.
2. Imaging
Images were obtained by means of a Sony colour 3CCD camera mounted onto a Zeiss 
Axioplan fluorescent microscope, linked to a PC driven image archiving system (Sirrius 
VI; Optivision). The threshold of the image acquisition equipment was set up such that 
the control level of staining obtained with secondary antibodies alone was zero. The 
model staining counts and micrographs shown in this study are based on the signal 
detected above the threshold level. The time involved in making individual teased fibre 
preparations for use for this study meant that the screening of large numbers of control 
samples was impractical. It was decided to control this study with a single, well 
characterised normal serum used extensively in other studies within the group (Plomp et 
al. 1999). In preliminary studies conducted by Dr. Graham O’Hanlon to assess the 
range of background signals produced by '‘normal” serum on neuronal membranes, a 
panel of 11 serum samples (including the control for this study), each lacking anti- 
ganglioside or known anti-neural activity, were screened in a quantifiable assay. The 
control serum was not significantly different from the pooled results from the other 10 
samples (2-tailed Mann Whitney U test; p = 0.42), and as such taken to be a reasonable
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representative of the population. For the fluorescein (C3c staining) and rhodamine 
(IgM) channels, images were integrated to obtain unambiguous signal intensities for 
counting nodes. On each slide, 25 consecutive nodes were identified at random under 
phase microscopy and scored either positive or negative for IgM and C3c. Bitmap 
processing and annotation were conducted on PhotoMagic and Windows Draw (both by 
Micrographx Inc.). Images were printed directly using a photographic-quality colour 
printer (Kodak ColourEase).
Data were analysed using Chi-square or Fisher exact test as appropriate. All analyses 
were performed using the Minitab 10.5 for windows statistical package.
B. Results
1. Preliminary immunohistochemical observations from the nerves used in 
electrophysiological recordings
We perfonned the electrophysiological experiments on mouse desheathed sciatic nerve 
preparation at the Department of Physiology and Pharmacology of Strathclyde 
University, and the nerves were incubated in ganglioside antibody antisera for periods 
up to 4 hrs. In order to examine immunoglobulin and complement deposition at the 
nodes of Ranvier, we kept some of these preparations at 4°C in paraformaldeyde. From 
these we prepared teased fibres, and we performed our first immunofluorescence study 
using nerves that were incubated with IgM anti-ganglioside sera, because of the very 
high background signals observed with immunostaining for IgG deposits. We examined 
four different IgM anti-ganglioside sera (GA, JW, BK, and PS) and two different 
monoclonal anti-ganglioside antibodies (Bol/Bo3, and Sml). As control we used 
nerves incubated with nonnal human IgM. In this study we did not perfonn a 
quantitative analysis for immunopositive and immunonegative nodes. However, GA,
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and JW sera show some staining at a proportion of nodes of Ranvier in many 
experiments. Also, BK, and PS sera gave rise to some immunodeposits at the nodes 
compared with normal human IgM, whereas Bol/Bo3 and Sml monoclonal antibodies 
showed very weak or no immunoreactivity.
2. Immunoglobulin and complement deposition following in vitro incubation with 
IgM anti-ganglioside antibody
In order to determine whether nerves incubated with sera contained immunoglobulin 
and complement deposits at nodes of Ranvier we investigated separately the effect of 
each Ab used in the electrophysiology section, following the same incubation period and 
concentration as described in that section. We examined the effects at two different 
temperatures, RT and 37°C. The results were quite ambiguous; monoclonal antibodies 
and anti-ganglioside sera showed characteristic diversity, although some were again 
proved highly immunoreactive (GA, and JW).
We wanted to have a clear view of the immunodeposition of the anti-ganglioside 
antibody. The incubation period was increased from 4 hrs to overnight and for each 
serum or/and monoclonal Ab examined, an observer blinded quantitative 
immunoanalysis was performed. Studies were again restricted to sera containing IgM 
anti-ganglioside activity because of the very high background signals observed when 
immunostaining for IgG deposits, with either normal of disease-associated sera at these 
low dilutions (1/10). The data are demonstrated in Figures 43, 44 and Table 15. The 
immunodeposits were more prominent at 37°C compared to RT with a statistically 
significant difference (p=0.007). Also, under the imaging conditions described above, 
25 of nodes of Ranvier (15%) stained positive for human IgM following incubation at 
RT with normal human serum, whereas this dropped to 16 positive nodes (8%) at 37°C
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(p=0.048). One of the monoclonal antibodies (W ol) and one of the anti-GMl antibody 
containing sera studied (GA) gave rise to abundant immunodeposits at 60-90% nodes of 
Ranvier at both RT and 37°C (Table 15), although statistically significant difference 
between 37°C and RT was achieved only for one of these two samples (W ol, p=0.001). 
Five (GA, PS, BK, CH, W ol) out of eight anti-ganglioside samples showed statistically 
significant difference versus control serum at 37°C, whereas only two of them (GA, and 
W ol) had a similar effect at RT. Three tested samples (VP, B ol, and Sm l) failed to 
achieve significant differences in the frequency of nodal staining at either temperature. 
The vast majority of IgM positive nodes were also positive for the complement 
activation product C3c. Examples of these immunostaining patterns are shown in 
Figure 45.
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Table 15 Immunofluorescence studies on teased fibres prepared from desheathed 
mouse sciatic nerve pre-incubated with anti-ganglioside antibodies
Antibody code Immunopositive nodes of Ranvier
37°C RT
Pos Neg to t % Chi2*
(+/-VS
NS)
Pos Neg to t % Chi2*
(+/-VS
NS)
Chi2*
(+/-VS
37°C)
NS 16 173 189 8 nsd 25 139 164 15 nsd *
Total
(GA-Sml)
114 97 21 1 54 * * * 85 123 208 41 *** **
GA 60 15 75 80 * * * 40 20 60 67 *** nsd
PS 5 10 15 33 * 4 11 15 27 nsd nsd
BK 5 10 15 33 * 4 11 15 27 nsd nsd
CH 4 11 15 27 * 8 20 28 29 nsd nsd
VP 7 23 30 23 nsd 9 21 30 30 nsd nsd
W ol 29 1 30 97 ** * 18 12 30 60 *** **
Bol 13 16 19 nsd 2 13 15 13 nsd nsd
Sml 1 14 15 7 nsd 0 15 15 0 nsd nsd
# or Fisher exact test where required. Nsd; no significant difference.
* p<0.05, ** p<0.01, *** p<0.001
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Fig. 43 Immunofluorescense studies on mouse sciatic nerve teased fibres (Data from 
Table 15). Three different anti-GMl monoclonal antibodies (2, 3, 4) and five different 
sera, of which two anti-GMl (1,5) and three anti-GQlb (6, 7, 8) positive, were tested. 
All the tested antibodies were of IgM type. In the control experiments we used a single 
normal human serum (see page 134).
1=GA, 2=W ol, 3=Bol, 4=Sml, 5=PS, 6=BK, 7=VP, and 8=CH.
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Fig. 44 A significantly increased deposition of IgM at nodes of Ranvier was observed 
in nerves exposed to anti-ganglioside antibodies (p<0.001). For anti-ganglioside 
samples (AS) the immunodeposits were more prominent at 37°C compared to RT 
(p<0.01), whereas a significant increase in staining at RT versus 37°C for control serum 
(NS) was also observed (p<0.05) (data from Table 15).
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Fig. 45 Deposition of antibody and complement in mouse sciatic nerve teased-fibre 
preparations. Phase-contrast images (panels a, e, and i) of positively stained nodes of 
Ranvier (arrows). GA anti-GMl IgM serum treated nerve (a-d) was stained with 
fluorescein-labelled cholera toxin B subunit (b) which binds the paranodal myelin and 
for human IgM deposits (c) which are deposited at the nodal gap. Wol anti-GMl 
monoclonal antibody treated nerve (e-h) was stained with fluorescein-labelled cholera
142
toxin B subunit (f) and for human IgM deposits (g) which occupy a nodal and paranodal 
distribution. W ol-treated nerve (i-1) stained for complement C3c (j) and human IgM (k) 
which again occupy a nodal and paranodal distribution. Scale bar = 20 pm; xlOO, under 
oil).
C. Discussion
Over the last decade immunohistochemistry has been an intense field in investigating 
the role of anti-glycoconjugate antibodies in peripheral neuropathies and numerous 
immunohistological studies have suggested that some of these disorders are anti- 
glycolipid antibody-mediated syndromes. Circulating monoclonal IgM anti-MAG 
antibodies have been proved to be associated with a specific type of human peripheral 
nerve demyelination. Positive serum immunofluorescence studies and the presence of 
widening of myelin lamellae have demonstrated that human anti-MAG neuropathy is 
likely to be antibody mediated (Hays et al. 1987; Willison et al. 1988; Trojaborg et al. 
1989; Vital et al. 1989; Tatum 1993; Vallat et al. 1996).
On the other hand the anti-ganglioside antibodies have been postulated to be 
implicated in the pathogenesis of some autoimmune peripheral neuropathies. It remains 
unclear whether these antibodies are primarily responsible for causing damage to the 
nerves and conflicting results have been obtained from electrophysiological and 
pathological studies (Thomas et al. 1991; Santoro et al. 1992; Arasaki et al. 1993; 
Uncini et al. 1993; Harvey et al. 1995; Takigawa et al. 1995; Hirota et al. 1997). 
However, several immunohistochemical studies provide strong evidence that supports 
their implication in the pathogenesis of human neuropathies and anti-ganglioside 
antibody deposits have been detected in peripheral nerve structures, including nodes of 
Ranvier (Santoro et al. 1990; Gregson et al. 1991; Thomas et al. 1991; Santoro et al.
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1992; Adams et al. 1993; Kusunoki et al. 1993; Nardeli et al. 1994; Harvey et al. 1995; 
Hafer-Macko et al. 1996; Oka et al. 1996; Willison et al. 1996; Kusunoki et al. 1996b; 
Kusunoki et al. 1997; Paparounas et al. 1999). The purpose of the present 
immunofluorescence study was to investigate the anti-ganglioside antibody and 
complement deposition at nodes of Ranvier. The node of Ranvier is a narrow gap of 
axon along a myelinated fibre that generates currents for nerve impulses. This nodal 
region is a mere 0.5-1.0 pm wide and contains the highest density of ion channels of all 
known excitable membranes (Waxman & Ritchie 1985).
The data presented in this study suggest that antibody and complement products can 
be deposited at a proportion of nodes of Ranvier and this finding may explain the 
possible pathophysiological effect of anti-ganglioside antibody. It is possible that these 
antibodies block sodium channels at the node of Ranvier which is highly differentiated 
in that region, exhibiting unique morphological, electrophysiological and cytochemical 
properties compared to other sites along the fibre (Waxman & Ritchie 1985). GM1 
ganglioside has been localized at the node of Ranvier (Ganser et al. 1983; Corbo et al. 
1993) where sodium channels are clustered (Waxman 1995) and IgM deposits have been 
observed at nodes of Ranvier in our study. We do not know the mechanism that may 
elicit the production of antibodies that may block sodium channels. Also, the initial 
events that cause exposure of the GM 1 epitopes to the antibodies are similarly unknown. 
Previously, binding of anti-GMl antibodies to the nodal region has been suggested to 
block ion channels and disrupt the membrane at the node of Ranvier, causing conduction 
block (Takigawa et al. 1995), although this hypothesis has been recently disputed 
(H irotaetal. 1997).
The fine specificities and the differences in the sources of the antibodies may also 
play an important role in the nature and extent of nodal binding. It is known from
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immunohistological studies that different anti-GMl antibodies are highly diverse in their 
peripheral nerve staining patterns, including the presence or absence o f binding to nodes 
of Ranvier (O' Hanlon et al. 1998). Similarly there are marked species differences in the 
distribution and immunoreactivity of gangliosides, including differences in peripheral 
nerve between rat and mouse (O' Hanlon et al. 1996). For these reasons we checked for 
the binding of antibody and complement deposition in the same preparations from which 
electrophysiological recordings have been made and observed high degrees of nodal 
binding with some anti-ganglioside antibodies. Also, the period of time during which 
the nerve fibre is exposed to antibody may be another important factor, as we observed 
substantial differences in antibody binding between overnight and four hours incubation 
periods. This could offer a possible explanation for our negative electrophysiological 
results, where the exposure of the nerve to antibody was no longer than four hours.
Our findings suggest that the antibodies might exert their effect by binding to the 
nodal regions of peripheral nerve. This might set into motion a cascade of sequential 
reactions through complement activation. The activation of terminal complement 
components (membrane attack complex) might lead to the insertion of pore forming 
molecules into the nodal membrane. Thus, ions can move through these pores and the 
antibodies may disturb conduction of action potentials through direct or indirect 
interference with sodium channels or other structures, which are located at the nodes of 
Ranvier in peripheral nerve. The reason for the increased binding at 37°C is unknown, 
but the antigen may be more accessible at 37°C than at RT. Moreover, we do not know 
if there was any preferential involvement of motor or sensory fibres since the nerve we 
used was a mixed peripheral nerve. This study revealed that one of the tested anti-GMl 
sera and one of the monoclonal antibodies gave rise to antibody and complement 
deposits at over 50% of nodes of Ranvier in some preparations. In contrast, some other
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antibodies derived from different patients showed a lower affinity for their target epitope 
and in some other cases the immunostaining at the nodes of Ranvier was absent. The 
effect of antibodies might also depend on their size or local factors, which allow them to 
penetrate most cryptic and unavailable epitopes or not. Also, the ability of the antibody 
to access an antigenic site may be determined by the epitope density and interactions 
with neighbouring molecules. In addition, the nature and severity of the disease and 
antibody titre may play another significant role.
Thus, although the hypothesis that these antibodies may play a pathogenic role in 
autoimmune peripheral nerve disorders is still disputable, this study clearly shows that 
anti-ganglioside antibody could cause conduction abnormalities through binding at the 
nodes of Ranvier. However the data are insufficient to conclude that the anti- 
ganglioside antibodies are responsible for the nerve damage and new efforts are needed 
to further investigate their pathogenic effects against peripheral nervous system targets.
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CHAPTER FOUR: TWITCH TENSION IN MOUSE PHRENIC NERVE-
HEMIDIAPHRAGM PREPARATION AFTER ANTI-GANGLIOSIDE 
ANTIBODY APPLICATION 
Introduction
Our immunochemistry studies clearly showed that two anti-GMl positive sera (GA, 
and JW) were at high percentages immunoreactive at body temperature, and also the 
anti-GQlb containing serum (CH) had a significant immunolocalization at nodes of 
Ranvier at the same temperature (see Table 15). However, these sera did not have any 
deleterious effect on isolated mouse sciatic nerve physiology at 37°C (see pages 120- 
121). We wished to detect any acute effect of these antibodies on neuromuscular 
transmission at physiological temperature. We used mouse phrenic nerve- 
hemidiaphragm preparation, which is a useful model in investigating the antibody- 
mediated disorders of neuromuscular junction.
A. Method and materials
Phrenic nerve-hemidiaphragm preparations were dissected from male Balb-C mice, 20- 
25g that were killed by exposure to carbon dioxide. The preparation was mounted in a 
10 ml tissue bath containing a physiological salt solution of the following composition 
(mM): NaCl 118.4, KC1 4.7, M gS04 1.2, K H P04 1.2, CaCl2 2.5, N aH C03 25, and 
glucose 11.1. The solution was maintained at 37°C and was aerated throughout the 
experiment with gas containing 95% oxygen and 5% C 0 2. The experiments were 
carried out at pH=7.4 and osmotic pressure 320110 mOsm/kg. The pH of the solution 
was checked after the initial 100% saturation and also at the end of each experiment. 
Phrenic nerve was stimulated with pulses of 0.01 msec duration and 10 V stimulus 
strength, once every 10 sec via a platinum ring electrode. Twitches were recorded on
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Grass 79B and Washington ink writing polygraphs using Grass FT03 or SRI 
transducers. We employed low voltage and short duration pulses in order to ensure that 
the evoked twitch was due to indirect (via the nerve) stimulation; if with such 
stimulation the elicited tension of the hemidiaphragm was of very small amplitude or 
unrecorded the preparation was discarded. Before the optimization of the muscle length 
the resting tension of 1 g was used. Preparations were allowed to stabilize for about 20 
min before the addition of the compounds.
Two anti-GMl IgM anti-ganglioside antibodies from two different patients with 
MMN (GA, and JW) were highly immunoreactive in mouse sciatic nerve teased fibres at 
37°C, as previously described. We examined these two anti-GMl IgM highly positive 
sera and one anti-GQlb and anti-GDlb IgM from a patient with PPN (CH) (see Table 
4). The source of complement was normal human serum, which was also used as 
control compound. Patients’ sera and normal serum were diluted 1:40 and complement 
1:50. Both were applied together from the start of each experiment.
The data are presented as mean±SEM. All measurements were normalized according 
to the control values at time zero, without the presence of anti-ganglioside antibody. 
Statistical significance was tested with non-parametric statistics (Mann-Whitney’s test) 
and Chi-square test as appropriate. All analyses were performed using the Minitab 10.5 
for Windows statistical package.
148
B. Results
1. Neuromuscular blockade induced by curare
In preliminary control experiments we studied the acute physiological effects of 
tubocurarine on neuromuscular transmission. Tubocurarine combines with 
acetylcholine receptors postjuctionally producing neuromuscular block (competitive 
blockade). Figure 46 is a characteristic example of the effect of tubocurarine on mouse 
phrenic nerve-hemidiaphragm twitch tension. Also this Figure clearly depicts the 
completely reversible effect of the drug after the washout of the preparation.
Effect o f  curare on  twitch ten s ion
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Fig. 46 Acute neuromuscular block in mouse phrenic nerve-hemidiaphragm preparation 
produced by tubocurarine (10'8 M) at 37°C. Preparations were washed out after 7min 
(arrow). Points are means of two experiments and SEM are indicated by error bars 
unless they were smaller than symbols.
2. Pitfalls in mouse phrenic nerve-hemidiaphragm recordings
In early twitch tension recordings, in order to reveal any subtle change in neuromuscular 
transmission due to anti-ganglioside antibody activity, we decided to induce a partial 
block by curare in order to increase the sensitivity of observing an effect. Thus, a 70%
o
reduction in the twitch height was induced by tubocurarine (10' M). The
neuromuscular block may be antagonized by any compound that increases the release of
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acetylcholine by nerve impulses. With the safety factor reduced, any alteration in the 
release of acetylcholine would be more apparent. With this method, in about 15 mins 
after the application of anti-ganglioside antibody, a gradual increase in twitch tension 
was observed despite the presence of tubocurarine, and it was thought that this effect 
was due to anti-ganglioside antibody activity (Figure 47A). The same phenomenon was 
observed in the corresponding control experiments after the application of nonnal 
human (Figure 47B). Therefore, the method of investigating the acute physiological 
effects of anti-ganglioside antibodies in partially curarized neuromuscular junction was 
abandonded. We postulate that the recovery observed after the application of normal or 
anti-ganglioside sera was most likely a dilution phenomenon.
Fig. 47A Misleading effect of anti-ganglioside Ab on mouse phrenic nerve- 
hemidiaphragm twitch tension experiments at 37°C with the safety factor reduced.
IgM serum (diluted 1/40), respectively. SEM are indicated by error bars unless they 
were smaller than symbols.
Fig. 47B When we applied normal human serum (diluted again 1/40) we again 
observed the same phenomenon as with anti-ganglioside sera.
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3. Physiological effect of anti-ganglioside antibody on muscle twitch tension
We first applied fresh normal human serum to the preparation for periods up to 3 hrs and 
we observed no significant changes in the recording twitch tension (Tables 16, 17 and 
Figure 48). When we applied the patients’ IgM anti-ganglioside containing sera, we 
again observed no significant changes in phrenic nerve twitch tension in up to 3 hrs of 
recording (Figure 48 and Tables 16, 17). Table 16 shows the absolute values of all 
performed experiments, and Table 17 the percentage changes after application of test 
compounds for up to 3 hrs.
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Fig. 48 Results from mouse phrenic nerve-hemidiaphragm twitch tension experiments 
at 37°C. We tested the following anti-ganglioside sera: A. Anti-GMl IgM from a 
patient with MMN (JW, n=5) B. Anti-GMl IgM from another patient with MMN (GA, 
n=5) and C. Anti-GQlb IgM from a third patient with PPN (CH, n=5). Normal human 
serum was used as control serum (n=3) and as a source of active complement. 
Complement was added with patient serum at the beginning of incubation period. SEM 
are indicated by error bars unless they were smaller than symbols.
Table 16 Twitch tension in absolute values (g) recorded from  mouse phrenic nerve- 
hemidiaphragm preparation at 37° C after the application o f anti-ganglioside sera fo r  up 
to 3 hrs
T IM E  (m in) SA M PLES
NS (n=3) JW  (n=5) GA (n=5) C H  (n=5)
0.0 1,6±0.2 1.8±0.2 1.3±0.2 1.7±0.1
15.0 1.6±0.2 1.8±0.2 1.3±0.2 1.7± 0 .1
30.0 1.6±0.2 1.8±0.2 1.3±0.2 1.7±0.1
45.0 1.6±0.2 1.8±0.1 1.3±0.2 1.7±0.1
60.0 1.6±0.2 1.8±0.1 1,4±0.2 1.7±0.1
75.0 1.6±0.2 1.8±0.2 1,4±0.2 1.7±0.1
90.0 1,6±0.2 1.8±0.2 l.3±0.2 1.7±0.1
105.0 1.6±0.2 1.8±0.1 1.3±0.2 1.7±0.1
120.0 1,6±0.2 1.8±0.2 1.3±0.1 1.7±0.1
135.0 1.6±0.2 1.7±0.2 1.3±0.2 1,7±0.1
150.0 1,6±0.2 1.7±0.2 1.3±0.2 1.6±0.1
165.0 1,6±0.2 1.7±0.2 1.3±0.2 1.6±0.1
180.0 1.5±0.2 1.7±0.1 1.3±0.2 1.6±0.1
NS = normal serum; JW = serum with anti-GMl IgM antibody; GA = serum with anti- 
GM1 IgM antibody; CH = serum with anti-GQlb IgM antibody.
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TABLE 17 Mouse phrenic nerve-hemidiaphragm preparation. Twitch tension 
experiments at 37°C. The table shows the percentage changes after application o f  test 
compounds fo r  up to 3 hrs
T E S T E D  SER A T IM E  Z E R O END O F  IN C U B A TIO N  (%  T IM E  Z E R O )
Anti-G M l Ab (JW , n=5) 100.0% (1 .8g±0.2) 94.7±1.2
A nti-G M l Ab (GA, n=5) 100.0% (1.3g±0.2) 96.612.9
A nti-G Q lb  Ab (C H , n=5) 100.0% (1.7g±0.1) 94 .1% 11.8
NS (n=3) 100.0% (1.6g±0.2) 94.011.1
Values are means ±SEM. The absolute values at time zero are indicated in parentheses. 
NS = normal serum.
C. Discussion
Two anti-ganglioside antibodies, anti-GMl and anti-GQlb, have been described to be 
associated with specific neurological syndromes and much of the recent literature 
supports their pathogenic role in human autoimmune peripheral neuropathies. The 
clinical presentation of neuropathy may depend on whether the nerve dysfunction occurs 
in myelin, the nodes of Ranvier, or neuromuscular junction. In this study we examined 
the acute neurophysiological effects of anti-GMl and anti-GQlb positive sera using a 
motor nerve-muscle preparation.
Electrophysiological studies have previously implied the possible presynaptic effect 
of anti-GQlb antibody on acetylcholine release from motor nerve terminals in mouse 
phrenic nerve-hemidiaphragm preparation at room temperature (Roberts et al. 1994), 
and mouse neuromuscular junctions have been found important sites of antibody action 
in conjunction with activated complement (Plomp et al. 1999). However, the 
aetiopathogenic role of anti-GQlb antibody in causing dysimmune clinical syndromes 
cannot be established with certainty since immunoglobulin G as well as its Fab
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fragments from anti-GQlb negative MFS patients has been shown to depress evoked 
quanta end plate currents from mice hemidiaphragms (Buchwald et al. 1998b). 
Similarly, the neuromuscular blockade induced by IgG antibodies from patients with 
GBS was independent of the presence or absence of detectable anti-GMl or anti-GQlb 
antibodies (Buchwald et al. 1998a). Moreover, sera and plasma from patients with 
MMN can interfere with distal motor nerve function and block nerve conduction at 
distal motor nerves, although the anti-GMl antibody may not be the cause of such 
dysfunction since anti-GMl negative sera from patients with MMN can have the same 
activity in motor nerve-muscle preparation (Roberts et al. 1995). Also, Miller Fisher 
sera/plasmas showed no effect on transmitter release from PC 12 cells (Benatar, Willison 
& Vincent 1997).
This study failed to demonstrate the neuromuscular blockade induced by these 
antibodies. Our results imply that the anti-GQlb or anti-GMl antibodies are not 
sufficient by their own in inducing muscle weakness in MFS and other related 
neuropathies. Maybe there are other or additional serum factors or antibodies against 
undetermined antigens which interfere with presynaptic calcium inflow or prevent the 
activation of post synaptic channels and so, play a primary but still unknown role in 
these neurological disorders. The causal role of an antibody (not necessarily the GQlb 
or anti-GMl) responsible for muscle weakness observed in some of these syndromes 
seems more likely since muscle strength improves rapidly after therapeutic 
plasmapheresis or immunoadsorption (Yuki 1996a; Yuki 1996b; Ohtsuka et al. 1998b). 
It must be emphasised that we took all necessary precautions to minimise artificial 
effects since it is well known that neurotransmitter release from motor nerve terminals 
can be influence by many factors (Hubbard, Jones & Landau 1968). Also, the 
experiments described here were performed at body temperature and we investigated the
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effects of IgM antibodies; maybe we would obtain different results at room temperature 
or with antibodies of IgG type. These may more easily reach nerve terminals and the 
nodes of Ranvier would be easier accessible antigenic targets. Perhaps only the high 
affinity anti-ganglioside antibodies can bind to the presynaptic membranes and nodes of 
Ranvier and, therefore, exert their neurophysiological effects. By contrast, the presence 
of anti-ganglioside antibodies might be a secondary phenomenon to the destruction of 
neurons and following exposure of neuronal antigens to the immune system. May be 
humoral immunity to other antigens, or cell-mediated immunity and immune complexes 
are of pathogenic significance in autoimmune polyneuropathies.
In conclusion, although our observations cannot support the hypothesis that anti- 
G Q lb and/or anti-GMl anti-ganglioside antibodies have a primary effect on 
neuromuscular junction and subsequently play a key pathogenic role in some 
neuromuscular disorders, additional studies may provide clues to the events that 
stimulate these antibodies and may further clarify their pathophysiological relevance and 
their potential role in neuromuscular transmission.
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PART THREE - GENERAL DISCUSSION 
Summary
This study has examined the binding, complement activating potential and acute 
physiological effects of neuropathy-associated human anti-ganglioside antibodies. We 
tested in vitro a range of human anti-ganglioside antisera and monoclonal antibodies 
with high titers of IgM or IgG antibodies to GM1 and G Q lb (and structurally related) 
gangliosides. Sera were obtained from nine different patients with multifocal motor 
neuropathy, Guillain-Barre syndrome or Miller Fisher syndrome. Monoclonal 
antibodies were cloned from peripheral nerve lymphocytes of three different patients 
with anti-GMl associated neuropathies. No abnormal physiological effects were 
observed on nerve conduction in isolated mouse sciatic or rabbit sural nerve organ bath 
preparations. Neither the anti-ganglioside sera nor the monoclonal antibodies produced 
acute conduction block; even with the presence of activated complement products nerve 
conduction remained unchanged. Moreover, anti-ganglioside antibodies were without 
effect on muscle twitch tension recorded from mouse phrenic nerve-hemidiaphragm 
preparation. However, quantitative immunohistochemical analysis of mouse sciatic 
nerve teased fibres exposed to anti-ganglioside antibodies, revealed a significant 
increase in IgM (immunoglobulin M) and complement deposition at nodes of Ranvier. 
These data indicate that anti-ganglioside antibodies cannot induce any overt 
physiological injury on nerve conduction in vitro, despite that antibody and complement 
products can deposite at a significant proportion of nodes of Ranvier.
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1. Autoimmunity in peripheral nervous system disorders: a brief introduction
The pathogenic role of autoantibodies in causing peripheral neuropathies and 
neuromuscular diseases is well established in some disorders (Dalakas 1995; Vincent et 
al. 1999). The classical antibody-mediated neurological disease is myasthenia gravis. In 
this disease, circulating autoantibodies to acetylcholine receptors are found in more than 
80% of patients and their pathogenicity has been demonstrated by “passive transfer” of 
the disease into experimental animals, resulting in impairment of neuromuscular 
transmission postsynaptically with weakness and loss of muscle acetylcholine receptors 
(Toyka et al. 1977). Lambert-Eaton myasthenic syndrome is another disorder associated 
with antibodies to voltage-gated calcium channels (Vincent, Lang & Newsom-Davis 
1989) and, also, antibodies to voltage-gated potassium channels have been demonstrated 
to be of pathogenic importance in acquired neuromyotonia (Isaacs’ syndrome) 
(Newsom-Davis & Mills 1993; Vincent 2000).
Much of the research efforts over the past ten years have focused on lipid and 
glycoconjugate antigens and substantial bibliographic evidence implicates them as major 
targets for antibody responses in some peripheral neuropathy syndromes with suspected 
autoimmune basis. The autoimmune pathogenesis seems to be well characterised in the 
IgM-associated polyneuropathy with anti-MAG antibodies where the pathological 
process (Vital et al. 1989; Steck & Kappos 1994; Trojaborg et al. 1995) can be 
transferred to experimental animals causing demyelination and conduction block (Hays 
et al. 1987; Willison et al. 1988; Trojaborg et al. 1989; Tatum 1993). On the other hand, 
although strong circumstantial evidence support the link between antibodies to 
gangliosides and autoimmune responses in some peripheral nerve disorders, the precise 
role which these antibodies play in the disease process is not understood. It remains to 
be elucidated to what extent these antibodies are responsible for autoimmune peripheral
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neuropathies, including Guillain-Barre syndrome (GBS) and Miller Fisher syndrome 
(MFS). Moreover, important aspects of polyneuropathies associated with 
immunoglobulins that bind to gangliosides remain unclear. Can they initiate the disease 
process and are they indicators of primary immune attack, or are the antibody responses 
merely secondary to neural tissue damage by other mechanism(s)?
2. Autoimmune responses in peripheral nerve gangliosides
It has been known for more than two decades that peripheral nerve contains gangliosides 
(Svennerholm 1963; Svennerholm 1994; Svennerholm et al. 1994). Gangliosides are 
complex glycosphingolipids which contain at least one sialic acid residue (N- 
acetylneuraminic acid) attached to the internal and/or the terminal galactose of an 
oligosaccharide core composed for up to four sugars. Gangliosides reside in the outer 
layer of plasma membrane and the hydrophilic sugars are located on the outer surface of 
the membrane. They are linked to the cell by the hydrophobic lipid moiety ceramide, 
which is immersed into the membrane. There is an abundance of literature suggesting 
that gangliosides may play a role in membrane and cell functions. The binding of 
cholera toxin to GM1 ganglioside is well documented (van Heyningen et al. 1971; 
Cuatrecasas 1973a; Holmgren 1981) and gangliosides on nerve terminals may also act as 
receptors for tetanus and botulinium toxin (Fishman 1982; Willison & Kennedy 1993).
The abundance of gangliosides in the nervous system and the extracellular display of 
their sugars make them attractive potential antigenic targets in autoimmune neurological 
disorders. Many attempts have been made to link anti-ganglioside antibody responses 
with the pathogenesis of these disorders and to explain specific features of these 
diseases: whether they are entirely motor or sensory in presentation, demyelinating or 
axonal on electrophysiological study or pathological examination or associated with a
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particular regional distribution of deficits. The subject of polyneuropathies associated 
with immunoglobulins that bind to gangliosides has produced considerable controversy 
and despite efforts, the presence of measurable antibodies to gangliosides in some 
peripheral neuropathy syndromes has not yet provided proof that they are pathogenic.
3. Anti-ganglioside antibodies in the present study
In this study we attempted to clarify the role of anti-ganglioside antibodies in mediating 
acute experimental conduction block in vitro; we investigated their binding and 
complement fixing capacity to nodes of Ranvier, in conjuction with physiological 
recordings from isolated mouse sciatic nerve, rabbit sural nerve and mouse phrenic 
nerve-hemidiaphragm preparations under a range of experimental conditions.
We first investigated the very acute physiological effects of the anti-GQlb and 
structurally related disialosyl antibodies. The anti-GQlb antibody may be of pathogenic 
importance in MFS. Since the first report involving the anti-GQlb antibody in the 
pathogenesis of MFS (Chiba et al. 1992), several studies have found increased anti- 
GQlb antibody titres in MFS with the immunoglobulin being of IgG class rather than 
IgM. The antibody titre decreases with the clinical course of the illness (Chiba et al. 
1993; Yuki et al. 1993b; Willison et al. 1993c; Jacobs et al. 1995; Yuki 1996a; Carpo et 
al. 1998; Suzuki et al. 1998; Schwerer et al. 1999). Electrophysiological evidence has 
revealed that anti-GQlb positive sera from patients with Miller-Fisher syndrome induce 
severe defects in acetylcholine release from motor nerve terminals and lead to block 
neuromuscular transmission on mouse phrenic nerve-hemidiaphragm preparation. This 
suggests that the GQlb antibody, in the presence of activated complement, plays the 
principal role in MFS motor symptomatology (Roberts et al. 1994; Plomp et al. 1999). 
However, contrary to the generally accepted view that the GQlb antibody plays a crucial
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role in MFS, another recent study demonstrated that serum without any detectable 
ganglioside antibodies was as effective as serum IgG containing GQlb antibody in 
blocking evoked quanta! release of acetylcholine in mouse phrenic nerve- 
hemidiaphragm preparation (Buchwald et al. 1998b).
Initially, we examined the electrophysiological effects of this antibody on ensheathed 
mouse sciatic nerve preparation at room temperature and we did not note any 
abnormality. Having observed overt differences of saxitoxin action in ensheathed and 
desheathed nerves, we assumed that the sheath of the nerve acted as a significant 
diffusion barrier for antibody penetration and all subsequent electrophysiological 
recordings were performed on desheathed nerve preparations. We tested both IgM and 
IgG antibody from four different patients and we did not observe any defect on nerve 
conduction at room temperature. Also, the same antibody in the presence of active 
complement did not have any abnormal effect on other two different preparations: on 
rabbit desheathed sciatic nerve at room temperature and on twitch tension in mouse 
phrenic nerve-hemidiaphragm preparation at physiological temperature. However, the 
anti-GQlb IgM antibody does bind to a significant proportion peripheral nerve nodes of 
Ranvier; two out of three anti-GQlb antibodies from different patients demonstrated 
significant ability of binding to the nodes of Ranvier in sciatic nerve teased fibres 
preparations after overnight incubation at 37°C.
In this study, the anti-GMl antibody was also included. The role of this antibody in 
autoimmune peripheral neuropathies is controversial. Previous electrophysiological and 
immunohistological studies have shown divergent findings. Intaneural injection of 
antibody into rat sciatic nerve produced acute conduction block with significant fall in 
the amplitude ratio (Santoro et al. 1992) and rabbits immunised with GM1 ganglioside 
revealed electrophysiological abnormalities, mild axonal degeneration and
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immunoglobulin deposits at the nodes of Ranvier (Thomas et al. 1991). Uncini et al. 
showed that sera from patients with MMN containing anti-GMl antibodies produced 
conduction block and demyelination when injected into rat tibial nerve. However, in the 
same study, injection of sera with high titres of anti-GMl antibodies obtained from 
patients with spinal muscular atrophy did not produce block and pathological analysis 
did not indicate demyelination (Uncini et al. 1993). On the contrary, other 
electrophysiological and morphological studies have revealed different findings. Harvey 
et al. (Harvey et al. 1995) injected intraneurally into rat tibial nerve immunoglobulin 
fractions with high titres of anti-GMl IgG or IgM anti-ganglioside antibodies from 
patients with GBS or MMN; the antibody did not induce acute conduction block, and 
histological examination of the injected nerves did not show demyelination despite the 
binding of the anti-GMl antibody to the nodes of Ranvier. Similarly, previous studies 
using antisera against GM1 ganglioside failed to induce demyelination after injection 
into rat sciatic nerves, in contrast to the marked demyelination produced by anti- 
galactocerebroside and anti-Po antisera (Hughes et a). 1985).
In vitro studies on the effects of anti-GMl antisera have also been conflicting. 
Arasaki et al. reported a minor reduction in the amplitude of compound nerve action 
potential in desheathed rat sciatic nerve (Arasaki et al. 1993) and more recently they 
found conduction block with 4 out 14 examined anti-ganglioside sera (Arasaki et al. 
1998). Takigawa et al. (Takigawa et al. 1995) found that anti-GMl antibody increased 
potassium current elicited by step depolarisation, and in the presence of active 
complement blocked sodium channels irreversibly. This finding supported the 
hypothesis that Na+ channels may be targets of immune attack in some neurological 
diseases (Waxman 1995). However, this hypothesis has recently been disputed; the 
application of the same sera with high titres of anti-GMl antibody did not cause
161
conduction block or block sodium channels, suggesting that it is insufficient to conclude 
that anti-GMl antibody alone play a pathogenic role in some neuropathies (Hirota et al.
1997). Also, another in vitro study applying MMN sera to the mouse phrenic nerve- 
hemidiaphragm preparation found dysfunction at motor nerve tenninals with anti-GMl 
positive and anti-GMl negative sera (Roberts et al. 1995).
We investigated the acute physiological effects of IgM and IgG anti-GMl sera and 
IgM monoclonal antibodies in two different preparations. Also, we examined the nodal 
binding ability of anti-GMl IgM sera and monoclonal antibodies using 
immunofluorescence techniques. Exposure for up to four hours of the desheathed sciatic 
nerve to either IgM monoclonal anti-ganglioside antibody or sera of IgM and IgG classes 
did not induce any significant alteration in the amplitude, latency, rise time, and 
threshold of the obtained compound nerve action potentials. The presence of 
complement did not change the nerve conduction. In contrast, the immunofluorescence 
studies demonstrated significant reactivity of the antibody with nodes of Ranvier in 
mouse sciatic nerve teased fibres preparations. The results from two anti-GMl 
antibodies were impressive; they showed intense staining at the nodes of Ranvier in high 
percentages and characteristic ability to fix complement, especially at 37°C. But, 
surprisingly, these two antibodies did not have any positive physiological effect on nerve 
conduction when we test them again in sciatic nerve preparation at 37°C. Moreover, 
neither of these two antibodies, in the presence of complement, demonstrated any acute 
harmful effect in muscle twitch tension through indirect stimulation in mouse phrenic 
nerve-hemidiaphragm preparation.
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4. Anti-ganglioside antibodies in peripheral neurological disorders: a mystery?
Although our electrophysiological findings do not support the pathogenic role of anti- 
ganglioside antibodies, the immunofluorescence studies have clearly shown that the 
node of Ranvier is capable of binding antibodies and fixing complement. Our findings 
are entirely consistent with those reported by Harvey et al. (Harvey et al. 1995) and 
Hirota et al. (Hirota et al. 1997) and not with those reported by others (Arasaki et al. 
1993; Takigawa et al. 1995). But the controversy still exists. Do the anti-ganglioside 
antibodies produce conduction block in vitro or not? And why the experimental studies 
have shown so great diversity? And more importantly, are the anti-ganglioside 
antibodies of primary pathogenic importance in autoimmune peripheral neuropathies or 
does their existence simply signify a nerve tissue breakdown epiphenomenon? Do they 
cause the human disease or are other as yet unidentified factors responsible for the 
disease process?
4a. Variability in experimental studies: some considerations
The divergent findings from the in vitro and in vivo experimental studies may have many 
explanations. Technical factors were of great importance in our studies. In particular, it 
is well established the effect of osmotic pressure changes upon transmitter release from 
mammalian motor nerve terminals. Hyperosmotic solutions initially increase miniature 
end-plate potentials transmitter release from motor nerve terminals and then block 
neuromuscular transmission (Hubbard et al. 1968). Also, pH and osmotic changes can 
significantly influence nerve impulse propagation in isolated nerve in vitro (Orchardson 
1978; Minwegen & Friede 1984). We noticed profoundly negative effects on 
electrophysiological parameters following alterations in bath pH, osmolarity, and ionic 
strength of incubation solutions and took great care to control these variables. Early in
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the course of this work, a significant amount of preliminary experimental data were 
collected in order to control these technical factors. It is possible that technical and 
operator dependent factors may be contributing to discrepancies between some of the 
previously published data.
The route of access by which antibody penetrates nerve is another important factor in 
these types of experiments. Organ bath preparations may have advantages over in vivo 
models in this respect since direct application of a fixed antibody concentration to intact 
or desheathed preparations can be studied. Another advantage of organ bath physiology 
is that ionic and buffering conditions, electrode placement and stimulation/recording 
conditions can be carefully controlled under direct visualisation. In vivo studies of a 
disease induced in an experimental animal could provide evidence that a disorder is 
mediated by circulating factors.
Intraneural injection of patients’ sera or various solutions has been widely used in 
research studies in order to examine various neuropathologic and demyelinating effects. 
Intraneural injection has been used to examine the pathogenic role of sera from patients 
with anti-MAG (Hays et al. 1987; Willison et al. 1988; Trojaborg et al. 1989) or anti- 
sulfatide antibodies (Quattrini et al. 1992), and also the in vivo demyelination and nerve 
conduction block induced by anti-galactocerebroside antibodies (Saida et al. 1979; 
Sumner et al. 1982). Intraneural injection studies were employed to study the effects of 
anti-ganglioside antibodies and the results were contradictory, as it has already been 
described (Santoro et al. 1992; Uncini et al. 1993; Harvey et al. 1995; Wirguin et al. 
1995). However, passive transfer by intraneural injection of antibodies is a highly 
artificial and poorly controllable experimental model (Low et al. 1982; Oomes et al. 
1991). Multiple technical factors associated with the intraneural injection technique 
itself have to be taken into account. Increasing needle size, rapid injection, and large
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volumes of testing compound may contribute to or even cause pathological changes of 
the injected nerve. Also, extraneous movement of the needle or the animal may increase 
the rate of axonal degeneration and segmental demyelination, as interesting studies have 
shown (Dyck et al. 1982). On the other hand systemic injection of antibody may require 
large amounts of antibodies to bypass the blood nerve barrier which is relatively 
impermeable to some macromolecules such as IgM antibody.
However, the experimental models are different and certainly not identical to human 
disease. The experiments perfonned in this study have examined only the very acute 
effects of exposure to anti-ganglioside antibody. The duration of antibody exposure to 
the target sites does not correspond to the human disease and binding to the target 
appeared to be more efficient after overnight incubation which may have limited the 
potential of the in vitro approach. Moreover, the pathophysiological environment of the 
human disease is very different. In normal nerve, the blood-nerve barrier prevents the 
free passage of immunoglobulins from the blood into the endoneurial space. The blood- 
nerve barrier formed by the endoneural capillaries with their tight junctions and the 
perineurium protects the nerve by its relative impermeability. In experimental models 
the blood-nerve barrier either does not exist, as in peripheral nerve cultures in vitro, or is 
bypassed, as in intraneural injection. Maybe, some degree of dysfunction in blood-nerve 
barrier in vivo seems to be a prerequisite for anti-myelin antibody to penetrate into 
peripheral nerve environment, although some gangliosides, in particular GM1, are 
enriched in the membrane of the motor nerve terminals which lack the blood-nerve 
barrier and so anti-neural antibodies can easily gain access. How this may be triggered 
in these disorders is unknown, and whether the anti-ganglioside antibody responses play 
a predominant or secondary role in the pathogenesis of demyelination remains uncertain. 
In human disease an impaired blood-nerve barrier would permit the chronic exposure of
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nerve fibres to serum constituents, while in the experimental model nerve fibres are 
exposed to antibody activity for a brief period. Patients with some chronic autoimmune 
neuropathies suffer for years, or even decades, from the disease. Thus, to induce 
conduction block or other electrophysiological abnormalities acutely in up to four hours 
is a different model.
Also, the affinity of the antibody and their ability to fix complement is likely to be 
different in experimental models in comparison to human disease. Our 
immunohistochemistry studies of desheathed sciatic nerves exposed to anti-ganglioside 
antibodies demonstrated antibody deposition and complement activation in the majority 
of nodes of Ranvier in some but not all preparations. The apparent discrepancies may be 
explained by the fact that different or the same clinical syndromes affected different 
patients because of differences in antibody affinity, and/or ability to fix complement. 
Additionally, circulating factors other than, or in addition to, anti-ganglioside antibodies 
may be present and play an important role in patients with autoimmune peripheral 
neuropathies. Maybe these still unidentified factors contribute to the disease process or 
play an important pathogenic role and then the detected anti-ganglioside antibody is 
simply a consequence of a still unknown mechanism.
Perhaps we would detect electrophysiological failure of nodal and neuromuscular 
conduction if we were able to conduct longer-term recordings under experimental 
circumstances in which nodes and neuromuscular junctions were exposed to prolonged 
pro-inflammatory insults. Unfortunately, it was not feasible because our experience has 
shown that a good and well-controlled preparation can be alive and reliable for not more 
than 5-6 hours.
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4b. Molecular mimicry in antibody-mediated peripheral neuropathies
Recent neurophysiological and pathological studies have led to a reclassification o f GBS 
into acute inflammatory demyelinating poluneuropathy (AIDP), acute motor axonal 
neuropathy (AMAN), and acute motor sensory axonal neuropathy (AMSAN) (McKhann 
et al. 1993; Powel & Myers 1996; Hahn 1998). Significant antecedent infections include 
Campylobacter jejuni (4-66%), Cytomegalovirus (CMV) (5-15%), Epstein-Barr virus (2- 
10%), and Mycoplasma pneumoniae (1-5%). These infections are not obligatorily 
associated with any clinical subtype, although severe axonal degeneration follows 
Campylobacter jejuni infection and severe sensory deficits is more common following 
CMV.
Strong evidence supports the important role of antibodies to gangliosides in GBS 
pathogenesis. Ganglioside-like epitopes exist in the lipopolysaccharide bacterial wall of 
Campylobacter jejuni. In particular, the Campylobacter jejuni lipopolysaccharide 
fraction contains side chains with the same structure as gangliosides GM1, GQlb, 
GDI a, GD3 and GTla, and these findings support the hypothesis of molecular mimicry 
between gangliosides and surface epitopes on Campylobacter jejuni strains from patients 
with GBS or MFS (Yuki et al. 1993c; Aspinall et al. 1994; Jacobs et al. 1995; Oomes et 
al. 1995; Yuki 1997; Jacobs et al. 1997a; Hao et al. 1998). Also, antibodies to GM1 
ganglioside are frequent in cases with severe axonal degeneration following 
Campylobacter jejuni infection, although not all Campylobacter jejuni associated GBS 
patients have anti-GMl antibodies (Yuki et al. 1990; Rees et al. 1995a; Jacobs et al. 
1996; Feasby & Hughes 1998). Additionally, only half of patients with GBS and anti- 
GMl antibodies have had preceding enteritis suggesting a recent Campylobacter jejuni 
infection. Recent studies have found that sera from GBS patients without evidence of 
Campylobacter jejuni infection also frequently reacted with GM1 ganglioside (Hao et al.
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1998). Studies for the presence of cross-reactive antigens in other than Campylobacter 
jejuni infectious agents would be an interesting subject. A very recent report suggests 
the presence of a GMl-like structure on the surface of a particular strain of Haemophilus 
influenzae isolated from a patient with axonal GBS associated with anti-GMl antibody 
after Haemophilus influenzae infection (Mori et al. 1999b). Attempts to match the 
subtypes of GBS to the fine specificity of anti-ganglioside antibodies continue but, so far 
have not fully explained the pathogenesis. Some studies underscore the great diversity 
of lipopolysaccharide structures in Campylobacter jejuni (Penner & Aspinall 1997), and 
the substantial heterogeneity among Campylobacter jejuni strains in their expression of 
GMl-like epitopes and among the fine specificities of different neuropathy-associated 
anti-GMl antibodies (Prendergast, Willison & Moran 1999).
Although Campylobacter jejuni strains from GBS patients can induce antibodies that 
cross-react with gangliosides and Campylobacter jejuni lipopolysaccharides, the 
question whether these antibodies are pathogenic remains unanswered. Even though 
these antibodies can bind to peripheral nerve structures, as others and we have shown, 
again this crucial question remains unanswered. In a recent study, all rabbits immunised 
with Campylobacter jejuni lipopolysaccharides from GBS-associated strains that contain 
a GMl-like epitope produced high cross-reactive antibodies, but none of the animals 
developed any neurological sign of the disease (Ang et al. 2000). Thus, the hypothesis 
of molecular mimicry of Campylobacter jejuni lipopolysaccharides with gangliosides 
has been confirmed from many results, but whether the anti-ganglioside antibodies are 
of pathogenic value in the development of neurological disorders remains to be 
determined.
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4c. Immune responses directed against sodium channels?
The interesting hypothesis that anti-ganglioside antibodies may induce immune- 
mediated changes and may block ion channels is another matter of controversy and 
needs further investigation. Maybe the diversity of Na+ channels provide a basis for 
selective immune attack in different types of axons: different types of sodium channels 
in different types of sensory and motor axons may explain the selective involvement for 
large versus small sensory fibres or pure motor or myelin involvement. The striking 
selection of motor over sensory axons in AMAN (McKhann et al. 1993) implies that 
motor axons may be antigenically distinct targets (Hafer-Macko et al. 1996). Motor 
axons are known to have distinctive electrophysiological properties, derived from a 
distinctive assembly of ion channels. Since antibodies to ganglioside GM1 are more 
common in patients with AMAN, this ganglioside may be considered to be the most 
likely target for the autoantibodies. Although high IgM anti-GDI a antibody titres may be 
found in several motor syndromes including pure motor demyelinating neuropathy 
associated with IgM MGUS (Carpo et al. 1996), most recently an association between 
IgG antibodies to GDI a ganglioside and predominantly motor axonal GBS was 
suggested (Yuki et al. 1992b; Lugaresi et al. 1997; Ang et al. 1999; Ho et al. 1999; 
Kaida et al. 2000). The hypothesis that the anti-ganglioside antibodies may block ion 
channels camiot be supported from our electrophysiological data. Moreover this 
hypothesis cannot apply to the anti-GQlb antibody-mediated attack in MFS, since 
important studies have emphasised that sodium channels are practically absent from the 
terminal part of the presynaptic endings in mouse motor nerve terminals (Brigant & 
Mallart 1982).
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4d. T cell responses in autoimmune peripheral neuropathies
Cellular phenomena may involve in the pathogenesis of autoimmune human 
neuropathies. Migration of activated T cells across the blood-nerve barrier, recruitment 
of macrophages into the endoneurium, and macrophage-mediated demyelination may are 
important factors in the pathophysiology of these diseases. On the other hand, humoral 
factors including antibodies and complement may enhance the peripheral nerve damage 
induced by T cells. The autoimmune hypothesis in demyelinating GBS is based largely 
011 the close clinical and histopathologic similarities between GBS and experimental 
allergic neuritis (EAN) (Vriesendrop 1997) and the continuing failure of 
epidemiological studies to associate a single infectious agent with the disease. 
Furthermore, extensive studies over many years have failed to associate autoimmune 
responses with a defined peripheral myelin autoantigen in this disease. It implies that 
not one but a number of peripheral nerve myelin autoantigens may be implicated in the 
pathogenesis of GBS, if indeed this disease does involve an autoimmune basis. T cells 
responses to any of myelin proteins, P2 , Po and PMP22 may be responsible for some or 
perhaps all forms of GBS, but identification of the specificity of these T cells is still in a 
preliminary stage (Hughes et al. 1999). T cell-mediated cytotoxic attack against 
ganglion neurons in patients with acute sensory neuronopathy has been proposed 
(Minwegen & Friede 1984).
The variation in disease severity of both primary demyelinating GBS and primary 
axonal GBS is likely to be dependent on the intensity of the immune response provoked 
by the preceding event (Griffin et al. 1996b). Transfer of antigen-specific T cells from 
EAN rats to naive rats also induces similar disease, and the clinical and histological 
severity is dependent on the antigen dose in EAN induced by immunisation (Hahn et al. 
1988). Transfer a low number of cells causes mild disease that is predominantly
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characterised by demyelination, whereas transfer of a high number of cells causes severe 
paralysis and widespread axonal degeneration (Hahn et al. 1988). Although good 
recovery is described in Chinese children with axonal GBS (AMAN), several clinical 
studies from other geographically different areas emphasised the correlation of 
antecedent Campylobacter jejuni infection with axonal GBS and poor recovery 
(Vriesendrop et al. 1993; Hartung et al. 1995; Visser et al. 1995; Rees et al. 1995b). This 
may reflect axon-specific anti-ganglioside antibody-mediated primary axonal injury in 
some patients.
5. Future research studies and conclusions
The anti-ganglioside antibodies are likely to be pathogenic. However, we failed to prove 
that in our electrophysiological study, despite the immunohistological results of antibody 
binding and complement activation at the nodes of Ranvier in up to 90% of nodes in 
some preparations. Our data indicate that the node of Ranvier is relatively resistant to 
acute anti-ganglioside antibody-mediated damage. These data also suggest that anti- 
ganglioside antibodies are unlikely to have major pharmacological effects on nodal 
function.
So, the relationship between autoimmune peripheral neuropathy syndromes and anti- 
ganglioside antibodies remains controversial. In particular the role of anti-GMl 
antibodies in the pathogenesis of multifocal motor neuropathy (MMN) is still debated. 
These antibodies are not specific for MMN or even for lower motor neuron syndromes. 
High titres of antibodies to GM1 ganglioside are present in only about 50% of patients 
with MMN and the absence of anti-GMl antibodies does not rule out the diagnosis of 
MMN if the clinical and electrophysiological findings are characteristic. Also, anti- 
ganglioside antibodies are found in normal population even at low titres, in neurological
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disorders other than lower motor neuron syndromes and also in a variety of non- 
neurological diseases in which there is evidence for an autoimmune pathogenic 
mechanism. Thus anti-ganglioside antibodies have been reported in patients with SLE, 
rheumatoid arthritis, myasthenia gravis, polymyositis, and cervical spondylosis (Sadiq et 
al. 1990; Lamb & Patten 1991; Willison et al. 1993a; Taylor et al. 1996).
The presence of anti-ganglioside antibodies might be a secondary phenomenon to 
destruction of neurons and following exposure of neuronal antigens to the immune 
system. Moreover, the fact that antibodies reactive with gangliosides have been detected 
in some, but not all patients with autoimmune peripheral polyneuropathies makes it 
likely that humoral immunity to other antigens, or cell-mediated immunity and immune 
complexes are of pathogenic significance. This view raises a dilemma. Taking as an 
example the neuropathies with IgM monoclonal gammopathy, approximately half show 
binding to MAG and the others do not. Does this mean that MAG binding is an 
epiphenomenon and is extraneous to the pathogenesis of neuropathy? Maybe there are 
strong arguments on both sides of this question.
The overriding challenge for the future is to determine the role of anti-ganglioside 
antibodies in the underlying pathology of autoimmune human neuropathies and also to 
further investigate the precise site(s) of the responsible epitopes within the peripheral 
nervous system. Detailed clinical, neurophysiological and pathological studies are 
required to explain how antibody binding might lead to the various symptoms of patients 
with these disorders. For example, biopsy samples of motor point from patients with 
MFS might determine the anti-GQlb antibody and complement binding to 
neuromuscular junctions and also the structural disruption of the integrity of 
neuromuscular junction in MFS patients. Also, future studies on the fine specificity of
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anti-ganglioside antibodies in relationship to clinical features may explain the 
heterogeneity in the clinical manifestations of these disorders.
The role of T cell and its possible implication in the pathogenesis of GBS and related 
disorders is another opening field for investigation. Activated T cells that cross the 
blood-nerve barrier may recognize an antigen in the endoneurial space and produce 
cytokines and chemokines which open the blood-nerve barrier and allow the egress of 
antibodies. Then, antibodies can recognize cell surface molecules and activate the 
complement cascade or opsonize Schwann cells or the axolemma for the attachment of 
macrophages which then lead to the cascade of pathological events in AIDP and AMAN.
On the other hand, the report by Kusunoki et al. has established the first animal model 
for anti-ganglioside antibody-mediated neuropathy. This study provides clear and 
specific evidence that GDlb antibodies can mediate injury to sensory neurons in dorsal 
root ganglia and cause sensory ataxic neuropathy in rabbits (Kusunoki et al. 1996b). 
The existence of a reproducible specific animal model that could be studied in detail 
would give a new dimension in understanding basic aspects of Campylobacter jejuni- 
induced GBS. An animal disease model would be useful to broaden our knowledge 
about the implicated immune mechanisms and further explain differences between 
axonal and demyelinating GBS, antibody specificity, location of antigenic epitopes, 
location of complement deposition and cell infiltration. An animal would contribute to 
the ability to investigate in more detail other important aspects including 
electrophysiological effects, clinical illness and recovery. Overall, it may offer an 
opportunity to explore future therapies that remove or inactivate the pathogenic agent 
that causes human peripheral neuropathies.
In conclusion, the occurrence of antibodies to gangliosides is well recognised in 
various neurological diseases with a suspected autoimmune basis. However, neither the
clinical relevance, nor the mechanism which is responsible for this immune response has 
been fully elucidated. Further studies are needed to determine in more detail the 
antibody characteristics, the epitope specificity, and the antigen accessibility. Moreover, 
animal model studies have to be performed to understand the underling mechanism and 
answer the crucial question: are anti-ganglioside antibodies of diagnostic and clinical 
significance?
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